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ABSTRACT 
Drug delivery to the brain has challenged medical professionals for several decades, with 98% of 
small molecules and 100% of large molecules unable to cross the blood brain barrier (BBB). 
Biocompatible, biodegradable polymers have been extensively researched for the oral delivery of 
therapeutic agents, but to date has not been successfully manipulated for the formulation of an 
implantable device. We have therefore utilised such polymers for the formulation and design of an 
implantable nanoenabled multipolymeric drug delivery device (NMDDD) for the management of AIDS 
Dementia Complex (ADC). 
 
ADC is a central nervous system (CNS) complication of HIV, associated with a host of debilitating 
cognitive, motor and behavioural symptoms. ADC remains a serious manifestation of HIV/AIDS in 
both developing and developed countries, affecting both adults and children, with death expected 
within 6 months of initial diagnosis. Zidovudine (AZT), the current gold standard for the management 
of ADC, has demonstrated the best penetration into the CNS. It is capable of reducing viral replication 
in the CNS and managing neurological abnormalities associated with ADC, with clinical efficacy 
evidenced by the decline in morbidity and mortality of patients treated with this drug.  
 
Nanotechnology, an interdisciplinary field of research, involving the manipulation of matter on a 
submicron level, is receiving emerging interest for the formulation of novel drug delivery systems. As 
they can potentially be manipulated to react in a bioresponsive manner, nanopharmaceuticals have 
received much attention for site-specific drug delivery and were therefore employed in the formulation 
of an implantable NMDDD, with AZT employed as the model drug, for the management of ADC.  
 
Nanoparticles were prepared by means of an approach utilising controlled gelation of alginate, 
employing cationic crosslinking of the anionic alginate to precipitate nanoparticles. A 3-factor Box-
Behnken statistical design was employed for the optimisation of nanoparticle and multipolymeric 
scaffold formulations. Nanoparticles measuring 68.04nm (SD<0.0002) in size with a zeta potential of -
13.4mV (SD<0.0005) were formulated. Nanoparticles presented with a mean dissolution time (MDT) 
of 46.046 hours 30 days post exposure to phosphate buffered saline (PBS), pH 7.4. In an attempt to 
further retard drug release and to formulate a device for implantation in the frontal lobe of the brain, 
nanoparticles were dispersed within a robust multipolymeric matrix. Matrix erosion was calculated at 
28%
w
/w (SD<0.001) for multipolymeric scaffold and a matrix resilience of 4.451%
w
/w (SD<0.007) was 
observed 30 days post exposure to PBS, indicating slow degradation of the NMDDD. MDT was 
reduced to 12.570 hours (SD<0.0005) with dispersion of the nanoparticles within a polymer matrix, 
supporting the application of the drug-loaded MDDD in the management of ADC patients. 
 
The optimised multipolymeric nanoparticulate scaffold was implanted into the frontal lobe of the rat 
brain, for investigation of drug release characteristics and tissue response to the device following in 
vivo administration. 
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CHAPTER 1 
 
Literature Survey and Motivation for this study 
 
1.1 Introduction 
The last three decades has witnessed a rise in the number of people infected with the 
Human Immunodeficiency Virus (HIV), making HIV/Acquired Immunodeficiency Syndrome 
(AIDS) a global concern as the number of people living with the disease increases every 
year. HIV accounted for 33 million infections by 2007, with 25 million HIV-related deaths 
reported since 1981. In 2006, 4.3 million new infections were reported, with 430 000 new 
HIV infections occurring in infants each year, despite an increase in prevention programmes 
and access to antiretroviral (ARV) therapy. Approximately 2 million HIV-related deaths was 
reported in 2007 (UNAIDS/WHO, 2006; UNAIDS Epidemic Update, 2008; das Neves et al., 
2009; Varatharajan and Thomas, 2009; Akhtar et al., 2010, Fowler et al., 2002).  
 
Sub-Saharan Africa remains the epicenter of HIV/AIDS infections, with 67% of the HIV-
infected population living in this area. Southern Africa accounts for 32% of the global 
HIV/AIDS population, with the only country experiencing a decline in the incidence of new 
HIV infections being Zimbabwe. South Africa itself houses 5.5 million HIV/AIDS sufferers, of 
which 240 000 are children under 15 years of age, with HIV accounting for 8.7% of deaths 
as recorded in the last census performed in 2001 (Statistics South Africa, 2001; 
UNAIDS/WHO, 2006; Yeboah, 2007; UNAIDS Epidemic Update, 2008; das Neves et al., 
2009; Fowler et al., 2010; Kanmogne et al., 2010). 
 
A member of the subfamily of retroviruses, HIV is known to affect most, if not all systems of 
the body, causing a variety of immunological and neurological diseases as a result of attack 
on the body‟s immune system, particularly by cluster of differentiation 4 (CD4) T-lymphocyte 
depletion, leaving the body susceptible to fatal infections and cancers (World Health 
Organisation, 1993; Bowers, 1996; Penedo et al., 2003; Pirzada et al., 2006; Samikkanu et 
al., 2010). Viral entry into the body results in an initial flu-like symptom or viraemia due to the 
immune reconstitution symptom, which occurs as the body‟s immune system rapidly 
degrades. After this initial phase, the patient goes in to an asymptomatic period which can 
last for months or years prior to the onset of AIDS, a syndrome which results from advanced 
HIV infection. AIDS is diagnosed when life-threatening opportunistic infections, such as 
Kaposi‟s sarcoma and lymphoma‟s occur or if the CD4 or T4 lymphocyte count falls below 
200 cells/mm3 (Pirzada et al., 2006).  
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The HIV pandemic is said to have started in Leopoldville, Cameroon in 1927, with the virus 
being noticed during a clinical trial of the antimalarial drug, plasmaquine (Parris, 2007). The 
pandemic was thought to have been due to the polio vaccine programme in Stanleyville, 
1958 (Parris, 2007). However, the first official AIDS patient was identified in 1981 with AIDS 
developing into a global pandemic shortly after (Wu et al., 2007), with the effects of 
HIV/AIDS was only felt in sub-Saharan Africa in the early 1990‟s (Yeboah, 2007). 
 
HIV infection of the CNS is associated with a host of complications including 
encephalopathy, dementia and motor dysfunction, with 7-20% of patients exhibiting 
neurological symptoms as the initial signs of infections. Autopsy studies have found that 75-
90% of HIV/AIDS patients exhibit neurohistological damage (Bodor and Buchwald, 1999; 
Sawchuk and Yang, 1999). AIDS Dementia Complex (ADC), a CNS condition caused by the 
HIV-1 strain of the retrovirus, is a serious manifestation of HIV/AIDS in both developed and 
developing countries (Portegies et al., 1994; Kim et al., 1996; Vitiello et al., 1997; Saksena et 
al., 1998; Pemberton et al., 2001; Schutzer et al., 2004; Giunta et al., 2006). Affecting one 
third of adults and one half of children living with AIDS, ADC is a source of severe morbidity 
and limited survival, with death being expected within 6 months after diagnosis is made. 
Developmental delays in cognitive and motor function, as well as loss of acquired skills have 
been noted in children with ADC. The dementia is also responsible for declined intellectual 
scores in children and is the leading cause of dementia in young adults worldwide (Portegies 
et al., 1989; Frumkin, 1992; Wong et al., 1992; Bower, 1996; Gabuzda, 1996; Vitiello et al., 
1997; Price, 1998; Chang et al., 2004; Wu et al., 2007; Perry et al., 2010). 
 
The condition consists of many progressive diseases which can easily be mistaken for other 
problems, such as depression, drug-induced side effects and opportunistic infections of 
brain, like toxoplasmosis or lymphomas. Due to the variety of manifestations of the complex, 
ADC is poorly understood and frequently misdiagnosed (Link, 1992).  With little being known 
of the pathogenesis of the condition, it is a source of severe morbidity, as well as being 
associated with limited survival (Price, 1998).  ADC is responsible for a host of cognitive, 
motor and behavioural symptoms ranging in severity from minor cognitive symptoms, such 
as forgetfulness, lack of attention and disturbed sleep patterns, to severe dementia and 
paralysis (Portegies et al., 1989; Lawrence et al., 2002; Yiannoutsos et al., 2004; Thompson 
et al., 2005; Martín-García et al., 2006; Cook-Easterwood et al., 2007; Akhtar et al., 2010).  
 
The presentation of symptoms of ADC is associated with severe immunosuppression.  At 
this stage the patient is susceptible to opportunistic infections, which further compromises 
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the immune system.  Initiation of highly active antiretroviral therapy (HAART) at this stage is 
beneficial to the patient as HAART serves to decrease viral load and improve immune 
function.  The incidence of ADC has declined by 50% with the introduction of antiretroviral 
therapy in first world countries (Avison et al., 2002, Chang et al., 2004; Valcour et al., 2004; 
González-Scarano et al., 2005; Cook-Easterwood et al, 2007; Beblo et al., 2010) as HAART 
prevents and reverses clinically symptomatic ADC.  HAART consists of the use of a triple 
regimen of ARV‟s, consisting of two nucleoside reverse transcriptase inhibitors (NRTI‟s) in 
combination with either a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease 
inhibitor (PI) or and integrase inhibitor (Rao et al., 2008; das Neves et al., 2009; Cihlar and 
Ray, 2010). The addition of zidovudine (AZT) into this regimen is beneficial in that AZT 
demonstrates the best penetration into the brain among the NRTI‟s (Galinsky et al., 1990; 
Gallo, 1994). 
 
Drug incorporation into nanosystems is used to achieve site-specific drug delivery, therefore 
providing better control of drug release.  This improves the efficacy, pharmacokinetics and 
pharmacodynamics, as sub-micron distribution of the drug particles improving the 
physicochemical properties of the encapsulated drug (Roney et al., 2005). Targeted drug 
delivery improves the therapeutic efficacy of the drug, as well as resulting in a reduction in 
the quantity administered to achieve a therapeutic response and minimises side effects 
experienced due to drug therapy. Drug delivery devices using nanosystems can be 
manipulated to react in a bioresponsive manner, to provide site-specific drug delivery and to 
control drug degradation. Nanoparticles are capable of opening tight junctions and are 
therefore capable of crossing the BBB (Roney et al., 2005; Jolck et al., 2010; Subbia et al., 
2010).  Nanoparticles can also be used as carriers for poorly soluble drugs, thereby 
improving their bioavailability (Pison et al., 2006; Popovic and Brundin, 2006; Reis et al., 
2006; Anderson and Power, 2010).  
 
Polymers with desirable physicochemical and physicomechanical properties can be 
successfully used to develop nano-enabled implantable devices, which are capable of 
prolonged drug release over desired time periods.  Biodegradable polymers such as 
polycaprolactone (PCL), pectin, and alginate can be used in the design of nano-enabled 
implantable drug delivery systems, as byproducts of such polymers are biocompatible, 
nontoxic, and readily excreted from the body (Liu et al., 2005; Popovic and Brundin, 2006;  
Rezwan et al., 2006; Cameron et al., 2010).  These polymers are non-mutagenic, non-
cytogenic and non-teratogenic and are therefore safe for implantation.  Such polymers have 
been employed in simulating a polymer scaffold to deliver drug-loaded polymeric 
nanoparticles, due to their desirable mechanical properties and superior drug permeability 
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(Liu et al., 2005; Luong-Van et al., 2006; Popovic and Brundin, 2006; McKenzie et al., 2003; 
Rezwan et al., 2006).  The device, comprising of a polymeric scaffold and drug-loaded 
nanoparticles will be implanted intracranially to achieve modulated drug release in a site-
specific manner. 
 
Intracranial implantation of the drug loaded nanoparticulate multipolymeric device into the 
frontal lobe of the brain yields site-specific presentation of the drug, negating the need for 
the drug to bypass the blood brain barrier.  Direct implantation into the brain allows for lower 
doses of drug to be administered and prevents the occurrence of systemic adverse effects 
resulting from the systemic circulation of drug molecules. The frontal lobe is the preferred 
site of implantation as no sensory or motor functions are located at the chosen site of 
implantation (Figure 1.1).   
 
 
                        
 
 
 
 
Figure 1.1: Anatomical illustration of the brain indicating the presence of sensory and motor 
sites within the different lobes of the brain. The site of implantation is indicated (adapted 
from Bina, http://massoudbina.com/neurodisorders/BrainAnatomy.php, (24/07/2010). 
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1.2. Rationale for the study 
ARV medication and immune reconstitution drugs have accounted for an increase in the 
number of people living with chronic HIV/AIDS in the last decade, resulting from a decrease 
in immunosuppression and opportunistic infection, which is usually responsible for death in 
AIDS sufferers. This in turn led to an increase in the number of people developing ADC, as 
more HIV patients have progressed to old age, when neurological disorders due to aging 
precipitates ADC. However, milder symptoms of ADC are commonly experienced. This can 
be managed with adequate ARV therapy which is capable of penetrating the blood brain 
barrier (Lawrence et al., 2002; Valcour et al., 2004; Beblo et al., 2010). The symptoms of 
ADC can be managed using psychoactive drugs, including antipsychotics, antidepressants, 
anxiolytics, psychostimulants, antimanics, and anticonvulsants. Neuroprotective agents may 
also work to retard neuronal death and therefore improve mental function (Thompson et al., 
2005). However, these do not treat the underlying cause of the disease, nor do they halt its 
progression, as they do not target the HI virus. ARV‟s that target the HI virus are therefore 
required (Link, 1992). 
 
Existing therapies used for the management of ADC are mainly administered via the oral 
route, employing triple-drug therapy, with a combination of nucleoside reverse transcriptase 
inhibitors (NRTI‟s), non-nucleoside reverse transcriptase inhibitors (NNRTI‟s), nucleotide 
reverse transcriptase inhibitors (NtRTI‟s) or a protease inhibitors (PI‟s) (Ramachandran et 
al., 2006; Varatharajan and Thomas, 2009).  There are many barriers to the absorption of 
these drugs from the gastrointestinal tract. Acidic conditions in the stomach are responsible 
for the reduction in the bioavailability of didanosine, a nucleoside reverse transcriptase 
inhibitor (NRTI), whereas the reduced aqueous solubility is responsible for the reduction in 
the bioavailability of the non-nucleoside reverse transcriptase inhibitors (NNRTI‟s).  Oral 
bioavailability of the protease inhibitors (PI‟s) is reduced due to poor solubility of the drugs in 
the gastrointestinal fluid, decreased intestinal permeability, as well as first-pass metabolism.  
Zidovudine therapy is hindered by the first pass metabolism, which reduces the 
bioavailability of this drug (Allan Macnab et al., 1996; Carvalho et al., 2010).  Higher 
concentrations of this drug are therefore required when employed to treat ADC; however this 
has been shown to increase the risk of severe anaemia (Aungst, 1999; Agarwal et al., 2010).  
The poor bioavailability as well as the associated side effects creates the need for localized 
drug delivery of ARV agents for the management of ADC (Alavijeh et al., 2005). It is also 
thought that systemic ARV‟s are not sufficient to eradicate HIV in the CNS, creating a need 
for localised drug therapy (Lawrence et al., 2002). In a study conducted by Pialoux et al. 
(1997), it was established that therapy with a combination of AZT, lamivudine, and indinavir 
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served to reduce plasma viral loads below 200copies/mL, indicating effective management 
of the HI virus within the body, however neurological disorders resulting from HIV still 
ensued. This supports the need for localised delivery of ARVs for the management of ADC 
as adequate distribution of ARVs following systemic administration is not achieved (Pialoux 
et al., 1997; Sawchuk and Yang, 1999).  
 
The BBB restricts the entry of substances into the brain depending on the size and 
endothelial permeability of the substance.  It comprises of tight cell junctions and an ATP-
dependent efflux pump, which hinders the delivery of drug into the brain, thus making 
therapy to the brain via the systemic route difficult.  Small lipophilic molecules and peptides 
are able to cross the BBB, however these molecules undergo rapid systemic degradation 
prior to reaching the site of action (Pardridge, 1995; Varatharajan and Thomas, 2009).  High 
dose parenteral therapy is often necessary to achieve sufficient concentrations of drug in the 
brain; however, this is accompanied by a host of systemic side effects. 
 
Polymeric nanoparticles used for the controlled delivery of drug were first developed in the 
1970‟s (Feijen et al., 2005).  Nanomaterials are defined as materials containing components 
with a minimum of one dimension in the nanometer size range (Yang et al., 2008). 
Commercially available nanomaterials, a term which refers to a range of materials including 
nanotubes, nanospheres, nanomicelles and nanoliposomes, extend into many scientific 
fields, including electronics, cosmetics, and medicine (Liu et al., 2008; Yang et al., 2008). 
The formulation of a nano-enabled polymeric implant allows for site specific drug release 
within the CNS, negating concerns such as first pass metabolism, systemic side effects due 
to the high dosages required for therapeutic efficacy and the challenges posed by the BBB. 
Safe and effective drug delivery into the brain resulting from localized delivery will ensue, 
with subsequent improvement in patients‟ quality of life as the management of the ADC will 
be considerably enhanced (Price, 1998; Ghaderi et al., 2010; Jolck et al., 2010; Subbia et 
al., 2010). 
 
Various applications exist for the nanoparticle-loaded system. It can be utilised for the 
prolonged drug delivery, where controlled delivery over extended periods of time is required. 
Other possible applications for such a device are for use as a subcutaneous implant to 
achieve systemic drug release which bypasses the gastrointestinal tract and the liver, or for 
the local treatment of skin conditions. The device is useful for drugs which are sensitive to 
the acidic environment of the stomach and drugs which are susceptible to a high degree of 
first pass metabolism. Nanosystems are capable of penetrating barriers such as the blood 
brain barrier, the pulmonary system and the tight junctions of the skin, which were previously 
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difficult to treat due to their complex anatomic make-up. Nanoparticles can act to enhance 
the uptake and retention of drug at these sites, thereby serving to successfully manage the 
numerous disease conditions by achieving superior therapeutic efficacy (Hughes, 2005; Rao 
et al., 2008; Jolck et al., 2010). The effective management of ADC and other neurological 
manifestations of HIV/AIDS require sustained concentration of drug in appropriate dosages 
delivered site specifically (Brewster et al. 1995). This can be acheived with nanotechnology. 
 
1.3 Novelty of this study 
• The first implantable NMDDD for application in ADC. 
• Novel combination of polymers for the formulation of nanoparticles and scaffolds. 
• An innovative polymeric modification technique was employed for scaffold fabrication which  
  is proposed to emanate in a unique modulated drug release mechanism. 
• The first in vivo implantation of AZT loaded NMDDD into the brain of Sprague Dawley rats. 
 
1.4 Aim and Objectives 
The aim of this study is to develop a nano-enabled multipolymeric drug delivery device for 
intracranial implantation into the frontal lobe of the rat brain, enabling controlled, site-specific 
delivery of drug, for application in ADC. AZT was employed as the model drug due to its 
demonstrated favorable penetration into the CNS. 
 
To achieve this, the following objectives are outlined: 
1. To formulate drug-loaded nanoparticles investigating various methods such as the 
salting-out approach, the emulsification-diffusion approach, or the nanoprecipitation 
approach. 
2. To formulate robust multipolymeric scaffolds employing a crosslinking approach. 
3. To evaluate the physicochemical and physicomechanical properties of the 
nanoparticulate and multipolymeric platform. 
4. To assess the drug release behaviour from the nanoparticulate system. 
5. To incorporate the drug-loaded nanoparticles into a multipolymeric scaffold device and 
assess the in vitro release, swelling, and erosion studies in simulated biological media.  
6. To employ a 3-factor Box-Benhken statistical design for the synthesis of variants to 
explicate the effect of independent variables set during preliminary studies to establish a 
correlation between variables by the analysis of the physicochemical characteristics of 
the prepared formulations, with subsequent formulation optimisation. 
7. Development and optimization of a surgical protocol for the implantation of 
multipolymeric devices into the rat brain employing a Sprague Dawley rat model. 
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8. To perform in vivo animal studies to determine drug release, polymer degradation and 
resultant histomorphological changes in the brain post implantation. 
 
1.5 Overview of the dissertation 
Chapter 1 briefly outlines the rationale for the study being carried out. The challenges faced 
with the management of neurological diseases, including ADC due to the restrictions 
imposed by the BBB are also noted. The rationale for the study being conducted as well as 
the aims and objectives and an overview of the chapters are summarized in Chapter 1. 
 
Chapter 2 contains information regarding the HIV pandemic and ADC, including the severity 
of the condition and limitations associated with current therapeutic agents available for the 
management of this condition. The limitations posed by the BBB and techniques used CNS 
drug delivery are also highlighted. Nanotechnology, the latest revolutionary field of research 
in science today is discussed, including its application in medicine and the benefits of 
polymeric nanosystems for the management of ADC. 
 
The pre-formulation studies carried out are highlighted in Chapter 3. The formulation of 
polymeric nanoparticles employing two preparation techniques, namely the controlled 
gelification of alginate and the salting out approach are explored. The formulation of 
multipolymeric scaffolds using a variety of hydrophilic and hydrophobic polymers employing 
a crosslinking approach using multivalent salt solutions is also assessed. Physicochemical 
characterisation and drug release parameters are ascertained for the prepared formulations, 
with the rationale for the chosen formulations for further studies highlighted. 
 
The optimization of AZT-loaded alginate nanoparticles and the formulation of multipolymeric 
polycaprolactone/epsilon caprolactone/cellulose acetate phthalate scaffolds are presented in 
Chapter 4. A 3-factor Box-Behnken design was employed to optimise nanoparticle and 
polymer scaffold formulations which were then analyzed to ascertain the physicochemical 
and physicomechanical properties of the prepared formulations. Drug release from both the 
nanoparticles and multipolymeric device containing dispersed nanoparticles were also 
evaluated in this chapter. Evaluation of the optimized formulation then followed. 
 
Chapter 5 highlights in vivo studies utilizing a male Sprague Dawley rat model. Implantation 
of the optimized NMDDD in the frontal lobe of the brain employing a technique analogous to 
that used for the insertion of an intra-cranial pressure monitor in the human subject was 
undertaken. This was followed by histomorphological analysis, bioerosion, and drug release 
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in the CNS ascertained by means of ultra performance liquid chromatographic (UPLC) 
analysis.  
 
Chapter 6 includes recommendations for future work to be carried out to further improve the 
device for human application. 
 
Chapter 7 outlines concluding remarks for the performed study. 
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CHAPTER 2 
 
AIDS Dementia Complex: Currently Available Treatment Strategies 
and Limitations Posed by the Blood Brain Barrier 
 
2.1 Literature Survey  
2.1.1 AIDS Dementia Complex: The neurological manifestation of HIV 
Human Immunodeficiency Virus (HIV) infection of the central nervous system (CNS) is 
associated with neurocognitive impairment, ranging in severity from mild cognitive disorder 
(MND) to AIDS dementia complex (ADC), resulting from HIV replication within the CNS. 
ADC is a clinical manifestation resulting from the presence of the HIV-1 strain of the 
retrovirus within the CNS. The condition remains a serious manifestation of HIV in both 
developed and developing countries (Portegies et al., 1994; Kim et al., 1996; Vitiello et al., 
1997; Saksena et al., 1998; Pemberton et al., 2001; Schutzer et al., 2004; Giunta et al., 
2006; Varatharajan and Thomas, 2009). ADC occurs in the late stage of infection due to 
severe immune suppression and has been considered an Acquired Immunodeficiency 
Syndrome (AIDS) defining condition since 1987 when a diagnosis is made in the absence of 
AIDS, however this is uncommon (Portegies et al., 1989; Kim et al., 1996; Sawchuk and 
Yang, 1999; Lawrence et al., 2002). The dementia results in a host of cognitive, motor and 
behavioural symptoms, ranging in severity from minor cognitive symptoms, such as 
forgetfulness and lack of attention, to severe dementia and paralysis (Portegies et al., 1989; 
Lawrence et al., 2002; Yiannoutsos et al., 2004; Thompson et al., 2005; Martín-García et al., 
2006; Cook-Easterwood et al., 2007). 
 
Neurological dysfunction of the brain, spinal cord, meninges and neurons are observed in 
AIDS patients. However, of these, ADC remains the most clinically significant, affecting 
approximately 60% of HIV-infected individuals (Sawchuk and Yang, 1999; Robertson et al., 
2010). 
 
HIV has been identified in the brain as early as 2 days after initial infection; however, this 
remains clinically insignificant until the onset of full blown AIDS. (Bower, 1996; Sakaie et al., 
1999; Enting et al., 2000; Chang, et al., 2004; Wu et al., 2007). ADC results from HIV 
infection in the brain in the absence of opportunistic infections, such as cryptococcal 
meningitis, Toxoplasma gondii, Epstein Barr virus, tumours and other causes of dementia, 
narcotic, and alcohol abuse and drug therapy being examples of such causes (Lawrence et 
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al., 2002). The virus enters and is harboured in the CNS, resulting in a subcortical dementia 
affecting the subcortical regions of the brain, namely the basal ganglia and the deep white 
matter. This can be noted by the increased metabolism occurring in these regions of the 
brain (Gallo, 1994; Bower, 1996; Kim et al., 1996; Sawchuk and Yang, 1999; Avison et al., 
2002; Chang et al., 2004; Yiannoutsos et al., 2004).  
 
ADC progresses rapidly, with global mental impairment occurring within 2months of the initial 
symptoms in some patients. Death follows within 1 to 6months, usually as a result of 
systemic infection or aspiration pneumonia (Kim et al., 1996; Sawchuk and Yang, 1999; 
Giunta et al., 2006). Early identification and treatment of ADC is crucial, especially for 
patients in which ADC progresses rapidly (Pemberton et al., 2001). Magnetic resonance 
imaging (MRI) of the brain identifies abnormal brain pathology with the ADC sufferers as 
seen in Figure 2.1 
 
  
Figure 2.1: (a) Dynamic contrast functional MRI images of normalised cerebral blood 
volumes at the level of the basal ganglia. (1) A healthy subject (left) and an HIV positive 
patient (right) with Stage 2 ADC. (2) MRI images from the same patient before treatment 
with AZT (left) and after 6months of treatment with AZT (right) and (b) MRI of a patient with 
ADC, displaying diffuse white matter abnormalities at the level of the lateral ventricle. The 
cortical sulci are prominent, indicating atrophy (Sakaie and Gonzalez, 1999). 
 
 
The manifestations of ADC, a name coined in 1985 by Drs. Navia and Price, have been 
reported since the early days of the HIV epidemic and had previously been given a variety of 
names and descriptions, “HIV encephalopathy or encephalitis”, “multifocal giant-cell 
encephalitis”, “subacute encephalitis”, “HIV associated dementia” and “progressive 
(a) (b) 
1 
2 
Control ADC = 2 
ADC = 2 ADC = 0 
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dementia”, being just a few. The most acceptable definition of ADC had been published in 
May 1991 by Dr. Janssen and colleagues. This includes only the most debilitating 
manifestations of ADC, being major cognitive and motor disorders, and neglects the more 
common, but harder to detect symptoms, such as irritability and moodiness (Link, 1992). 
ADC is characterised by neurocognitive deficits which impairs a person‟s ability to function at 
work and perform tasks of daily activity (Vitiello et al., 1997; Robertson et al., 2010). 
 
ADC is a serious concern in developing countries due to inadequate access to ARV therapy. 
Poor compliance due to the complicated drug regimens has increased resistance to ARV‟s, 
compounding the ADC pandemic (Wu et al., 2007). 
 
2.1.2 HIV entry into the brain 
ADC is thought to be as result of immune activation and viral replication in the brain 
(Pemberton et al., 2001). The HIV virus is thought to enter the CNS within days to weeks 
after initial infection through infected immune cells, including T cells, monocytes, and trojan 
horse trafficking of infected macrophages across the blood brain barrier (BBB), which 
migrate into the brain to replenish the perivascular population in the brain (Sawchuk and 
Yang, 1999; Thompson et al., 2005; Giunta et al., 2006; Varatharajan and Thomas, 2009; 
Akhtar et al., 2010; Valcour et al., 2010; Vinogradov et al., 2010).  HIV entry can also be 
attributed to infiltration of infected cells across the choroid plexus and compromised BBB, 
allowing the entry of free viruses into the CNS (Avison et al., 2002; Martín-García et al., 
2006). A viral reservoir within the brain is thus established soon after initial HIV infection, 
which is resistant to anti-retroviral (ARV) therapy (Melton et al., 1997). However, clinically 
significant infection of the CNS only occurs later in the course of the disease when patients 
are significantly immunocompromised, with a resulting cluster of differentiation 4 (CD4) T cell 
depletion below 200cells/mm3, with resultant cognitive, motor and behavioural defects 
associated with ADC (Giunta et al., 2006; Varatharajan and Thomas, 2009). CD4 cells are 
glycoproteins expressed on the surface of T cells, assisting with T cell activation and 
subsequent activation of the immune cascade upon interacting with antigens. CD4 depletion 
is significant in HIV due to it being an indicator immune system function and subsequently an 
indicator of AIDS when the count falls below 200cells/mm3. Healthy individuals have a 
circulating CD4 count of 800-1200cells/mm3 (Rocha and Tanchot, 2004; Pirzada et al., 2006; 
Cai and Li, 2009; Wolbers et al., 2010). 
 
ADC does not result from direct neuronal infection within the CNS and is instead as a result 
of neuronal dysfunction and death (apoptosis) caused by dendritic degeneration, due to toxin 
release within the CNS, specifically in the hippocampus (affecting cognition) and the basal 
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ganglia (affecting motor function), by viral protein release from infected mononuclear 
phagocytes (Avison et al., 2002; Lawrence et al., 2002; González-Scarano et al., 2005; 
Thompson et al., 2005; Giunta et al., 2006; Martín-García et al., 2006). 
 
Perivascular macrophages (derivatives of monocytes), multinucleated giant cells (caused by 
HIV induced fusion of microglia and macrophages), microglia, endothelial cells (cells which 
line blood vessels in the brain), astrocytes (cells which fill the spaces between neurons and 
provide support and insulation for neurons) and T lymphocytes, are all infected by the HIV-1 
virus as these cells have CD4 receptors to which the HIV-1 can bind, facilitating viral entry 
into the cell (Budka, 1991; Lawrence et al., 2002; Avison et al., 2002; Cook-Easterwood et 
al., 2007; Akhtar et al., 2010; Valcour et al., 2010; Vinogradov et al., 2010). Of these cells, 
macrophages are the primary source of indirect nerve damage, as they act as viral 
reservoirs within the CNS. Infected macrophages and astrocytes shed gp 120 (proteins on 
the outer coat of the HIV virus) and tat genes (a transactivator proteins which aids viral 
production). These proteins are both directly and indirectly neurotoxic (Link, 1992; Gabuzda, 
1996; Xiong et al., 2000; Lawrence et al., 2002; Sammikkannu et al., 2010). Tat genes 
increase intracellular Ca2+ which causes oxidatitive damage and apoptosis. Tat genes may 
also facilitate apoptosis indirectly by stimulating the secretion of matrix metalloproteinase 
and other such substances. These substances activates macrophages and microglia, which 
in turn increases the availability of nitric oxide, superoxide anions, platelet activating factor 
and arachidonic acid metabolites, which are not unique to ADC, but is found in most 
neurodegenerative diseases (Lawrence et al., 2002; Sammikkannu et al., 2010). 
 
Proinflammatory cytokines such as tumour necrosis factor alpha, gamma (TNFα, TNFγ), 
alpha interferon (IFNα), platelet activating factor (PAF), nitric oxide (a free radical 
responsible for vasodilation), arachidonic acid, as well as chemokines are produced in 
abundance by cells infected by HIV (Avison et al., 2002, Cook-Easterwood et al., 2007; 
Ramirez et al., 2010). Proliferation of astrocytes (astrogliosis), indicative of widespread 
astrocyte activation and damage, causes demyelination of neurons, which in turn increases 
the synthesis of inflammatory cytokines and arachidonic acid metabolites. Astrocyte 
glutamate clearance is blocked by gp 120, resulting in an exocitotoxic neurotoxic cascade, 
which is initiated due to activation of the arachidonic pathway (Bowers, 1996; Avison et al., 
2002; Wu et al., 2007). In addition to this, macrophages release quinolinic acid into the brain, 
which binds to nerve cells and causes nerve cell death (Link, 1992). This series of events 
leads to inflammation, causing a general pattern of dysregulation within the CNS, associated 
with all cases of clinical dementia, which in turn results in apoptosis (Bowers, 1996; Avison 
et al., 2002; Lawrence et al., 2002; Ramirez et al., 2010; Wang et al., 2010). 
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Apoptosis occurs not only at the site of HIV exposure, but also at remote regions due to gap 
junctions, which are used by astrocytes for communication. Infected astrocytes are therefore 
able to communicate with other astrocytes distant in proximity to initial viral exposure, 
causing proliferation of HIV damage throughout the CNS (Bowers, 1996; Lawrence et al., 
2002; Wang et al., 2010). 
 
Histological findings indicate astrogliosis, myelin pallor and loss of myelin surrounding 
neuronal axons, loss of synaptic connections, and neuronal loss, which are commonly seen 
in brain tissue from individuals who died as a result of AIDS (Vitiello et al., 1997; Lawrence 
et al., 2002). Histopathological abnormalities predominate in the central white matter and 
subcortical grey matter of the brain (Kim et al., 1996; Lawrence et al., 2002). The extent of 
these neuropathological changes varies between individuals and, in a single individual, from 
one brain region to another. Hypertrophy is also seen in histological and imaging (computed 
tomography [CT] and magnetic resonance imaging [MRI]) assessments of brain tissue, 
which is characteristic of reactive astrocytes. Imaging studies also indicate a reduction in the 
basal ganglia volume and cortical hypometabolism in patients with advanced ADC. 
Hypermetabolism of the thalamus and basal ganglia is seen in patients with milder ADC. 
This leads to dysregulation of neural homeostasis, which upsets neuronal function, causing 
neuronal death and neurobehavioral dysfunction (Vitiello et al., 1997).  
 
The microenvironment of the CNS is sensitive to change, with minor disruptions having 
major impacts on cognition, behaviour and motor skills. This altered microenvironment of the 
CNS, as described in Figure 2.2, due to HIV results in neurotoxicity, producing the 
symptoms experienced by ADC sufferers (Polianova et al., 2005). 
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Figure 2.2: Illustration of the entry of HIV into the central nervous system with transportation 
of the virus into differentiating macrophages or through lymphocyte-macrophage cell 
interactions (adapted from AIDS Read, 2002). 
 
2.1.3 Symptoms of ADC  
ADC was originally identified as being an encephalitic disorder, characterised by cognitive 
and behavioral symptoms, as per a review of neurological disorders relating to HIV/AIDS 
(Wu et al., 2007). Since then, it was found that ADC is responsible for a host of other 
neurological symptoms including disturbed sleep patterns, loss of fine motor skills, speech 
impairment and symptoms of affect, being apathy lethargy and social withdrawal (Link, 1992; 
Bower, 1996; Gabuzda, 1996; Kim et al., 1996; Fernandes et al., 2006; Wu et al., 2007).  
 
The term dementia describes a clinical syndrome composed of memory loss, decreased 
mental concentration and loss of intellectual functions due to progressive disease in the 
brain. Symptoms experienced by ADC suffers is in accordance with this definition, consisting 
of cognitive, motor and mood impairments which is progressive in nature (Bower, 1996).  
 
The first symptoms which appear in ADC suffers are short-term memory loss and poor 
concentration. This is difficult to recognise and if recognised, it is rarely attributed to ADC as 
stress, depression and many other conditions can be implicated for such symptoms (Bower, 
1996). Cognitive impairment is characterised by memory impairments, speech problems, 
inability to concentrate, poor judgement, impaired learning ability and speed of processing 
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information (Link, 1992; Bower, 1996; Kim et al., 1996). Global cognitive dysfunction is found 
late in the course of the illness (Kim et al., 1996). 
 
Motor impairment is characterized by impaired speed of movement, loss of balance, gait 
ataxia, fine motor speed, and manual dexterity impairment, bladder and faecal incontinence, 
paralysis, poor coordination, hyper-reflexia of the lower extremities, stiff and awkward, or 
markedly slow movements (Link, 1992; Bower, 1996; Kim et al., 1996).  
 
Mood or affect impairments are defined as changes in emotional responses to experiences, 
being apathy, personality changes, irritability, lack of inhibition and loss of libido (Link, 1992; 
Bower, 1996; Kim et al., 1996). Poor concentration, loss of short- or long-term memory, 
social withdrawal, slowed thinking, irritability, apathy, poor coordination, impaired judgement, 
and personality change are all symptoms associated with impairment of affect (Link, 1992; 
Vitiello et al., 1997; Fernandes et al., 2006; Wu et al., 2007).  
 
Behavioural changes are the least understood and often missed in a diagnosis of ADC. They 
are characterised as impairments in the ability to perform tasks and activities of daily living.  
These changes have found in 30-40% of patients in the early stages of ADC (Link, 1992). 
Severe mental conditions, such as depression, psychosis, and mania are also experienced 
by ADC sufferers, however this occurs later in the course of the condition (Link, 1992; 
Bower, 1996). As the condition progresses, patients develop symptoms associated with 
advanced dementia, as well as mutism, paraplegia, and spontaneous tremors and seizures 
amongst others (Gabuzda, 1996; Kim et al., 1996). 
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Figure 2.3: Diagnosis of dementia (adapted from Washington, D.C: American Psychiatric 
Association, Diagnostic and statistical manual of mental disorders, 4th edition, 1994).  
 
2.1.4 Diagnosis of the condition 
Many AIDS related opportunistic infections present with symptoms similar to that of ADC, 
toxoplasmosis, cryptococcal meningitis, and cytomegalovirus (CMV) encephalitis being a 
few. Direct and indirect evidence, by means of neurological, psychological and cognitive 
tests, are therefore required for an accurate diagnosis of ADC to be made (Bower, 1996). 
Assessment of cognitive function forms a crucial part in the classification of ADC, with the 
various stages of the condition highlighted in Table 2.1. Cognitive function is also used to 
differentiate ADC from other manifestations of HIV in the CNS and for appropriate 
therapeutic management of the condition. ADC is diagnosed primarily using a mental status 
test, which reveals problems such as loss of short and long term memory, orientation and 
concentration impairment, abstract thinking, slow verbal and motor responses, memory 
recall, speed of information processing, mood swings and blunted affect (Link, 1992; Kim et 
al., 1996; Lawrence et al., 2002).  
 
A. Impairment of short 
and long term memory 
 
B. At least one of the following: 
 
1. Impairment of abstract thinking 
2. Impaired judgment 
3. Disturbances of higher cortical function 
4. Changes in personality 
 
D. Absence of occurrence solely 
during delirium 
C. Memory and intellectual 
impairment with noteworthy 
social and occupational 
difficulty. 
E. Either: 
1. Evidence of an organic factor causing impairment 
in memory an intellect 
2. Impairment in memory and intellect cannot be 
accounted for be a non-organic mental disorder 
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Cerebrospinal fluid (CSF) examinations are also conducted, with CSF obtained from a spinal 
tap or a lumbar puncture, in which CSF is tested for the presence of active HIV infection. 
Information regarding levels of HIV DNA and RNA can also be obtained from the CSF 
(Bower, 1996).  It has also been found that that the viral load in the CSF correlates to 
progressive dementia in children. Non-specific abnormalities with CSF, including mild 
elevations of proteins and white blood cells are observed in the CSF of patients with ADC 
(Epstein et al., 1987; Link, 1992; Bower, 1996; Sawchuk and Yang, 1999). CSF examination 
is therefore used to exclude infectious and neoplastic conditions manifesting as dementia 
(Sawchuk and Yang, 1999). 
 
CT scans are used to detect atrophy of brain tissue, occurring mainly in the cerebral 
ventricular and subarachnoid regions, which is diagnostic of ADC. These scans are also 
used to rule out other causes of dementia and symptoms experienced, such as subcortical 
lesions and toxoplasmosis (Bower, 1996; Sawchuk and Yang, 1999). MRIs, a scan far more 
sensitive than CT scans, which are capable of supplying a quantitative measure of 
metabolite concentrations, is used when CT scans are inconclusive due to the high costs 
incurred with the use of MRI. MRIs are capable of detecting neurochemical abnormalities in 
the CNS early in the course of infection, however, the cost of the scan precludes this from 
being carried out (Link, 1992; Sakaie et al., 1999; Cysique, 2006).  Single Photon Emission 
Computed Tomograms (SPECTs) scans employs radioactive material to measure blood flow 
in the brain and is used to detect early dementia due to HIV. SPECTs scans are also used to 
observe responses to ARV therapy by monitoring whether ARV‟s improves blood flow to the 
brain (Link, 1992; Cysique, 2006). Photon emission tomography (PET) scans are used to 
detect patterns in glucose metabolism. Hypermetabolism of glucose is associated with early 
stage ADC and hypometabolism of glucose is characteristic of late stage ADC (Bower, 
1996). 
 
Subcortical regions of the brain are most affected, being the deep white matter and the basal 
ganglia. However, neuronal loss can also be seen in the cortex as well, and damage to the 
synaptic dendritic tree also occurs. These findings can be viewed in histological analysis of 
ADC affected brain tissue. Onset of cognitive impairment and severity can be correlated to 
the extent of pathology in the subcortical brain regions (Chang et al., 2004). Altered 
metabolic activity at various regions in the brain as well as a decrease in brain volumes and 
augmented water content is observed with an increase in disease severity (Sawchuk and 
Yang, 1999). 
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2.1.5 Management of ADC utilising drug therapy 
With the introduction of ARV‟s, 2 million lives have been spared since 2002 in low and 
middle income countries, with a dramatic improvement observed in the quality of life of 
individuals living with HIV/AIDS. There has been a conspicuous increase in the number of 
people with access to ARV‟s in sub-Saharan Africa, with over 1 million people receiving 
treatment by June 2006. However, due to volumes of infected individuals, this accounts for 
less than one quarter of the population being treated in this region (UNAIDS, 2006; das 
Neves, 2009).  
 
ARV‟s work to manage ADC indirectly by interfering with systemic viral production. Systemic 
viral load is decreased, resulting in a decrease in the number of viral cells available for entry 
into the CNS with a subsequent decline in the incidence of dementia. ARV‟s also serve to 
protect the neurons by minimising damage caused by elevated levels of cytokine and nitric 
oxide in the brain (Bower, 1996; Lawrence et al., 2002). 
 
2.1.5.1 Highly Active Antiretroviral Therapy 
Highly Active antiretroviral therapy (HAART) has been shown to prolong life expectancy and 
slow the progress of HIV in infected adults and children, with a major improvement in patient 
quality of life (Puthanakit, 2007). The incidence of life threatening opportunistic infections, 
Kaposi‟s sarcoma, Mycobacterium avium complex related disease, cryptococcal menigitis 
and Pneumocystis jirovicii pneumonia, associated with high morbidity and mortality, has 
dramatically declined with the introduction of HAART in 1995, resulting in HIV becoming a 
chronic disease rather than an acute rapidly progressing condition (Sacktor, 2002; 
Thompson et al., 2005; Cook-Easterwood et al., 2007; Puthanakit, 2007; das Neves, 2009; 
Varatharajan and Thomas, 2009). HAART is found to be effective in suppressing systemic 
viral replication and subsequently decreasing viral load to nearly undetectable levels within 
weeks of initiating treatment. Lymphocyte function is restored, thereby decreasing mortality 
and the incidence of systemic opportunistic infections due to AIDS. The frequency of HIV 
dementia has decreased by 50% with the introduction of HAART (Lawrence et al., 2002; 
Sacktor, 2002). HAART regimens are often complicated and require strict adherence to 
therapy, more than 95%, in order for therapeutic benefits to be achieved and viral mutation 
and drug resistance to be prevented. Such stringent drug criteria and drug toxicity, resulting 
in poor patient compliance, as well as drug interactions, have resulted in an increase in 
resistance to ARV‟s and subsequent declines in CD4 cell counts. It is therefore thought that 
neurological diseases associated with HIV may begin to rise once again (Lawrence et al., 
2002; Sacktor, 2002; Penedo et al., 2003; Smit et al., 2004; Beblo et al., 2010).  
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Table 2.1: ADC has been classified according to stages, ranging in severity from normal, as in early infection, to end-stage dementia, 
associated with severe immune depletion and death (adapted from Link 1992; Worley and Price, 1992). 
Early Stage  
Stage I 
Middle Stage  
Stage II 
Late Stage  
Stage III 
 
Stage 0:  
Normal neurological activity in the 
presence of HIV infection in the brain 
Symptoms of motor dysfunction Incontinence 
Stage 0.5:  
Sub-clinical stage 
Poor memory and concentration Spastic gait 
Minimal or ambiguous neurological 
symptoms 
Slowed response to stimuli Loss of initiative 
No impairments of daily activity Frequently dropping objects Withdrawal 
Stage 1: 
Explicit intellectual or motor impairment 
marked slowness of activities Psychosis or mania 
All but the most demanding activities of 
daily living can be performed 
Reversing of words and numbers Confinement to bed 
Difficulty concentrating Ambulatory but requires assistance Severe Dementia End Stage 
Slowed thinking Capable of self care 
Major intellectual 
disability 
Near vegetative state 
Memory loss 
Incapable of performing demanding task of 
daily activities 
Cannot walk 
unassisted 
Rudimentary cognition 
Poor coordination 
 
  Para- or quadraplegia 
Change in handwriting    
Patients rely on lists to keep track of 
daily activities 
   
Mental status test remains normal 
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Prior to HAART, therapy utilising single or dual nucleoside reverse transcriptase inhibitors 
(NRTI) were widely implemented (1992-1995). This rapidly led to ARV resistance and 
subsequent lack of efficacy. However, a combination of at least three ARV‟s from different 
classes proved to be more effective in managing HIV and is now the standard care for 
patients (Ves et al., 2001; Lawrence et al., 2002; das Neves, 2009; Varatharajan and 
Thomas, 2009). In 2003, approximately 370 000 AIDS related deaths were reported. It was 
estimated that the mortality rate would rise to approximately 4 to 7 million people by 2010 if 
no medicinal intervention was made (Badri et al., 2006). With the introduction of HAART into 
the South African public health centres in 2002, the incidence of public hospital admission 
due to AIDS-related conditions has declined significantly (Badri et al., 2006). HAART works 
to combat immunosuppression, thereby reducing disease progression and patient mortality 
(Thompson et al., 2005). The rationale behind HAART was the use of multiple ARV‟s which 
would act synergistically at different stages of the virus‟s life cycle to reduce viral replication 
(Orsega, 2006). It was also thought that combined therapy would reduce the incidence of 
drug toxicity and drug resistance (Bean, 1992). 
 
HAART helps alleviate dementia in 2 ways: (1) drugs enter the CNS to treat HIV infection, 
and/or (2) systemic viral load reduction and reconstitution of body-wide immunity has a 
positive influence on neurological function. In a study conducted by Cook-Easterwood et 
al.(2007) it was found that HAART reduced astrogliosis and TNFα production in a mouse 
model, supporting the use of HAART for managing ADC (Cook-Easterwood et al., 2007). 
The problem that remains, however, is that few drugs are capable of penetrating the BBB 
and reaching optimal drug concentrations in the CNS. This results in suboptimal drug 
concentrations in the brain, which augments ARV resistance. The use of systemic treatment 
for the management of ADC is therefore ineffective in yielding significant declines in viral 
replication and viral load within the CNS (Bower, 1996; Smit et al., 2004; Wu et al., 2007).  
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Table 2.2.1: Adult HAART regimens implemented in the South African public sector of 
health care (adapted from the South African National Department of Health, National 
Antiretroviral Treatment Guidelines, 2004). 
 
Regimen 1a Regimen 1b1 Regimen 2 
•Stavudine (40mg 12hourly, or 
30mg if weight is < 60kg) 
•Lamivudine (150mg 12hourly) 
•Efavirenz (600mg at night, or 
400mg if weight is < 40kg) 
•Stavudine (40mg 12hourly, or 
30mg if weight is < 60kg) 
•Lamivudine (150mg 12 hourly) 
•Nevirapine (200mg daily for the 
first 2 weeks of therapy, 
increased to 200mg 12hourly 
thereafter 
•Zidovudine (300mg 12hourly 
•Didanosine (400mg daily, or 
250mg if weight is < 60kg, taken 
alone, dissolved in water, 
unless enteric coated, on an 
empty stomach) 
•Lopinavir/Ritonavir (400/100mg 
12hourly, to be kept in a cool, 
<25°C, dry place) 
 
1 
Administered if female patient is unable to guarantee reliable contraception whilst on ARV therapy 
 
Table 2.2.2: Paediatric HAART regimens implemented in the South African public sector of 
health care (Adapted from the South African National Department of Health, National 
antiretroviral treatment guidelines, 2004). 
 
Regimen 
1 
< 6 months > 6 months,  
< 3 years 
> 3 years 
 •Stavudine (substituted 
with Zidovudine if no 
refridgerator is available at 
the patients home) 
•Lamivudine 
•Ritonavir or Nevirapine if 
no previous exposure has 
occurred  
•Stavudine (substituted 
with Zidovudine if no 
refridgerator is available 
at the patients home) 
•Lamivudine 
•Ritonavir or Nevirapine if 
no previous exposure to 
nevirapine occurred  
•Stavudine (substituted with 
Zidovudine if no 
refridgerator is available at 
the patients home) 
•Lamivudine 
•Efavirenz  
 
Regimen 
2 
< 3 years or < 10kg > 3 years or > 10kg 
 •Didanosine (to be taken alone, dissolved 
in water, on an empty stomach) 
•Zidovudine (substituted to Abacavir if no 
refridgerator is available at the patients 
home) 
•Lopinavir/Ritonavir or Nevirapine if no 
previous exposure has occurred 
•Didanosine (to be taken alone, dissolved 
in water, on an empty stomach) 
•Zidovudine (substituted to Abacavir if no 
refridgerator is available at the patients 
home) 
•Lopinavir/Ritonavir  
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All paediatric doses are calculated according to the paediatric dosing schedule with body 
surface area (BSA) used to calculate patient dose, refer to Equation 2.1. 
                       
2
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
               (Equation 2.1) 
 
2.1.5.2 Zidovudine therpary for the management of ADC 
Prior to the introduction of zidovudine (AZT) in May 1987, the incidence of ADC in AIDS 
suffers was as high as 53%, as seen in the first half of 1987. After the introduction of AZT 
the incidence of ADC decreased to 10% in the second half of 1987 and to 3% in 1988 
(Portegies et al., 1989; Foudraine et al., 1998; Parris, 2007). A British study conducted 
between 1982 and 1988 found that only 2% of AIDS patients taking AZT developed ADC, 
whereas 20% of patients not receiving the drug developed ADC. AZT, (3'-azido-3'-
deoxythymidine), formerly known as azidothymidine, is a nucleoside analogue which has a 
similar structure to that of thymidine, a pyrimidine deoxyribonucleoside which is naturally 
present in the brain (Bean, 1992; Danesi et al., 1998; Uslu et al., 2002; Brown et al., 2003, 
Dunge et al., 2005; Thomas and Segal, 2009; Varatharajan and Thomas, 2009). AZT was 
the first ARV to be developed and marketed for the treatment of HIV/AIDS (Dallas et al., 
2000). However, the drug was first developed as an antitumor agent, with inhibition of HIV 
replication been discovered in 1985. The drug is active in its phosphate form, with the 
triphosphate form being the competitive inhibitor of reverse transcriptase (Bean, 1992; 
Danesi et al., 1998; Sawchuk and Yang, 1999; Dallas et al., 2000). Figure 2.4 illustrates the 
target site of ARV‟s on the HI virus with Figure 2.4b highlighting the mechanism of action of 
AZT.  
                    
As a class, the NRTI‟s display poor penetration into the brain, due to poor BBB permeability 
(Gallo, 1994). However, certain NRTI‟s are capable of crossing the BBB, didanosine and 
zalcitabine being examples of such, and are used to manage ADC. In a study conducted by 
Foudraine et al, it was found that Stavudine and lamivudine are also capable of penetrating 
the BBB, however, not as well as AZT. Of the ARV‟s currently approved for utilization in 
HAART, (refer to Table 2.3), AZT therefore remains the current gold standard for the 
management of ADC (Bean, 1992; Foudraine et al., 1998; Dallas et al., 2000). 
 
AZT is rapidly absorbed from the gastro-intestinal tract and peak plasma concentration is 
reached within 0.6-2hours.It has a plasma half life (t1/2) of approximately 1.5hour. Rapid 
elimination of the drug occurs by the liver, necessitating frequent administration (Lotterer et 
al., 1991; Bean, 1992; Moore et al., 1995; Uslu et al., 2002). However, toxicity is a major 
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concern with AZT therapy, especially with the high doses used to treat ADC. Doses as high 
as 1000mg to 2000mg, as compared to the 600mg used in HAART therapy, are required to 
achieve optimal therapeutic levels in the CNS (Aungst, 1999; Bean, 1992; Link, 1992; Moore 
et al., 1995; Bower, 1996; Brown et al., 2010). This can be attributed to the low bioavailability 
of the drug due to first pass metabolism in the liver, with only 60 to 70% of the drug present 
in blood plasma, of which only 25% enters the CSF circulation (Routy et al., 1990; Link, 
1992; Aungst, 1999; Carvalho et al., 2010). However, such high doses have been revealed 
to increase the risk of severe aplastic anemia due to suppression of circulating erythrocytes 
and neutrophils (Agarwal et al., 2010; Anderson and Power, 2010; Kiragga et al., 2010). Pre-
existing cytopenias and low CD4 counts predisposes individuals to this condition. This in turn 
increases the risk of opportunistic infections (Bean, 1992; Hewitt et al., 1993; Moore et al., 
1995; Bower, 1996; Aungst, 1999). Aplastic anemia is a major limitation to AZT therapy and 
usually necessitates blood transfusions of recombinant human erythropoietin to replenish 
erythrocyte levels, dose reduction and discontinuation of AZT therapy in severe cases 
(Bean, 1992; Hewitt et al., 1993; Dallas et al., 2000). Also, patients, especially those who are 
severely immunocompromised, are incapable of tolerating such high doses (Link, 1992), 
leading to non-compliance. The poor bioavailability as well as the associated side effects, 
the more common ones being headaches and nausea, experience commonly with higher 
doses, creates the need for localized drug delivery. Localized delivery would bypass the 
BBB and systemic circulation, which are responsible for poor bioavailability and many of the 
side effects experienced with current therapies (Bean, 1992; Alavijeh et al., 2005; Agarwal et 
al., 2010; Anderson and Power, 2010; Carvalho et al., 2010). 
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Figure 2.4: (a) Target sites of currently available ARV drugs (adapted from 
http://www.oyageninc.com/drugs, (14/092010). (b) Mechanism of action of NRTI’s (adapted 
from http://depts.washington.edu/hivaids/arvres/case3/discussion.html, (14/09/2010). 
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Table 2.3: ARV’s currently approved for utilisation in HAART (adapted from Warnke et al., 
2007; Ramautarsing and Ananworanich, 2010; cme.medscape.com/viewarticle/418820 
(21/06/2010); www.avert.org/aids-drugs-table.htm (21/06/2010); 
http://www.natap.org/2003/march/031703_2.htm (21/06/2010). 
     
Antiretroviral 
agent Trade name Class Manufacturer    FDA approval 
Zidovudine (AZT) Retrovir NRTI GlaxoSmith Kline March 1987 
Lamivudine 3TC NRTI GlaxoSmith Kline November 1995 
Zalcitabine (ddC) Hivid NRTI Roche June 1992 
Didanosine (ddI) Videx NRTI Bristol-Myers Squibb October 1991 
Stavudine (d4T) Zerit NRTI Bristol-Myers Squibb June 1994 
Abacavir Ziagen NRTI GlaxoSmith Kline December 1998 
Emtricitabine (FTC) Emtriva NRTI Gilead Sciences July 2003 
Efavirenz Stocrin NNRTI MSD September 1998 
Nevirapine Viramune NNRTI Boehringer Ingelheim June 1996 
Delaviridine Rescriptor NNRTI Pfizer April 1997 
Saquinavir Forto-vase PI Roche December 1995 
Ritonavir Norvir PI Abbott Laboratories March 1996 
Lopinavir Aluvia PI Abbott Laboratories September 2000 
Amprenavir Agenerase PI GlaxoSmith Kline April 1999 
Indinavir Crixivan PI MSD March 1996 
Nelfinavir Viracept PI Roche March 1997 
Atazanavir Reyataz PI Bristol-Myers Squibb June 2003 
Fosamprenavir Lexiva PI GlaxoSmith Kline October 2003 
Tipranavir Aptivus PI Boehringer Ingelheim June 2005 
Darunavir Prezista PI Tibotec Inc. June 2006 
Raltegravir Isentress Intergrase inhibitor Merck and Co., Inc September 2007 
Enfuvirtide Fuzeon Entry inhibitor Roche and Trimeris March 2003 
Maraviroc Selzentry Entry inhibitor Pfizer June 2007 
Tenofovir (PMPA) Viread NtRTI Aspen August 2008 
          
 
Direct injection of AZT into the spinal canal and by intracerebroventricular infusion has been 
shown to improve neurological function in patients with ADC (Link, 1992; Wang and Sawchu, 
1995). In a pilot study conducted by Routy et al., in 1989 and 1990, the effects of AZT was 
tested when administered orally and intrathecally. Patients were administered with 800mg of 
oral AZT daily, which was seen to have improved neurological function. However, therapy 
needed to be ceased due to haematological toxicity. With the end of AZT therapy, 
neurological function declined within months, necessitating AZT to be reinstated. The 
intrathecal route was used, resulting in an improvement in ADC symptoms, with doses as 
low as 50mg administered 12 hourly via a catheter implanted into the intrathecal sac of the 
spinal cord, in the absence of haematological side effects (Routy et al., 1990). This serves to 
support the need for localised therapy to manage AZT, however direct implantation of a drug 
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delivery device into the brain, capable of releasing drug over extended periods is anticipated 
to be preferable to twice daily injections into the spinal cord. AZT was originally thought to 
cross the BBB by means of active transport using a deoxynucleoside transport system, due 
to the structural similarity exhibited by AZT to the endogenous  nucleoside, thymidine. 
Thymidine actively transported into the CNS at the choroid plexus by means of the 
deoxynucleoside transport system (Sawchuk and Yang, 1999). Later studies have however 
revealed that thymidine does not cross the BBB. Research has now suggested that AZT is 
transported across the BBB and blood-CSF-interface by passive diffusion across 
transcellular pathways (Sawchuk and Yang, 1999).  
 
The accumulation of AZT within the CNS is hindered, however, by the presence of active 
efflux transports, such as P-gp, present on the luminal interface of the BBB and blood-CSF-
interface, which are responsible for the active transportation of AZT out of the CNS 
(Sawchuk and Yang, 1999; Gelperina et al., 2006; Varatharajan and Thomas, 2009). This is 
supported by the AZT steady-state brain extracellular fluid (ECF) or CSF:plasma ratio, 
described as per Equation 2.2 (Sawchuk and Yang, 1999).  
 
CLout
CLin
ssCp
ssCbr

,
,
                                  (Equation 2.2) 
 
Where Cbr,ss is the steady-state drug concentration in the brain ECF or CSF; Cp,ss  is the 
steady-state drug concentration in plasma; CLin is the influx clearance of drug and CLout is 
the efflux clearance of drug. Bulk flow rate of CSF and exchange between the CSF and brain 
ECF is assumed to be negligible when compared to efflux clearance. 
 
If passive diffusion is the only process governing AZT transport into and out of the CNS, a 
ratio of 1 is expected at steady-state. As this is not the case, the ratio at steady-state is less 
than 1, supporting the presence of active efflux transporters at the BBB and blood-CSF-
interface which are responsible for removing AZT out of the CNS faster than its entry. As 
AZT is minimally metabolised in the CNS, no other elimination mechanism is responsible for 
the ratio obtained (Wong et al., 1993; Sawchuk and Yang, 1999; Fox et al., 2002).  
 
Further supporting this theory of efflux is the coadministration of probenecid, a drug 
commonly used for the management of gout, acting as a competitive inhibitor of the efflux 
transporters governing AZT removal from the CNS. In a study conducted by Hedaya and 
Sawchuk, concomitant administration of probenecid in a rabbit model demonstrated a 
fourfold increase in the CNS:Plasma ratio (Hedaya and Sawchuk, 1989; Wong et al., 1993; 
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Sawchuk and Yang, 1999). Coadministration of probenecid has also been identified in a 
reduction in the hepatic glucuronidation of AZT, with a resultant increase in serum levels and 
t1/2 of AZT present in the body (McDermott et al., 1992). 
 
2.2 Nanotechnology: The Way Forward 
With mans‟ constant quest for superiority, emerges nanotechnology, a new multidisciplinary 
area of research and a rapidly growing area of science dedicated to the design, preparation 
and use of structures in the nanometer size range, being 1000nm and smaller (Sahoo et al., 
2003; Pison et al., 2006; du Toit et al., 2007; Park et al., 2007; Liu et al., 2008; Yang et al., 
2008; Singh et al., 2009; Suh et al., 2009; Silva, 2010). Nanotechnology enables the control 
and manipulation of basic characteristics of a material without changing the chemical 
composition. This is due to nano-sized materials possessing novel properties and functions 
that are markedly different from those of the identical bulk material (Park et al., 2007; Yang 
et al., 2008; Singh et al., 2009). The small size, customized surface, improved solubility and 
multi-functionality of nanomaterials makes nanotechnology a field applicable to all areas of 
science (Singh et al., 2009).  
 
The term nanotechnology was coined by K. Eric Drexler in the mid 1980‟s. Since then, the 
hype of nanotechnology has escaped no field, offering unique advantages to multiple 
disciplines with progress in drug delivery, sensing, imaging, cosmetics and electronics. $4 
million has been injected by the defense bill into research and development associated with 
nanomanufacturing. The National Nanotechnology Initiative (NNI), the leaders in 
nanotechnology research and development, was implemented in 2001 to control Federal 
nanotechnology research and development. The aim of the NNI is expedite the responsible 
discovery and development of nanotechnology with the ultimate goal being to improve 
national economy and quality of life of citizens in the United States of America (USA). The 
2010 USA budget supplied $1.6 billion to the NNI, serving to further fire the hype associated 
with nanotechnology (du Toit et al., 2007; Zhan and Liu, 2010). 
 
Michael Faraday first prepared colloidal gold particles in the nanometer size range more 
than 150 years ago (Park, 2007). Polymeric nanoparticles used for the controlled delivery of 
drug were first developed in the 1970‟s (Feijen et al., 2005). Nanotechnology was being 
used long before it was recognized as being a science, with popularity growing 
approximately 20-30years ago (Suh et al., 2009). It is estimated that in 2014, approximately 
16% of revenue related to healthcare products will incorporate nanotechnological 
interventions, with nanoenabled drug delivery systems generating approximately $ 4.8 billion 
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in 2012, making nanotechnology one of the fastest growing industries to date (du Toit et al., 
2007).  
 
2.2.1 Application in drug delivery 
Nanomedicine is a multidisciplinary medical application of nanotechnology that according to 
the National Institute of Health (NIH) Nanomedicine Roadmap Initiative refers to specialized 
medical intervention at the nanometer scale for the diagnosis, prevention and treatment of 
diseases (Park, 2007; Bennewitz and Saltzmann, 2009; Wang et al., 2009; Subbia et al., 
2010). Nanomedicine allows for the creation and manipulation of materials and devices with 
high therapeutic selectivity, promising to significantly improve healthcare and potentially 
revolutionalise the practice of medicine (Bennewitz and Saltzmann, 2009; Modi et al., 2009; 
Singh et al., 2009; Wang et al., 2009). Recent advancements in the area of 
nanopharmaceuticals, nanoscaled drug delivery systems and biological compounds, 
promises to enhance patient care due to the progress made with the diagnosis and 
treatment of disease states with the implementation of research conducted on nanomedicine 
(du Toit et al., 2007). 
  
Cancer remains the current market leader with regards to nanopharmaceuticals, attributed to 
the funding of $144 million infused into cancer research in the USA. Nanoenabled drug 
delivery systems allow for rapid drug absorption, controlled release of therapeutics, 
enhanced bioavailability, targeted delivery or therapeutics and a subsequent decline in 
systemic side effects, a considerable improvement to existing products (Reis et al., 2006; du 
Toit et al., 2007; Modi et al., 2009; Jolck et al., 2010; Zhang and Liu, 2010). This is of 
particular significance with chemotherapeutic agents due to the high concentrations of toxic 
substances utilized in chemotherapy. 
 
Drug incorporation into nanosystems is used to achieve site-specific drug delivery, therefore 
providing better control of drug release as observed in Figure 2.5. This improves the 
efficacy, pharmacokinetics and pharmacodynamics of the drug.  Targeted drug delivery 
improves the therapeutic efficacy of the drug, as well as resulting in a possible reduction in 
the quantity administered to achieve a therapeutic response and minimises side effects 
experienced due to drug therapy.  Drug delivery devices using nanosystems can be 
manipulated to react in a bioresponsive manner, to provide site-specific drug delivery and to 
control drug degradation.  Due to their small size and large surface area, nanoparticles are 
capable of opening tight junctions and are therefore capable of crossing the BBB (Roney et 
al., 2005; Rahman et al., 2009; Ghaderi et al., 2010; Jolck et al., 2010; Silva, 2010). 
Nanoenabled drug delivery systems are capable of interacting with biological systems at a 
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molecular level, enhancing bioavailability and therapeutic efficacy of the administered drug 
(Modi et al., 2009). Furthermore, the bioavailabilty of poorly soluble drugs is enhanced as 
nanoparticles can also be used as carriers for these drugs, with the small size and large 
surface area afforded by nanoparticles acting to solubilise the drug molecules (Pison et al., 
2006; Popovic and Brundin, 2006; Reis et al., 2006; Majuru and Oyewumi, 2009). 
 
 
 
 
Figure 2.5: Active drug targeting of surface modified nanoparticles depicting site specific 
release of drug molecules (adapted from Ganta et al., 2008). 
 
Nanotechnology enables the reformulation of existing pharmaceutical products with an 
improved pharmacokinetic and safety profile of the nanopharmaceutical, serving to decrease 
competition and increase revenue for pharmaceutical industries. New innovative 
pharmaceuticals can be developed and patented with the aid of nanotechnology, with the 
potential to manage complex disease states which previously challenged scientists such as 
cancer and neurological disorders. This also serves to increase profitability by 
pharmaceutical industries. The last decade has witnessed the development and release of 
several pharmaceutical products, highlighted in Table 2.4 (Reis et al., 2006; Du Toit et al., 
2007; Ganta et al., 2008; das Neves et al., 2009; Majuru and Oyewumi, 2009; Subbia et al., 
2010). AbraxaneTM (produced and marketed by American Pharmaceutical Partners and 
American Bioscience Inc.) was the first polymeric, protein-conjugated nanoenabled product 
approved by the FDA and available on the market in January 2005. Composed of the 
Intracellular pH dependent 
drug release 
Endocytosis 
Albumin modified 
nanoparticles 
Nucleus 
Albumin receptors 
Drug-loaded core 
Receptor mediated 
endocytosis 
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albumin-based chemotherapeutic, paclitaxel, with application as an injectable drug delivery 
system for the treatment of metastatic breast, AbraxaneTM was a milestone for nanomedicine 
and pharmaceutical scientists. Previous paclitaxel formulations required toxic solvents such 
as cremophor-EL, implicated in life-threatening allergic reactions, to solubilise the drug. 
AbraxaneTM is superior to Taxol®, the original paclitaxel injectable formulation, due to the 
exclusion of toxic solvents decreasing the incidence adverse effects experienced with 
paclitaxel therapy as well as negating the need for premedication with cortisone and 
antihistamines which were required to prevent and manage allergic reactions associated 
with Taxol® administration. Targeted delivery of the chemotherapeutic agent to the cancer 
cells also accounted for the decline in the incidence of systemic side effects occurring with 
AbraxaneTM use, despite a 50% increase in the administer paclitaxel dose. Greater retention 
of AbraxaneTM within the cancer cells and passive diffusion of the nanoparticles within the 
cells accounts for superior efficacy observed with AbraxaneTM as compared to Taxol® (Koo 
et al., 2005; du Toit et al., 2007).  
 
Nanoparticles utilized for medical interventions range between 10-1000nm, with drug 
molecules entrapped, surface adsorbed or chemically bound to the solid nanoparticulate (du 
Toit et al., 2007; Benewitz and Saltzmann, 2009; Modi et al., 2009). Numerous 
methodologies have been implemented for the preparation of nanoparticulates including: 
 
 Polymerisation reaction 
 Emulsion polymerization (employing single and double emulsion techniques) 
 Polymer dispersion 
 Supercritical fluid technology 
 Emulsification solvent evaporation 
 Ion induced crosslinking 
 Desolvation or solvent deposition 
 Electrospinning 
 Salting out 
 Denaturation of solvent droplets 
 Foam droplet separation 
 Microfluidic synthesis 
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Table 2.4: Available nanoenabled formulations on the market for application in drug delivery 
(adapted from Harris et al., 2004; Roumeliotis, 2006, www.in-
pharmatechnologist.com/Materials-Formulation/Abbott-ordains-Elan-to-marry-Tricor-and-
Crestor Ahmed 2007 (21/06/2010); Hawkins et al., 2008; Gardner et al., 2008; Kratz, 2008; 
www.nanotechproject.org/inventories/medicine/apps (21/06/2010) 
 
Product Manufacturer Nanosystem Product information 
AbraxaneTM American 
Pharmaceutical 
Partners, Inc (USA) 
Erlan‟s Nanocrystals 
 
•Drug delivery systems 
employing Erlan’s 
nanocrystal technology, 
developed and patented in 
1992, exhibit superior rate 
of dissolution and 
bioavailability  
•Nanocrystals are small 
drug particles produce by 
milling the drug utilising a 
proprietary wet-milling 
technique 
•The surface adsorption of 
stabilisers prevents 
agglomeration of the 
nanocrystals. 
A nancrystal aqueous 
colloidal dispersion of drug 
results which is applicable 
for all routes of 
administration (du Toit et 
al., 2007; Majura and 
Oyewumi 2009) 
 
•An injectable dosage form of 
the chemotherapeutic agent 
paclitaxel 
•Particles present with a mean 
particle size of approximately 
130nm 
•FDA approval: January 2005 
 
Megace® Par Pharmaceuticals 
Companies, Inc 
(USA) 
Erlan‟s Nanocrystals •Appetite stimulant 
•Used for weight loss in patients 
with AIDS 
•Demonstrates superior rate of 
dissolution and bioavailability to 
the original oral suspension 
•FDA approval: July 2004 
 
Doxil® ALZA Corporation 
(USA) 
Liposome •Chemotherapeutic agent used 
for the treatment of refactory 
ovarian cancer and AIDS related 
kaposi‟s sarcoma 
•First marketed product to 
incorporate STEALTH
®
 
technology 
•FDA approval: February 2005 
 
Emend® Merck &Co., Inc 
(USA) 
Nanocrystals •Anti-nausea drug intended for 
use in patients receiving 
chemotherapy 
•FDA approval: March 2003 
•Launched: April 2003 
 
Tricor® Abbott Laboratories 
(USA) 
Erlan‟s Nanocrystals •Cholesterol lowering agent 
used to reduce elevated plasma 
triglyceride concentrations 
•FDA approval: February 1998 
•Launched: December 2004 
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EstrasorbTM Novavax Inc (USA) Micelles •Topical lotion containing 
estrogen 
•Used for the management of 
moderate to severe vasomotor 
symptoms associated with 
menopause 
•FDA approval: October 2003 
 
Rapamune® Wyeth (USA) 
 
Erlan‟s Nanocrystals •Immunosuppressant 
•Employed as a prophylactic 
anti-rejection drug following 
renal transplants in patients 
aged 13 and older 
•FDA approval: August 2000 
 
Triglide SkyePharma and 
Sciele Pharma Inc 
(USA) 
Nanoparticles  
•Obtained by high pressure 
homogenisation 
•Oral fibrate capable of reducing 
elevated plasma concentrations 
of circulating triglycerides 
•FDA approval: May 2005 
• Launched: July 2005 
 
VivaGel Starpharma 
(Australia) 
Dendrimers •Vaginal microbicide for the 
prevention of sexually 
transmitted infections, including 
genital herpes and HIV 
•US-based NIH awarded 
Starpharma $20.3 million for the 
continued development and 
testing of VivaGel against HIV 
•FDA approval: January 2006 
 
Ambisome Astellas Pharma US, 
Inc and Gilead 
Sciences, Inc (USA) 
Liposomes •Broad spectrum injectable 
antifungal agent 
•Approved for the treatment of 
cryptococcal meningitis, 
aspergillosis and candida in 
patients refractory or intolerant 
to conventional Amphotericin B 
•FDA approval: August 1997 
 
Amphotec Three Rivers 
Pharmaceuticals 
(USA) 
Liposomes •Amphotericin B complex for 
injection 
•Indicated for the treatment of 
invasive aspergillosis, a 
systemic fungal infection 
•FDA approval: November 1996 
 
Abelcet Enzon 
Pharmaceuticals, Inc 
(USA) 
Liposomes •Injectable broad spectrum 
antifungal agent 
•Approved for the treatment of 
invasive fungal infection in 
immunocompromised patients 
refractory or intolerant to 
conventional Amphotericin B 
•FDA approval: November 1995 
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2.2.2 Benefits of nanoscale drug carriers  
 Superior drug stability at the desired site of action. 
 Biocompatibility and biodegradability of the device are ensured. 
 Site-specific drug targeting can be achieved. 
 Entrapped drug molecules are protected from premature degradation in body fluids. 
 Controlled release of drug molecules can be achieved through manipulation of the 
polymeric structure. 
 Nanotechnology enables safe and effective administration of therapeutic agents which 
were previously difficult to administer due to toxic systemic effects. 
 Nanoenabled drug carriers demonstrate superior bioavailability and rapid onset of action. 
 Lower drug doses can be administer resulting from an increased therapeutic index of the 
administered drug and reduced clearance from the body. 
 Nanoparticles are capable of targeted delivery of drug due to the preferential 
accumulation of drug at the desired site of action, thereby reducing systemic toxicity. 
Targeted drug delivery also allows for treatment of the source of the disease instead of 
management of the symptoms of the disease, as drug accumulation in healthy tissue is 
minimised. 
 Nanoparticles can penetrate the tiniest capillary vessels attributed to their nanoscale 
size. 
 Prolonged residence time in the blood stream and at the site of action due to reduced 
uptake by the reticular-endothelial system. 
 They are capable of controlled release of drug, depending on the materials used to 
prepare the nanoparticles. 
 Nanoparticles are capable of high drug loading due to small size and large surface area. 
 Nanoparticles allows for the delivery of water-insoluble drugs as the large surface area 
afforded to the drug molecules enhances drug solubility and dissolution. 
 Nanoenabled drug delivery systems enables the extension of expiring patents with the 
potential to capitalize on the benefits afforded to the nanoenabled system. 
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2.3 The Blood Brain Barrier: The Ultimate Hurdle to CNS Drug Delivery 
The BBB is a membranous homeostatic defence mechanism formed by tight endothelial cell 
junctions, perivascular astrocytes and blood capillaries in the brain separating the brain from 
systemic blood circulation. The BBB physically and metabolically protects brain tissue 
enforcing barrier selectivity for the movement of substances into and out of the brain 
parenchyma, depending on size and endothelial permeation of the molecules, providing a 
stable environment for neuronal activity and protecting the brain from exogenous toxicants, 
pathogens and immunogens. However the BBB provides a challenge to drug delivery 
scientists as clinically significant drug concentrations within the brain is difficult to achieve 
with limited pathways allowing drug access into the brain (Pardridge, 1995; Sawchuk and 
Yang, 1999; Fox et al., 2002; Misra et al., 2003; Lemaire and Desrayaud, 2005; Popovic and 
Brundin, 2006; Hu et al., 2009; Modi et al., 2009; Wang et al., 2009; Georgieva et al., 2010). 
 
Blood capillaries make up 95% of the total surface area of the BBB. However, the blood 
capillaries present in the brain are structurally different to capillaries present in other tissue. 
Capillaries have a smaller diameter and thinner walls, with a higher mitochondrial density 
then other capillaries. The lack of small pores and intracellular fenestrations and more than 
99% of brain capillaries contains high resistance tight junctions between endothelial cells, 
paucity of endocytic vesicles and active transport systems restricting the movement of 
exogenous water soluble molecules into the CNS. The movement of solutes must therefore 
pass directly through the endothelial membrane, transcellular and intracellular movement, to 
gain access into the brain (Pardridge, 1995; Bodor and Buchwald, 1999; Sawchuk and 
Yang, 1999; Prokai et al., 2000; Misra et al., 2003; Varatharajan and Thomas, 2009). 
 
As the BBB is a bilayered lipid structure, 98% of small drug molecules and almost 100% of 
large drug molecules cannot cross the BBB, with only small lipophilic molecules with a 
molecular mass less than 400Da, capable of freely diffusing through the endothelial 
capillaries by means of passive diffusion (Pardridge, 1995; Misra et al., 2003; Lemaire and 
Desrayaud, 2005; Hu et al., 2009; Modi et al., 2009). Exogenous hydrophilic substances are 
allowed entry into capillary cells by various mechanisms. Paracellular movement of 
molecules between endothelial cells, facilitated or passive diffusion across cells, endocytosis 
and active transport directly across cells all enable the entry of drug molecules into the cells 
outside the CNS as highlighted in Figure 2.6. Active influx transporters present on the 
endothelium of blood vessels were first discover in 1946 by Krogh, who recognised that 
glucose entered the brain despite being a highly water soluble molecule. However, active 
efflux transporters are also present at the BBB, functioning to prevent or remove drug 
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molecules such as AZT, which is removed from the brain by MRPs, an ATP-driven efflux 
transporter. Substances that cross into the brain are also exposed to enzymatic degradation 
by the large mitochondria density within the endothelial cells as mentioned above (Bodor 
and Buchwald, 1999; Sawchuk and Yang, 1999; Lemaire and Desrayaud, 2005; 
Varatharajan and Thomas, 2009). 
 
Novel drug delivery systems are therefore required to circumvent the restrictions of the BBB, 
thereby enhancing the delivery of therapeutics to the brain to effectively manage 
neurological diseases. 
 
 
Figure 2.6: Schematic of (a) a normal capillary as compared to (b) a brain capillary, 
illustrating the mechanisms of drug entry into the capillaries (adapted from Misra et al, 2003).  
 
2.4 Drug Delivery for the CNS 
Over 1 billion people are plagued by CNS disorders worldwide. Several new approaches are 
currently being explored in an attempt to enhance drug delivery to the CNS. Lipophillic 
prodrugs, efflux pump inhibitors, transient hyperosmolar BBB “opening” by intracarotid 
arterial administration of a hypertonic solution, intranasal brain-targeting, circumvention of 
the BBB through direct drug delivery into the ventricles or cortex of the brain by direct 
injection or implantation and immune liposome drug delivery systems are but a few 
examples of such methods (Misra et al., 2003; Gelperina et al., 2006; Fiandaca et al., 2008; 
Benewitz and Saltzman, 2009; Varatharajan and Thomas, 2009; Hartz and Bauer, 2010). 
However, of these methods, drug encapsulation within non-toxic polymeric nanomaterials is 
the most popular means of enhancing drug delivery to the CNS (Bennewitz and Saltzman, 
2009; Modi et al., 2009; Varatharajan and Thomas, 2009; Wang et al., 2009).  
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The BBB is the most important constraint to the design and development of neurotherapeutic 
agents, due to the limited penetration of pharmaceuticals presented by the BBB creating an 
obstacle to CNS drug delivery (Lemaire and Desrayaud, 2005; Pardridge, 2005; Modi et al., 
2009). CNS conditions, including brain tumors, HIV encephalopathy, neurodegenerative 
diseases, epilepsy and cerebrovascular disease, remains the leading cause of disability and 
hospitalizations in the world, with more people are living with CNS disorders than with 
cardiac disorders, however, the global CNS market for therapeutic agents require a growth 
of approximately 500% to equal the global cardiac market (Misra et al., 2003; Pardridge, 
2005). Innovative solutions for the delivery of neurotherapeutics into the CNS are therefore 
required, with nanotechnology offering potential solutions to some of these constraints. The 
entry of systemical administered drugs is inhibited by the BBB, rendering existing therapeutic 
agents ineffective for the management of CNS conditions as therapeutically viable drug 
concentrations cannot be sustained with the CNS. Nanotechnology allows for the 
development of nanoenabled drug delivery systems capable of managing CNS disorders as 
the size limitations posed by both the BBB and neural tissue is accounted for (Misra et al., 
2003; Saito et al., 2005; Modi et al., 2009). 
 
Polymeric nanoparticles are capable of opening tight junctions in the BBB. Modification of 
particle size to 50nm and less as well as manipulation of surface charge of nanosystems 
enables penetration of drug molecule through BBB and distribution within the brain. The long 
blood circulation exhibited by nanoparticles potentially increases drug uptake into the CNS 
due to larger concentrations of drug-loaded nanoparticles present at the BBB  (Modi et al., 
2009; Muthu et al., 2009; Suh et al., 2009). Nanoparticles are currently being extensively 
researched for the diagnosis and treatment of CNS conditions including neurodegenerative 
diseases such as Parkinson‟s disease, Alzheimer‟s disease and ADC. Nanoparticles need to 
be sufficiently small, approximately 50nm, to cross the brain interstitial space, and require a 
surface charge which is either neutral or negative to attain a large volume of distribution 
within the brain (Thorne et al., 2006; Bennewitz and Saltzman, 2009; Modi et al., 2009). Due 
to their small size, enhanced stability, large surface area and surface charge, which can be 
manipulated to evade recognition by the reticuloendothelial system (RES), nanoparticles 
translocate to the CNS and cross the BBB (Rahman et al., 2009). They are also capable of 
controlled, targeted drug delivery and are ideal for the delivery of ARV‟s, such as AZT, into 
the brain (Pardridge, 2005). 
 
Poly(butylcyanoacrylate) (PBCA) nanoparticles coated with polysorbate 80, approximately 
250nm in diameter, is currently the only successful drug-loaded nanoparticulate system 
utilized for in vivo delivery of drug into the brain. PBCA nanoparticles adsorbed plasma 
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apolipoproteins post intravenous administration and is confused for low density lipoproteins, 
therefore crossing the BBB by receptor-mediated endocytosis (Modi et al., 2009). 
Polyethylene glycol-coated liposomes were prepared for the delivery of chemotherapeutics 
into the brain (Varatharajan and Thomas, 2009). Carbon nanofibres has shown promise as 
nerve regenerative agents attributed to the high conductivity observed which enhances 
nerve function and regeneration using electrical stimulation. The small size and mechanical 
strength of the fibres enables good conductivity which has been implicated in decrease 
foreign body reaction in response to the presence of these fibres in the body (McKenzie et 
al., 2004). Brain imaging techniques employing solid lipid nanoparticles has displayed 
potential to enhance MRI images obtained of the brain. Insoluble iron oxide molecules 
complexed with nanoparticlesto enable entry into the CNS allowing iron oxide use as super-
paramagnetic MRI contrast agents, revolutionalising brain imaging (Modi et al., 2009). 
 
Polymers such as polyglycolic acid, polyethylene glycol and polylactic acid, are commonly 
used to prepare intracranial implants. Chemotherapeutic agents are commonly delivered 
using polymeric intracranial implants, with polyethylene-co-vinyl acetate, a nonbiodegradable 
polymer, used previously for such a purpose. Limitations to nonbiodegradable implants are 
that they are permanent fixtures in the brain which are capable of eliciting a foreign body 
response, requiring further surgery for their removal (Bennewitz and Saltzman, 2009). 
However, biodegradable, biocompatible polymers have been chosen for the of the drug 
delivery device developed in this study, negating the need for further surgery after 
implantation of the device. Implantation of an AZT-loaded device into the brain alleviates 
problems associated with systemic drug delivery, such as systemic toxicity, drug metabolism 
in the systemic circulation and opsonisation by blood protein (Bennewitz and Saltzman, 
2009; Narishetty and Panchagnula, 2004).  
 
Polymeric nanoparticles are easy to scale up and are cost effective making them suitable 
drug carriers for CNS therapeutic agents (Wang et al., 2009; Modi et al., 2009). 
Nanoparticles dispersed within an implantable multipolymeric scaffold is therefore being 
explored in this research for intracranial implantation to manage ADC as localised delivery 
has been proven to enhance therapeutic efficacy of the administered drug a reduction in the 
incidence of system adverse effects.  
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2.5 Concluding Remarks 
The wide-spread use of HAART has shifted the focus of HIV from and acute condition to a 
chronic disease. This inturn has increased the prevelance of ADC among HIV sufferers. A 
neurological condition affecting both adults and children, ADC has been responsible for 
severe dementia and paralysis of individuals not adequately treated.  
 
Current therapeutic regimens have demonstrated poor management of the neurological 
manifestations of HIV due to the restrictions posed by the BBB. As the BBB poses as a 
resevior for the HI virus, drug penetration into the brain is imperative for the effective 
management of ADC.  
 
The era of nanotechnology is upon us. The implementation of this novel technology for the 
development of a localised nanoenabled drug delivery system for the management of ADC 
could herald revolutionary advances for the future treatment and management of HIV/AIDS 
and ADC. 
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CHAPTER 3 
 
Preparation and Evaluation of a Multipolymeric Nano-Enabled 
Configuration 
 
3.1. Introduction 
The National Science Foundation in the United States of America (USA) estimates that by 
2015, the annual global market for nanotechnological-related goods and services will reach 
$1 trillion. It has also been estimated that by 2014, 16% of healthcare and life sciences 
related commodities will incorporate nanotechnology, making it one of the fastest growing 
industries in history, and an exceptionally large economic force (du Toit et al., 2007).  
 
Nanotechnology offers much promise for the enhancement of disease diagnosis, 
management and prevention (Ganta et al., 2008; Subbia et al., 2010). Nanocarriers include 
a range of products, with biodegradable polymeric nanoparticles, lipid liposomes, micelles 
and nanocrystals being just a few. Organic and inorganic materials are used for the 
preparation of these products, illustrated in Table 3.1 below (Sahoo and Labhasetwar, 2003; 
du Toit et al., 2007; Ganta et al., 2008).  
 
Biocompatible and biodegradable polymers have been researched extensively for the 
formulation of novel drug delivery systems, as illustrated in Table 3.4 (Hughes, 2005, 
Rezwan et al., 2006). This study therefore employed degradable, biocompatible, non-
mutagenic, non-cytogenic, and non-teratogenic for the preparation of nanoparticles and 
multipolymeric scaffolds. The byproducts of these polymers are nontoxic and readily 
excreted from the body (Liu et al., 2005; Popovic and Brundin, 2006; Rezwan et al., 2006). 
They possess desirable mechanical properties and superior drug permeability and are 
therefore safe for use in the human body (McKenzie et al., 2003; Liu et al., 2005; Luong-Van 
et al., 2006; Popovic and Brundin, 2006; Rezwan et al., 2006).  
 
Nanoparticles were prepared using two methods, the salting out approach and the controlled 
gelification of alginate approach. Nanoparticles were dispersed within a multipolymeric 
scaffold, prepared by means of polymer crosslinking, to obtain a drug delivery device 
capable of sustained drug release over prolonged periods. The antiviral agent, AZT was 
employed as the test drug.  
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Nanosystem Description of nanosystem Method of drug entrapment Illustration of 
nanosystem 
References 
Polymeric 
Nanoparticles 
 
 
 
 
 
 
 
 
 
Nanoparticles 
 
 
 
 
 
Nanocapsules 
 
 
 
Nanospheres 
•Formulated from biodegradable polymers in 
an attempt to increase circulating the half life 
of the entrapped drug and to evade uptake 
by the reticuloendothelial system 
•Superior stability in biological fluids and 
under storage conditions 
•Easy preparation methodology 
•Sustained and controlled drug release 
 
•Colloidal particles 
 
 
 
 
 
•Vesicular systems 
 
 
 
•Matrix systems 
•Protects drug from premature 
degradation and prevents drug 
toxicity 
 
 
 
 
 
 
•Drug entrapment within the polymer 
matrix. Drug can be 
dissolved/dispersed within the 
nanoparticles or  attached to the 
surface 
 
•Drug entrapment within a  
cavity surrounded by a  
polymer membrane 
 
•Uniform dispersion of drug  
within the matrix 
 
 
 
•Sahoo and 
Labhasetwar, 2003 
•Reis et al., 2006 
•Benewitz and 
Saltzman, 2009 
     
  
     
Drug 
Table 3.1: Nanoparticulates currently under investigation for in vivo drug delivery, diagnostics and imaging 
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Table 3.1: continued 
Polymeric 
Micelles 
•Self-association of amiphillic    copolymers 
to form spherical supramolecular core-shell 
structures in aqueous systems, with 
hydrophobic interactions driving the 
assembly of the amiphiles 
•Narrow size distribution (20-100nm), 
allowing for prolonged circulation in the blood 
as RES uptake and renal excretion is 
avoided 
•Thermodynamic stability in  
physiological environments due to  
low critical micelle concentrations 
•Distinctive core-shell architecture   
(hydrophobic inner with an aqueous  
exterior)  
•Unique properties including high solubility, 
high drug loading capacity and low toxicity 
 
•Hydrophobic drugs are partitioned 
in the inner hydrophobic core 
•Outer hydrophilic surface serves to 
stabilise the micelle in aqueous 
environments 
 
 
 
 
 
 
 
•Sahoo and 
Labhasetwar, 2003 
•Koo et al., 2005 
•Du toit et al., 2007 
•Ganta et al., 2008 
•Benewitz and 
Saltzman, 2009 
Liposomes •Spherical bilayered phospholipid vesicles 
formulated from natural non-toxic 
phospholipids and cholesterol, with an inner 
aqueous core 
•Properties similar to plasma membranes 
•Range in diameter between 50nm-1µm 
•Contains hydrophilic and hydrophobic 
properties 
•Hydrophobic and amiphillic drug are 
incorporated into the lipid bilayer and 
hydrophilic drugs are incorporated 
into the aqueous core 
•Drug encapsulation within the 
liposome protects against premature 
degradation and avoids drug toxicity 
 
 
 
  
 
•Sahoo and 
Labhasetwar, 2003 
•Koo et al., 2005 
•Ganta et al., 2008 
•Benewitz and 
Saltzman, 2009 
     
  
 
  
     
Hydrophobic 
inner core 
Drug 
Inner aqueous 
core Bilayered  
phospholipid vesicle 
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Table 3.1:  continued 
Dendrimers •Synthetic macromolecules of nanometer 
dimension with  well defined architecture 
•Polymeric monomers which form spherical 
branched tree-like structures with an inner 
core (1-10nm in diameter) 
•Application as a coating agent for targeted 
rug delivery 
•Good control of polydispersity and the ability 
to display high surface functionality 
•Good aqueous solubility 
•Drug encapsulation within the inner 
core by inubation 
•Drug attachment to the outer 
surface branches by the formation of 
covalent or noncovalent bonds 
•Dendrimer-drug networks can form 
 
 
 
 
 
 
 
•Sahoo and 
Labhasetwar, 2003 
•Koo et al., 2005 
•du toit et al., 2007 
•Ganta et al., 2008 
•Benewitz and 
Saltzman, 2009 
Quantum Dots •Semi-conductor nano-sized crystals with 
unique photochemical and photophysical 
properties 
•2-10nm in diameter, with fluorescence 
emission achieved between 400-2000nm 
•Photostability of quantum dot probes 
enables continuos real-time tracking of 
molecules over extended periods, with 
researchers having observed quantum dots 
in the lymph nodes of mice over 4months 
•Ekiove and Elros first proposed the 
concept of quantum confinement of 
charge within a nanometer size 
range in 1982 
•In 1998, Alivisatos and Nie 
conjugation of quantum dots with 
biological molecules as well as water 
solubility of quantum dots, enabling 
application for optical imaging 
•Enhanced stability and brightness 
as compared to organic dyes and 
fluorescent proteins 
 
 
•Murray et al., 2000 
•Dahan et al., 2003 
•Bailey et al., 2004 
•Ballou et al., 2004 
•du toit et al., 2007 
•Ghaderi et al., 2010 
•Kato et al., 2010 
Carbon 
Nanotubes 
•Benzene rings assembled in a tubular 
structure, exhibiting chemical and 
mechanical stability and low cytotoxicity 
•Outer walls can be chemically modified to 
for targeted drug delivery 
•Single-walled CNT‟s range in diameter 
between2-5nm, with their aggregates 
matching the conditions to achieve enhanced 
permeability and retention effects 
 
•Drug attachment to the sides of the 
nanotubes or within the lumen of the 
tube 
•Capable of slow drug release 
 
 
 
•Ajima et al., 2005 
•Benewitz and 
Saltzman, 2009 
 
Core 
Branched tree-like 
structures 
Carbon fullerene rings 
http://www.networlddirectory.com/blogs/
permalinks/5-2008/pressure-effects-on-
nanomaterials.html, 14/09/2010) 
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3.2 Materials and Methods 
3.2.1 Materials 
Alginate, pectin, polyethylene oxide (PEO), polyvinyl alcohol (PVA) and  sodium 
carboxymethyl cellulose (NaCMC), were purchased from Sigma (St Louis, USA), epsilon 
caprolactone (ECL) and polycaprolactone (PCL) were purchased from Sigma-Aldrich (St 
Louise, MO, USA), and utilised to synthesize nanoparticles and the polymer scaffold. 
Calcium chloride, aluminum chloride and sodium thiosulphate salts (Sigma, St Louis, USA) 
were used as crosslinking agents in the synthesis of nanoparticles and the polymer scaffold.  
 
3.2.2 Preparation of Nanoparticles 
3.2.2.1 The salting out approach 
The first attempt to prepare nanoparticles employed a salting out approach, whereby a 
polymeric dispersion was formed by agitating a 0.8% pectin solution (50mL) with a 24%w/v 
zinc sulphate solution (ZnSO4) containing 0.6g polyvinyl alcohol (PVA) (75mL), which was 
used as the salting-out reagent. The rapid addition of deionised water to the polymeric 
dispersion induced the formation of nanoparticles, after which nanoparticles were lyophilised 
for 24 hours. For AZT-loaded nanoparticles, the drug was dissolved in the pectin solution 
prior to addition of the crosslinking solution. 
 
3.2.2.2 The controlled gelification of alginate approach 
Calcium (Ca2+)-alginate gel is frequently used as a drug delivery vehicle (Liu et al., 2008; 
Sriamornsak et al., 2007). Rajaonarivony et al. (1993) developed a method for the 
preparation of alginate nanoparticles using a novel cation induced pre-gelation of alginate 
approach in 1993. This method has been adapted by many scientists since, with chitosan 
being used instead of poly-L-lysine, a cationic natural polymer which is toxic and 
immunogenic if injected, to prepare alginate nanoparticles. These nanoparticles were used 
as carrier of a variety of drugs, including insulin, chemotherapeutics, as well as the 
hydrophobic antihypertensive agent, Nifedipine (Zahoor et al., 2005; Douglas et al., 2006; 
Zahoor et al., 2006; Li et al., 2007; Sarmento et al., 2007; Li et al., 2008; Liu et al., 2008). 
 
Nanoparticles were prepared by the ionotropic gelification of anionic sodium alginate 
(0.6%w/v) (200mL) with cationic calcium chloride (CaCl2) (10mL), after which a 0.5%
w/v pectin 
solution (40mL) was added to the Ca2+-alginate gel, to form a stable nanoparticle colloidal 
system. The crosslinked solution was then rapidly stirred for 1hour, centrifuged (Optima® LE-
80K, Beckman, USA) at 20 000rpm for 15minutes. The supernatant was then removed and 
freeze dried for 24hours at 25mtorrs (Virtis, Gardiner, NY, USA) to obtain a free flowing 
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powder, after having refrigerated the sample at -70°C (name of freezer, city, country). AZT-
loaded nanoparticles were prepared similarly, with 0.3g of AZT dissolved in the alginate 
solution prior to CaCl2 addition to enable encapsulation of the drug within a polymeric core.  
 
In an attempt to explore the effects of formulation variables on the size and stability of the 
prepared nanoparticles, preliminary modifications to the above mentioned method were 
investigated. Barium chloride (BaCl2) was used as the cationic crosslinking agent in one 
formulation and the other was prepared employing CaCl2 as the crosslinking agent, with the 
exclusion of pectin. A decreased rate of addition of CaCl2 and pectin was also explored in an 
attempt to decrease particle size, as illustrated in Table 3.2 below. 
 
Table 3.2: Independent variables investigated for the influence on particle size and zeta 
stability 
 
Formulation Independent Variable 
1 Crosslinking agent: CaCl2 
2 Decreased rate of pectin and CaCl2 addition 
3 Exclusion of pectin from the formulation 
4 Crosslinking agent: BaCl2 
  
 
3.2.3 Preparation of Polymeric Scaffolds 
3.2.3.1 Multipolymeric scaffolds prepared employing hydrophilic polymers 
Polymer scaffolds were prepared by mixing NaCMC (3%w/v, 100mL), PEO (1%
w/v, 100mL) 
and ECL (5%w/v, 100mL) solutions until a homogenous mixture was obtained, after which 
7.265g of alginate nanoparticles loaded with zidovudine (AZT) were dispersed within the 
multipolymeric solution. The polymeric mixture, in 5mL increments, were then placed into 
Teflon moulds (measuring 15mm in diameter and 20mm in height) lubricated with liquid 
paraffin, containing 2mL of a 10%w/v aluminium chloride (AlCl3), calcium chloride and sodium 
thiosulphate (Na2S2O3) crosslinking solution. The mixture was left to crosslink for 30minutes, 
after which the resultant scaffolds were removed and left to dry at ambient temperature 
(25°C).  
 
NaCMC-PEO-ECL crosslinked scaffolds were then agitated in a 1%v/v hydrochloric acid 
(HCl) solution for 15minutes. This was done in an attempt to reduce the swelling behavior of 
the scaffold, thereby improving erosion and drug release.   
 
 
 
 46 
 
3.2.3.2 Aliphatic polyester multipolymeric scaffolds 
Polymeric scaffolds were prepared by dissolving 20g of PCL in 100mL of acetone, followed 
by dissolution of 0.5g of AZT in the polymeric solution, after which the solution was poured 
into moulds lubricated with liquid paraffin and left to dry at ambient temperature for 48hours, 
with the scaffold forming upon evaporation of the acetone. 
 
Multipolymeric scaffolds were prepared by individually dissolving aliphatic polyesters PCL 
(20g) and ECL (20g) in 100mL of acetone. These solutions were then agitated until a 
homogenous mixture was obtained, in which AZT was dissolved. 
 
A second set of formulations were prepared with varying concentrations of PCL and ECL 
dissolved in acetone and crosslinked with a variety of CaCl2 solutions as per Table 3.3.  
 
Table 3.3: Formulation variables employed for the preparation of multipolymeric aliphatic 
polyester scaffolds. 
 
Formulation 
variables 
Lower 
limits 
Upper 
limits 
PCL (%w/v) 2.5 40 
ECL (%w/v) 5 50 
CaCl2 (%
w/v) 0 10 
   
 
3.2.4 Determination of polymeric structural variations incurred during 
nanoparticle and scaffold formation employing Infrared spectroscopy 
Fourier Transform Infrared (FTIR) spectroscopy was utilized to assess possible structural 
transitions which had occurred during the preparation process by comparing the functional 
groups of the parent compounds with that of the formulations produced. Polymer, 
nanoparticle and scaffold samples were analysed using a Perkin Elmer FTIR Spectrometer 
(Spectrum 100, Beaconsfield, United Kingdom). Spectra are recorded over the range 4000-
625cm-1, with a resolution of 4cm-1 and 32 accumulations. 
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Polymer Source Background Chemical Structure Reference 
Alginate •Natural polysaccharide 
•Algal origin 
•Forms insoluble gels in the presence 
of bivalent calcium (Ca
2+
) ions and 
other multivalent metals by binding to 
the carboxylic groups of adjacent G 
units in the polymer 
 
•Bajpai et al., 2004 
•Douglas et al., 2006 
•Liu et al., 2008 
•Sriamornsak et al., 2007 
Pectin •Natural polysaccharide 
•Plant origin 
•Derived from the aqueous 
extraction of edible plants 
•α-(1→4)-D-galacturonic acid residues 
in a linear arrangement,  
•Like alginaite, pectin forms gels in the 
presence of Ca
2+
 ions, sugars and 
acids 
 
O
O
OH
OH
OH
O
O
O
OH
OH
OH
O
O
OH
OH
OH
O
 
•Guo et al., 1998 
•Liu et al., 2003 
•Liu et al., 2008 
•Lee et al., 2009 
•Song et al., 2009 
NaCMC •Plant polysaccharide 
•A carboxymethyl ether of 
cellulose 
•Present in the fibrous tissue 
of all plants 
•A highly water soluble polymer 
•Attributed to the introduction of 
sodium carboxymethyl groups into the 
cellulose molecule 
•This is achieved by the etherification 
of the hydroxyl groups of the 
glucopyranose unit 
 
O
O
O
OH
OH
CH2
O
CH2
OH
OH
O
CH2
CO2-Na+
O
CH2
CO2-Na+
n
 
•Guo et al., 1998 
•Biswal et al., 2004 
•Pushpamalar et al., 2006 
•Rokhade et al., 2006 
•Yuan et al., 2009 
PEO •A semi-crystalline polymer • Hydrophillic hydroxyl (OH) groups 
present in the molecule, allowing for 
bioadhesivity and mucoadhesivity of 
the polymer 
• Swells and form a gel layer upon 
exposure to water 
•Controlled drug release is achieved 
due to this propensity of PEO to swell 
attributed to retarded erosion of the 
formulation 
 •Crowley et al., 2002 
•Maggi et al., 2002 
 
  
 
Table 3.4: Source and background of polymer used for the preparation of nanoparticle and scaffold formulation 
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Table 3.4: continued 
PVA •Synthetic, hydrophilic 
polymer 
•Demonstrates good emulsification 
and adhesive properties 
•Poor stability in water, requiring 
copolymerisation to reduce its 
solubility in aqueous systems 
OH
n
 
•Sudhamani et al., 2003 
•Sanli et al., 2007 
ECL & 
PCL 
•Synthetic, semi-crystalline, 
aliphatic polyester 
•PCL is prepared by the ring-
opening polymerisation of 
ECL 
•PCL is water insoluble, however ECL 
demonstrates  aqueous solubility 
 •Commonly employed for the 
preparation of bone implants, 
sustained drug delivery devices and 
tissue-engineering scaffolds 
•Demonstrates slow in vivo 
degradation (more than a year) post 
implantation in the absence of an 
acidic environment 
•Superior drug permeability, with 
various catergories of drug having 
been encapsulated within PCl/ECL 
drug delivery devices 
•Degradation products naturally 
present in the human body with 
excretion occurring through the natural 
metabolic pathways 
 
 •Tarvainen et al., 2002 
•Jeong et al., 2003 
•Huang et al., 2004 
•Sinha et al., 2004 
•Liu et al., 2005 
•Luong-Van et al., 2006 
•Rezwan et al., 2006 
•Uto et al., 2008 
•Abbah et al., 2009 
•Chang et al., 2009 
•Cameron et al., 2010 
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3.2.5 Morphological characterisation of nanoparticle and scaffold formulations 
3.2.5.1 Transmission electron microscopy 
Nanoparticles were dispersed in methanol and sonicated to deflocculate the particles. The 
samples were placed on carbon grids and analysed using transmission electron microscopy 
(TEM) (JEOL 1200 EX, 120keV) and photomicrographs were obtained to study the size and 
morphology of individual particles produced. 
 
3.2.5.2 Scanning electron microscopy 
Scanning electron microscopy (SEM), (JEOL, Tokyo, Japan) was employed for observation 
of the surface morphology of the multipolymeric scaffolds. Samples were coated with carbon 
and gold-palladium for 10minutes, after which they were visualized between 5-9keV under 
different magnifications. Photomicrographs were obtained at various magnifications and 
analyzed for description of the surface morphology. The degree of polymer entanglement, 
network density and porosity of the scaffolds was qualitatively determined using the 
photomicrographs obtained. 
 
3.2.6 Assessment of nanoparticle size and zeta potential 
A ZetaSizer Nano ZS (Malvern Instruments Ltd, UK) was utilized to determine the average 
sizes and size distribution of the nanoparticles, employing non-invasive back scatter (NIBS) 
technology with particle size distribution determined using dynamic light scattering. Brownian 
motion was measured and related to particle size. The Stokes-Einstein equation (Equation 
3.1) was used to determine the translational diffusion coefficient (D), which defines the 
velocity of Brownian motion. D depends on size of the particle core and the surface 
structures on the particle and the concentration and type of ions in the medium. Particle size 
is calculated using the translational diffusion coefficient (Malvern Instruments Ltd). 
  
DkHd 3/)(                              (Equation 3.1)                 
 
Where: d(H)=hydrodynamic diameter  
                  D=translational diffusion coefficient 
                  k=Boltzmann‟s constant 
                  T=absolute temperature 
                  η=viscosity 
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The advantages of NIBS technology are: 
• The laser does not have to travel through the entire sample, reducing the effect of multiple 
scattering, whereby the light from one particle is scattered by another particle. 
• The effects of dust present in the sample are greatly reduced as dust scatters light in the 
forward direction. 
 
Mean size (Z-average) and the width of the distribution, also known as the polydispersity 
index (PDI), is obtained from the correlation function. The correlation function determines the 
time it takes for the signal to decay (www.malvern.com).  
 
Zeta potential (ZP) studies were performed to determine overall surface charge distribution 
and stability of the nanoparticle systems. Laser Doppler velocimetry and phase analysis light 
scanning (PALS) technology was employed to determine zeta potential. ZP is a physical 
property which is exhibited by any particle in a colloidal system. ZP is used to assess the 
stability of the system and is calculated from the electrophoretic mobility. This is produced by 
fluctuations of light intensity when an electric field is applied to the sample 
(www.malvern.com).  
 
The DVLO theory developed in the late 1940‟s by Derjaguin, Verwey, Landau and Overbeek, 
suggests that the stability of a colloidal system is determined by the sum of the van der 
Waals attractive forces and the repulsive forces present in the electrical double layer, 
existing between particles as they approach each other due to Brownian motion. Repulsion 
between particles prevents particles from adhering together due to the existence of energy 
barriers between the particles. However collisions which occur with sufficient energy to 
overcome this barrier will be pulled together by attractive forces and will resultantly 
irreversibly adhere to each other. These colloidal systems therefore present with low zeta 
potential values. However, particles with sufficiently high repulsive forces will overcome 
flocculation due to adhesion, with a stable colloidal system prevailing. 
 
3.2.7 Textural profiling to determine the physicochemical behavior of 
crosslinked scaffolds 
Textural profiling of the 3D core of the crosslinked scaffolds enables characterisation of the 
physicomechanical properties of the prepared scaffolds. A TA.XTplus Texture Analyzer 
(Stable Micro Systems, Surrey, UK) was employed to establish various stress-strain 
parameters of the polymeric scaffolds. Samples in both the hydrated and unhydrated states 
were assessed. Force-distance and force-time profiles were obtained and matrix resilience 
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and hardness were calculated employing the parameters outlined in Table 3.5. 
 
Table 3.5: Textural Analysis settings to determine matrix resilience. 
 
 
Parameters Settings 
Pre-test speed 1mm/sec 
Test speed 0.5mm/sec 
Post-test speed 10mm/sec 
Compression force - 
Trigger type Auto 
Trigger force 0.5N 
Load cell 5kg 
Compression strain 50% 
  
 
3.2.8 In vitro determination of Matrix Erosion of crosslinked multipolymeric 
scaffolds 
NaCMC-PEO-ECL scaffold samples were immersed in 100mL of phosphate buffered saline 
(PBS) (pH 7.4, 37˚C) and placed into an orbital shaker incubator set to rotate at 20rpm at 
37°C, (LASEC, Model LM-530, South Africa). Samples were removed from the PBS solution 
at specified time intervals, convection dried at 25˚C for 48hours and weighed to 
gravimetrically determine degree of matrix erosion (ME) employing Equation 3.2.  
 
100% x
M
MM
ME
o
to               (Equation 3.2) 
 
Where, ME% is the extent of matrix erosion of the scaffold, Mo is the initial mass of the 
scaffold and Mt is the mass of the scaffold and time t. Studies were conducted in triplicate, 
(n=3). 
 
3.2.9 In vitro determination of matrix swelling following hydration of the 
multipolymeric scaffolds 
A second set of samples were tested for change in volume after exposure to 100mL of PBS 
at predetermined intervals to assess degree of swelling of the polymer scaffold. Samples 
were removed from the PBS, blotted on filter paper, after which the mean of three 
perpendicular diameters was calculated following measurement using calipers and volume 
(V) was calculated employing Equation 3.3.  
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3
4 3r
V

                      (Equation 3.3) 
 
Where, r is the radius (mm). 
 
Studies were conducted in triplicate to ensure accuracy of the results obtained. 
 
3.2.10 Drug entrapment efficiency of the prepared nanoparticles 
Drug entrapment efficiency (DEE) was performed by homogenising 100mg of AZT-loaded 
nanoparticles in 100mL of PBS, pH7.4 (Polytron PT2000, Kinematika AG, Switzerland), to 
completely release all entrapped AZT. Free drug molecules were removed from the 
nanoparticle formulation prior to homoginisation by washing the nanoparticles in distilled 
water. The total content of entrapped AZT was established in triplicate by means of 
ultraviolet (UV) spectroscopy, (Specord 40, Analytik Jena, AG, Germany) at a wavelength of 
267nm. Due to possible interference of the polymer and excipients used to prepare the 
samples, a solution of 100mg of drug-free nanoparticles dissolved in PBS was used as a 
reference. Equation 3.4 was employed to calculate DEE: 
 
100% x
D
D
DEE
t
a               (Equation 3.4) 
 
Where Da is the actual amount of drug (mg/100mL) entrapped with the formulation and Dt is 
the theoretical amount of drug (mg/100mL) entrapped within the formulation. 
 
The study was performed on 5 samples, (n = 5). 
 
3.2.11 Drug Release Studies 
Drug release studies were performed on nanoparticle formulations and scaffolds containing 
drug-loaded alginate nanoparticles in an orbital shaker incubator, after being immersed in 
100mL PBS. Samples were taken at predetermined intervals, which were analysed using UV 
spectroscopy. 
 
3.3. Results and Discussion 
3.3.1 Infrared spectroscopy 
FTIR studies indicated that the basic polymeric structures of the parent compounds was 
maintained, however surface interactions occurred in the formation of both the nanoparticles 
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and the scaffold, which is represented by the shifting of the transmittance peaks in the 
nanoparticle and the multipolymeric scaffold preparations. 
 
The FTIR spectra in Figures 3.1.1.1 and 3.1.1.2 illustrates the nanoparticle preparation 
compared with the parent polymeric compounds and AZT. A characteristic band between 
3600 and 3200cm-1 was observed in the spectra of alginate due to the hydroxyl groups as 
seen in the alginate molecule and bands at 1592 and 1406cm-1  are attributed to asymmetric 
and symmetric  –COO- stretching. From the FTIR spectra of pectin, the presence of hydroxyl 
groups was also observed between 3600 and 3200cm-1 and -COO- stretching occurred at 
1590cm-1. The peak at 3458cm-1 in the AZT spectra is indicative of hydroxyl substituents and 
the bands between 3200 and 3000cm-1 are due to amine groups. Bands between 2100 and 
1900cm-1 are attributed to multiple bonded N2 molecules. The -C=O moieties present in the 
AZT, molecule was observed at 2813 and 1671cm-1. Characteristic bands were present in 
the spectra of PVA at 3274 and 2907cm-1 indicating the presence of hydroxyl groups and     
–C-H stretching vibrations respectively. The bands present between 1300 and 1000cm-1 are 
due to the bending vibrations of alcohol moieties present in PVA molecule or to –C-O 
stretching vibrations (refer to Table 3.4). 
 
The alginate nanoparticle formulation presented with bands between 3600 and 3200cm-1 
indicating the presence of possible hydroxyl or amino substituents. The band at 3332cm-1 is 
more defined than that of alginate, indicating possible interactions of the polymers with AZT, 
as AZT has an amino substituent present at 3458cm-1 as seen on the FTIR spectra. Polymer 
interactions with AZT are further supported by the presence of a band at 2110cm-1 which can 
be attributed to N2 substitution or bonding (e.g. ionic bonds). Shifting of the –COO
- stretch to 
1642cm-1 on the nanoparticle spectra indicates possible interaction of the polymers with AZT 
or CaCl2. 
 
The FTIR spectra of pectin nanoparticles (Figure 3.1.1.2) displayed a broad band between 
3600 and 3200cm-1 indicating the presence of hydroxyls groups, consistent with the spectra 
of the parent polymers, PVA and pectin. Interaction of PVA and pectin is supported by the 
peak at 2944cm-1, attributed to –C-H stretching vibrations observed on the spectra of PVA as 
well. Multiple peaks observed between 1200 and 700cm-1 indicate possible interactions 
between ZnSO4 and the hydroxyl or methyl groups present in AZT during nanoparticle 
preparation as these peaks are absent in the spectra of pectin and PVA. 
 
The FTIR spectra in Figure 3.1.2 illustrate the parent polymer compounds compared with the 
prepared multipolymeric scaffold treated and untreated with HCl. From the FTIR spectra of 
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NaCMC, a broad band at 3216cm-1 can be observed due to hydroxyl stretch vibrations and 
bands at 2894 and 1321cm-1 are due to -C-H groups. The peak at 1588cm-1 is typical of the 
carboxymethyl ether, (-CH2-COOH), and that at 1412cm
-1 is due to symmetric stretching of 
the carboxylate group. Bands present at 1018cm-1 are representative of >CH–O–CH2 
stretching. Bands present in the FTIR spectra of PEO at 960cm-1 and between 900 and 
1250cm-1 are due to –C-O group vibrations and –C-O-C stretching respectively. The C-O 
groups present in the polymer structure allows for complexation of PEO with other polymers 
and salts (Crowley et al., 2004; Neto et al., 2005). Those at 2877cm-1 and between 1400 and 
1300cm-1  are due to –C-H stretching and the band` at 840cm-1 is due to –C-H bending 
vibrations. Bands between 1060 and 1150cm-1 can be attributed to the aliphatic ether 
moieties in the structure of PEO. The ECL spectra displays characteristic peaks between 
1050 and 1300cm-1, indicative of the cyclic ester present in the structure of ECL (refer to 
Table 3.4) and the carbonyl –C=O stretching was observed at 1652cm-1 and between 3400 
and 3150cm-1. Bands between 2800 and 3000cm-1 are due to –C-H stretching.  
 
 
 
Figure 3.1.1.1: FTIR spectra comparing the nanoparticle formulations to the native 
compounds of nanoparticles prepared by means of a controlled gelification of alginate. (a) 
Alginate nanoparticles, (b) AZT, (c) pectin, (d) alginate. 
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Figure 3.1.1.2: FTIR spectra comparing the nanoparticle formulations to the native 
compounds of nanoparticles prepared using the salting out approach. (a) Pectin, (b) PVA, (c) 
AZT, (d) pectin nanoparticles. 
 
The carboxymethyl ether groups can be observed in both the multipolymeric scaffolds 
exposed and unexposed to HCl at 1606 and 1610cm-1, respectively and bands present 
between 3450 and 3200cm-1 are due to hydroxyl groups. Bands present in the spectra of 
HCl treated and untreated scaffolds at 1610 and 1606cm-1 respectively indicate possible 
ester moieties, attributed to multipolymeric interactions. A shift in the occurrence of the 
hydroxyl groups can be seen from 3306 to 3224cm-1 in the untreated and HCl treated 
scaffolds respectively, indicating possible interactions of the hydroxyl groups in NaCMC with 
H+ ions upon exposure to HCl. This is further supported by fewer bands present in the FTIR 
spectra of HCl treated multipolymeric scaffolds as compared to untreated scaffolds. 
 
Strong carbonyl bands were observed on the spectra of PCL at 172.02cm-1, indicative of an 
aliphatic ester. –C-O groups were observed at 1163 and 1233cm-1 and –(CH2)4 moieties 
were seen between 1290-1420cm-1. No changes were seen when PCL was dissolved in 
acetone. Interaction of ECL with acetone was observed a reduction of bonds in the spectra 
as well as the presence of an additional bond present between 1700-1750cm-1, (refer to 
Figure 3.1.3). Crosslinking of ECL with CaCl2 served to alter the spectra of ECL, whereas 
few chemical changes were observed when PCL was crosslinked with CaCl2. This will 
potentially impact on matrix erosion and drug release of scaffolds prepared using PCL and 
ECL. 
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Figure 3.1.2: FTIR of the HCl treated and untreated multipolymeric scaffold produced, 
compared to the parent polymer compounds. (a) HCL untreated multipolymeric scaffolds, (b) 
HCl treated scaffolds, (c) ECL, (d) PEO, (e)NaCMC. 
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Figure 3.1.3: FTIR spectra of ECL and PCL blends indicating changes in the chemical 
structure of the polymers when crosslinked with CaCl2 and when dissolved in acetone. (a) 
ECL, (b) PCL, (c) ECL and PCL crosslinked with CaCl2, (d) PCL crosslinked with CaCl2, (e) 
ECL crosslinked with CaCl2, (f) ECL and PCL combined. 
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3.3.2 Microscopy Studies 
3.3.2.1 Morphological analysis of the nanoparticles employing Transmission electron 
microscopy 
TEM conducted on the drug-loaded alginate nanoparticles, prepared by means of the 
controlled gelification of alginate approach, revealed the presence of spherical particles 
ranging between 200-700nm, whereas drug-free nanoparticles displayed a tendency to 
agglomerate, as seen in Figure 3.2.1. Micrographs obtained from drug-loaded nanoparticles 
indicated the formation of nanotubes ranging between 500-900nm. Particles were present 
within the tubes ranging between 50-200nm. These particles are thought to be entrapped 
drug particles, as seen in Figures 3.2.2 and 3.2.3. 
 
Spherical nanoparticles were observed on the TEM images of nanoparticles crosslinked with 
BaCl2. A large variation in particle size, ranging between 50-600nm was observed with 
minimal agglomeration present, attributed to the large radius of Ba2+ ions imparting 
electrostatic charge repulsion to the nanoparticles (Bajpai et al., 2004; Malvern Instruments 
Ltd). Microparticles were also present on these micrographs. Nanoparticles prepared 
excluding pectin from the formulation displayed notable agglomeration with an even 
distribution of particle size, measuring 100nm. As no AZT was loaded into these 
formulations, nanotube formation was absent in the TEM images obtained. 
 
Figure 3.2: TEM images of nanoparticles prepared using the controlled gelification of 
alginate approach. 
 
 
  
                          
Figure 3.2.1: (a) Drug-free nanoparticles and (b) AZT-loaded nanoparticles displaying the 
presence of spherically shaped particles in the nanometer size range. AZT-loaded 
nanoparticles show lack of agglomeration, (1mm=20nm). 
 
(a) 
 
(b) 
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Figure 3.2.2: (a) AZT-loaded nanoparticles illustrating association between the particles, 
ranging 50-100nm in size, indicating the potential formation of nanotubes, (1mm=10 nm) and 
(b) an AZT-loaded nanorod measuring 275nm in diameter, (1mm=11nm). 
 
 
 
 
Figure 3.2.2c: A large variation in particle size observed with nanoparticles crosslinked with 
BaCl2. Agglomeration is present on the micrograph, however, it is minimal, (1mm=20nm). 
 
  
 
Figure 3.2.3: (a) TEM of nanoparticles prepared excluding pectin from the formulation 
indicating a uniform distribution of particle size and shape, with the agglomeration seen on 
the TEM image (1mm=25nm). (b) Notable agglomeration of AZT-loaded nanoparticles can 
be seen, measuring 175-700nm in diameter, prepared with pectin excluded from the 
formulation (1mm=11nm). 
 
Possible AZT encapsulated within  
a nanotubular structure, measuring  
55-132nm in radius. 
(a) 
 
(b) 
 
(a) 
 
(b) 
 
(c) 
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Micrographs obtained of drug-free Zn-pectin nanoparticles, prepared using the salting out 
approach, revealed agglomeration, as well as individual spherical particles with a sheath 
surrounding the particles, ranging in size between 10-350nm. Microparticles, due to 
nanoparticle agglomeration and poor crosslinking of pectin with ZnSO4, can also be seen on 
the micrographs of drug-free Zn-pectin nanoparticles. 
 
Agglomeration of drug-free and AZT-loaded nanoparticles prepared using both the salting 
out and the controlled gelification of alginate approach can be attributed to a low charge 
distribution within the colloidal systems. Addition of AZT to the formulation served to further 
reduce charge distribution within the formulations. Although AZT is an uncharged molecule, 
interaction of AZT with alginate, supported by FTIR analysis, would serve to modify charge 
distribution within the colloidal system (Oh et al., 1998), causing agglomeration of the 
nanoparticle formulation. 
 
Drug-loaded nanoparticles ranged between 20-200nm. Nanotube formation can also be 
observed with the salting-out approach. Nanotube formation is possibly due to the N2 group 
present in the structure of AZT which interact with pectin and alginate to form tubular 
structures (refer to Figure 3.2.2) 
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Figure 3.3: TEM images of Zn-pectin nanoparticles prepared using the salting out approach. 
 
  
  
 
Figure 3.3.1: Drug-free Zn-pectin nanoparticles prepared using the salting out approach. (a) 
Displays agglomeration of, and (b) displays individual particles displaying a large range of 
particle sizes, between 40-320nm. (c)Spherical nanoparticles in the absence of 
agglomeration, interdispersed within tubular nanostructures, (1mm=10nm). (d) A sheath can 
be seen surrounding the particles, (1mm=25nm).  
 
 
 
Figure 3.3.2: AZT-loaded nanoparticles with particles within which could possibly be drug 
particles. A nanorod can be seen, also possibly containing AZT particles within, 
(1mm=10nm). 
 
 
 
Possible AZT particles within, 
measuring 20nm in diameter. 
Nanorod measuring 150-
250nm in diameter 
(a) 
 
(b) 
 
(c) 
 
(d) 
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3.3.2.2 Scanning electron microscopic analysis of the multipolymeric scaffolds 
SEM conducted on the NaCMC-PEO-ECL multipolymeric scaffolds revealed a porous 
polymer matrix, as observed in Figure 3.4.1b. Scaffolds exposed to 1%v/v HCl exhibited 
smaller, more uniform pores than scaffolds untreated with HCl. HCl treated scaffolds 
contained large areas of densely packed polymer matrices, interspersed by porous regions, 
whereas HCl untreated scaffolds contained immense craters within the matrix and densely 
packed polymer regions were rarely noted on the photomicrographs. Two of the polymers 
used for the preparation of the multipolymeric scaffold are hydrogels, namely CMC and 
PEO. Hydrogels are three-dimensional crosslinked polymer capable of extreme swelling due 
to absorption and retention of water. Hydrogels therefore have a loosely crosslinked 
structure due to their hydrophilic nature, resulting in the presence of air bubbles in the 
scaffolds unexposed to HCl (Don et al., 2008). Exposure of the scaffolds to HCl causes the 
COONa group in CMC to change to the acidic COOH which displays a more compact 
polymeric matrix (Liu et al., 2002). The craters were attributed to entrapped air bubbles 
within the polymer matrix.  
 
The distinct bright white areas on the surface of multipolymeric scaffolds are due to a high 
electric charge on the scaffold surface accredited to the presence of multivalent ions, 
present on the surface of the polymer matrix (Parolis et al., 2008), as well as free H+ and Cl+ 
ions on scaffolds exposed to 1%v/v HCl. 
 
A porous polymer matrix is ideal for the dispersion of drug-loaded nanoparticles (Yuan et al., 
2009). Drug release is anticipated be enhanced as the nanoparticles will be released as the 
polymer matrix swells or erodes, allowing for the prolonged delivery of drug. Premature drug 
degradation will be prevented and drug toxicity will be reduced as controlled drug release will 
be achieved (Hughs, 2005; Zahoor et al., 2005). 
 
SEM was also conducted on multipolymeric scaffolds crosslinked once only. 
Photomicrographs obtained from these samples contained larger pores and more craters 
within the polymer matrix. Higher concentrations of Ca2+ and Al3+ ions form intramolecular 
complexes within CMC, resulting in a tightly coiled polymer matrix, causing smaller pores to 
be present in multi-crosslinked scaffolds (Don et al., 2008; Liu et al., 2002; Parolis et al., 
2008). Air pockets are clearly visible in the scaffold matrix as seen in Figure 3.2.2a. This 
formulation is not idyllic for nanoparticle dispersion, supporting the need for multiple 
crosslinking to achieve an optimum formulation.  
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A densely packed polymer matrix was observed with PCL scaffolds. Upon exposure to PBS, 
pH 7.4, an increase in porosity was not observed as water was unable to permeate into the 
polymer matrix due to the high degree of crystallinity observed with polyester polymers 
(Rezwan et al., 2006). However surface erosion of the polymer scaffold was observed. 
When PCL was blended with ECL, a more porous polymer matrix was produced, ideal for 
the dispersion of nanoparticles. Upon prolonged exposure to PBS, pH 7.4, the porosity of the 
scaffold matrix was observed to increase due to permeation of water into the matrix and an 
increase in crystalline regions was noted. This is due to PCL and ECL degrading by 
hydrolytic desterification (Rezwan et al., 2006; Tarvainen et al., 2002) occurring primarily in 
the amorphous regions of the polymer as these regions are less stable than the crystalline 
regions (Rezwan et al., 2006; Luong-Van et al., 2006).  
 
Figure 3.4: Scanning Electron Micrograph of crosslinked polymeric scaffolds, revealed 
surface morphology of the prepared scaffolds. 
 
   
 
Figure 3.4.1: (a) Densely packed polymer matrix due to efficient crosslinking of the 
multipolymeric scaffold, (1mm=50µm). (b)Uniform pores are present within the polymer 
matrix of scaffolds exposed to 1%v/v HCl, which can efficiently entrap drug-loaded 
nanoparticles, thereby serving to modulate drug release (1mm=125µm). Brighter white areas 
are attributed to multivalent ions present on the surface of the scaffolds. 
 
 
 
(a) 
 
(b) 
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Figure 3.4.2: (a) Craters can be seen between the pores in the matrix due to air bubbles in 
the polymer solution during scaffold preparation (1mm=50µm). (b) Upon closer 
magnification, densely packed polymer regions and porous areas can be observed 
surrounding the craters (1mm=250µm).  
 
  
 
  
 
Figure 3.4.3: SEM images of (a) PCL scaffolds indicating a densely packed polymer matrix 
(1mm=125µm). (b) Multipolymeric PCL-ECL scaffolds demonstrating porosity of the scaffold 
matrix with crystalline areas observed (1mm=100µm). (c) PCL-ECL scaffolds crosslinked 
with CaCl2 with larger pores observed in the polymer matrix as compared to (d) non-
crosslinked PCL-ECL scaffolds (1mm=250µm). 
 
 
(a) 
 
(b) 
 
(c) 
 
(b) 
 
(a) 
 
(d) 
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Crosslinking PCL-ECL solutions with CaCl2 served to further increase porosity of the 
scaffolds, (refer to Figure 3.4.3). As PCL and ECL demonstrate sow degradation in the body 
(Abbah et al., 2009; Luong-Van et al., 2006; Sinha et al., 2004), an increase in matrix 
porosity is required for release of nanoparticles and drug at the desired site of action. Porous 
regions are surrounded by regions of densely packed polymer matrices which would serve to 
sustain drug release over prolonged periods.  
 
3.3.6 Zeta Analysis 
Zeta potential and particle size distribution was determined in deionised water. Non-invasive 
back scatter (NIBS) technology was employed to determine particle size distribution using 
Dynamic Light Scattering (DLS), whereby Brownian motion was measured, which was then 
related to particle size.       
 
Zn-Pectin nanoparticles displayed an average size distribution of 1323nm (SD<0.008), with 
a polydispersity index (PDI) of 0.816 for AZT-loaded nanoparticles and 119.6nm 
(SD<0.005), PDI 0.676, for drug-free nanoparticles. Multiple wide peaks were obtained, 
indicating the tendency of the colloidal system to agglomerate, (refer to Figure 3.5.1). 
Microparticles were observed with AZT-loaded nanoparticles as agglomerates were formed 
which could not be redispersed upon sonication of the nanoparticles prior to analysis. This 
was confirmed with zeta potential analysis, whereby AZT-loaded nanoparticles displayed an 
average zeta potential of -0.012mV (SD<0.001), indicating an instable colloidal system, 
whereas drug-free nanoparticles displayed an average zeta potential of -0.419mV 
(SD<0.004), indicating a more stable colloidal system. This system is less likely to 
agglomerate. 
 
 
 
Figure 3.5.1: Size distribution profile of drug-free Zn-Pectin nanoparticles, indicating the 
presence of particles ranging from 1 to 1000nm. Multiple wide peaks indicate the tendency 
of the nanoparticles to agglomerate (n=3; SD<0.002 in all cases). 
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The use of DLS for the analysis of a sample containing a mixture of extremely large and 
small particles yields large Z-averages as the contribution to the total light scattered by the 
small particles will be extremely small, as seen in Figure 3.5.1 (Malvern Instruments Ltd). 
 
 
 
Figure 3.5.2: Size distribution profiles of AZT-loaded Zn-Pectin nanoparticles indicate the 
presence of particle in the 600nm size range. A single narrow peak was obtained indicating 
flocculation of the nanoparticles prior to analysis (n=3; SD<0.002 in all cases). 
 
Particle size distribution studies conducted on nanoparticles prepared using the controlled 
gelification of alginate approach revealed an average size distribution of 576.1nm 
(SD<0.005), PDI 0.464, for AZT-loaded nanoparticles, and 752.1nm (SD<0.005), PDI 0.547, 
for drug-free nanoparticles. Wider peaks were obtained as seen in Figure 3.5.1. This is due 
to the tendency of nanoparticles to agglomerate, which can be noted by the peak in the 
900nm range in Figure 3.5.4. Agglomeration of the nanoparticles can be reduced by the 
addition of a surface active agent to the formulation, which will be explored in further studies.    
 
Nanoparticles crosslinked using BaCl2 presented with an average size distribution of 
880.8nm (SD<0.002) with a PDI of 0.215. This indicated a large particle size variation of the 
colloidal system as the PDI is utilised to estimate the width of particle distribution (Malvern 
Instruments Ltd). Ba2+ ions have a larger radius (1.74A°) than Ca2+ ions (1.14A°) with Ba2+ 
crosslinking with alginate having been found to yield smaller beads than Ca2+ crosslinking 
attributed to Ba2+ capable of filling a larger space between alginate molecules with a more 
tightly packed matrix obtained (Bajpai et al., 2004). However, size distribution of 
nanoparticles formulated using BaCl2 as the crosslinking agent yielded larger particles. This 
is possibly due to the high concentrations of BaCl2 used, with resultant poor crosslinking of 
alginate due to the premature gelation of the solution occurring with the introduction of 
BaCl2.  
 
The absence of pectin from the formulation resulted in smaller nanoparticles being formed, 
161.9nm (SD<0.004), PDI 0.400. This was expected as pectin would add bulk of the 
crosslinked alginate nanoparticles, thereby increasing the size of the nanoparticles. 
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However, pectin served to add stability to the colloidal system as pectin is an anionic 
polymer (Liu et al., 2003). The absence of pectin in the nanoparticle formulation resulted in 
preparation of an unstable colloidal system due to a reduction in the repulsive forces present 
in the colloidal system. The zeta potential of 0.305mV (SD<0.007) obtained with this 
formulation confirmed this. The positive charge distribution present within this colloidal 
system can be attributed to free Ca2+ ions.  
 
 
 
 
 
 
 
 
 
 
Figure 3.5.3: Size distribution profile of drug-free nanoparticles prepared using the 
controlled gelification of alginate approach. The profile indicated the presence of particles 
ranging from 100nm to 1000nm (n=3; SD<0.002 in all cases).  
          
Wide peaks and peaks close to the 1000 nm range are due to agglomeration of the colloidal 
system.  
 
 
 
Figure 3.5.4: Size distribution profile of AZT-loaded nanoparticles indicated a uniform size 
distribution of particles, as seen by all three peaks appearing in the 400-600d.nm size range 
(n=3; SD<0.002 in all cases).  
 
The average zeta potential of AZT-loaded alginate nanoparticles was -3.53mV (SD<0.003) 
and that of drug-free nanoparticles was -6.39mV (SD<0.002). The poor zeta potential 
obtained can be attributed to the high degree of crosslinking between the cationic Ca2+ salt 
and the anionic alginate. A strong positive surface charge from the Ca2+ ions is prevented 
due to ionotropic crosslinking of the Ca2+ ions with the carboxyl groups of the guluronic acid 
residues, which makes up alginate, in which Ca2+ is held in the centre of the 3-dimensional 
structure. Alginate is an anionic polymer, resulting in the negative zeta potential obtained. 
Size (nm) 
In
te
n
s
it
y
 (
%
) 
In
te
n
s
it
y
 (
%
) 
Size (nm) 
 67 
 
(Bajpai and Sharma, 2004; Li et al., 2008; Zactiti and Kieckbusch, 2006).  Although AZT in 
an uncharged molecule (Oh et al., 1998), there is a possible interaction of AZT with the 
polymers, as observed from the FTIR spectra, with resultant inferior crosslinking of Ca2+ with 
alginate. Free Ca2+ ions are therefore present in the colloidal system, causing instability of 
the nanoparticle formulation. 
 
BaCl2 is more capable of donating negative ions to the colloidal system than CaCl2, indicated 
by the zeta potential of -7.54mV (SD<0.006) obtained with the nanoparticle formulation 
crosslinked with BaCl2, (refer to Firgure 5.5.5b) This can be explained due to the larger 
radius exhibited by Ba2+ ions allowing enhanced electrostatic charge distribution of the 
colloidal system (Bajpai et al., 2004; Malvern Instruments Ltd). 
 
However, alginate nanoparticles prepared by crosslinking with CaCl2 with pectin included in 
the formulation exhibited superior size distribution and formulation stability and were 
therefore chosen for further studies. 
 
 
 
 
 
Figure 3.5.5: (a) Multiple peaks obtained in the Zeta potential profile of AZT-loaded 
nanoparticles prepared by means of a controlled gelification of alginate approach indicates 
particles with an inconsistent distribution of potential. A Z-average of -3.53mV was obtained, 
indicating a degree of instability of the nanoparticles produced. (b) Enhanced stability was 
observed with nanoparticles crosslinked with BaCl2. This can be attributed to BaCl2 being 
capable of donating negative ion to the formulation for efficiently than CaCl2, leading to 
electrostatic/charge stabilization of the colloidal system (n=3; SD<0.002 in all cases). 
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Zeta potential results from either steric repulsion or electrostatic stabilisation of particles as 
per Figure 3.6. Steric repulsion involves polymer adsorption onto the particle surface, 
preventing the particles from coming into close contact with each other. Electrostatic charge 
stabilisation involves the distribution of charged species within the colloidal system, serving 
to enhance particle repulsion (Malvern Instruments). Electrostatic charge stabilisation 
accounts for the zeta potential obtained for colloidal systems prepared using both the salting 
out approach and the cation induced gelification of alginate approach attributed to the use of 
high concentration of salt solutions for the preparation of the nanoparticles. 
 
          
Figure 3.6: Schematic of (a) electrostatic stabilisation and (b) steric repulsion of 
nanoparticles in a colloidal system. 
 
3.3.8 Textural Analysis of multipolymeric scaffolf matrices 
Assessment of matrix resilience (MR) provides information regarding in vitro degradation 
and drug release behaviour of the multipolymeric scaffold device. MR also has implications 
for device storage. It is therefore imperative to have a rigid polymeric scaffold which can 
withstand fracture during storage and handling of the device. Textural analysis performed on 
unhydrated samples revealed a decrease in the resilience of HCl treated particles compared 
to untreated systems with a MR of 12.83% (SD<0.004) as compared 18.12% (SD<0.004) 
obtained with untreated particles. This was expected as scaffolds exposed to HCl presented 
with less porous matrices as observed in Figure 3.7.1a due to acid transition of the COONa 
groups in CMC to COOH. This could possibly result in a brittle scaffold, accounting for the 
low MR obtained. Less water will therefore permeate into the polymer matrix leading to 
reduced disentaglement of the polymer matrix, allowing for prolonged drug release. 
However, hardness of both treated and untreated particles was similar, with treated particles 
having a mean value of 3.45nm (SD<0.001) and untreated particles having a mean value of 
3.712nm (SD<0.006). 
 
(a) (b) 
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Figure 3.7.1: Typical (a) hardness and (b) resilience profiles of untreated particles (n=3; 
SD<0.001 in all cases). 
(b) 
(a) 
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Figure 3.7.2: Typical (a) hardness and (b) resilience profiles of HCl treated particles (n=3; 
SD<0.001 in all cases). 
(a) 
(b) 
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Upon hydration, matrix resilience declined with HCl treated and untreated samples, with 
scaffolds unexposed to HCl displaying a MR of 8.043% (SD<0.004) and scaffolds exposed 
to HCl displaying a MR of 6.361% (SD<0.004). MR of both sets of samples declines with 
further exposure to PBS, (refer to Figure 3.8), due to swelling and chain relaxation of the 
polymer matrix. The viscoelastic property of the scaffold resultantly increases and MR 
declines. 
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Figure 3.8: Percentage resilience of HCl treated and untreated scaffolds, indicating a 
decline in porosity with increased exposure to PBS, pH 7.4 (n=3; SD<0.004 in all cases). 
 
3.3.9 Matrix erosion and Swelling  
Upon treatment with 1%v/v HCl, the carboxylate COONa groups in NaCMC are converted to 
to the acidic COOH form. This COOH form is less susceptible to ionisation in PBS, as the 
COO- group has a greater affinity for the H+ ion resulting in a lower degree of ion exchange 
of the Na+ and H+ to reform COONa. The polymeric matrix resultantly imbibes less water, 
reducing the swelling behaviour of HCl treated particles. Exposure to HCl also leads to a 
more densely crosslinked polymer matrix which is less prone to swelling than the loosely 
packed untreated scaffolds (Liu et al., 2002; Rokhade et al., 2006). However, both sets of 
scaffolds still exhibit extensive swelling behaviour as seen in Figure 3.9 below. This is 
attributed to the highly hydrophilic nature of the polymers which enhances the rate and water 
uptake capacity (Rokhade et al., 2006). 
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Figure 3.9: Swelling behavior of HCl treated and untreated multipolymeric scaffolds (n=3; 
SD<0.001 in all cases). 
 
A decrease in the amount of water penetrating into the scaffold reduces the disentanglement 
of the polymeric matrix, leading to reduced erosion of the multipolymeric scaffolds treated 
with HCl, noticed in the first 24hours as compared to untreated scaffolds (refer to Figure 
3.10a) (Parolis et al., 2008; Baijpai et al., 2004). However, upon prolonged exposure to PBS, 
pH 7.4, NaCMC-PEO-ECL multipolymeric scaffolds, treated and untreated with HCl, 
displayed weight gain, thought to be due to sequestration of phosphate and Na+ ions within 
the polymer matrix and resultant decrease of the entanglement of the polymer chains (Liu et 
al., 2002). Multipolymeric scaffolds exposed to HCl displayed a larger percentage weight 
gain than those unexposed to HCl. 
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Figure 3.10: (a) Percentage weight change of HCl treated and untreated NaCMC-PEO-ECL 
crosslinked scaffolds, indicating the degree of entrapped moisture and ions within the 
polymer matrix accounting for the gain in weight of the scaffolds (b) Matrix erosion of 
scaffolds prepared using polyester polymers, crosslinked and not crosslinked with CaCl2 
determined over 30 days (n=3; SD<0.001 in all cases). 
 
Scaffolds prepared using a combination of PCL and ECL displayed a higher percentage 
weight loss, 16.737% (SD<0.002), than scaffolds prepared with PCL alone, 11.279% 
(SD<0.005) 30 days post exposure to PBS, pH 7.4 (refer to Figure 3.10b). PCL is a 
hydrophobic polymer which has been utilized extensively for the sustained delivery of 
pharmaceuticals in the past (Tarvainen et al., 2002; Sinha et al., 2004; Chang et al., 2009). It 
(a) 
(b) 
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was therefore expected that scaffolds prepared using PCL would display slow erosion of the 
polymer matrix. Although ECL is also a synthetic aliphatic polyester from which PCL is 
prepared (Chang et al., 2009; Tarvainen et al., 2002; Uto et al., 2008), it is not a hydrophobic 
polymer. Combining the two polymers to prepare a multipolymeric scaffold therefore served 
to increase the rate of scaffold erosion.  
 
Crosslinking PCL-ECL solutions with CaCl2 served to increase the porosity of the resultant 
scaffold, hence increasing matrix erosion to 38.253% (SD<0.002) 30 days post exposure to 
PBS, pH 7.4. Increased porosity of the crosslinked scaffold caused an increase in water 
penetration into the polymer matrix, causing disentanglement of the polymer chains, 
resulting in erosion of the scaffolds. 
 
Swelling was not observed with scaffolds prepared using PCL and ECL. This was expected 
due to the crystalline nature of the polymers which does not accommodate water uptake into 
the polymer matrix (Luong-Van et al., 2006; Sinha et al., 2004; Uto et al., 2008). 
 
3.3.10 Drug Entrapment Efficiency and Drug Release  
A calibration curve, as per Figure 3.11 was generated for AZT using PBS, pH 7.4 at 25°C, 
employing a UV spectrophotometry at the wavelength of maximum absorption, 267nm.  
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Figure 3.11: Calibration plot for zidovudine in PBS, pH 7.4 at λ267nm (n=3; SD<0.0002 in all 
cases). 
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Alginate nanoparticles exhibited superior DEE, 91.1%, as compared to 76.53% obtained with 
Zn-pectin nanoparticles. The unusually high DEE of the alginate nanoparticle formulation is 
accredited to the ability of alginate to form a gel in the presence of an aqueous medium, with 
the hydrophilic AZT entrapped within this gel structure with nanoparticle precipitation upon 
crosslinking of the alginate-AZT solution with CaCl2 (Muthu et al., 2009; Zahoor et al., 2005; 
2006).  
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Figure 3.12.1a: Drug release profile of Zn-pectin and alginate nanoparticles under 
cerebrospinal fluid simulated conditions (20rpm, 37ºC, 0.1M PBS, pH7.4) (n=3; SD<0.005 in 
all cases). 
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Figure 3.12.1b: Drug release profile of alginate nanoparticles dispersed within HCl treated 
and untreated polymeric scaffolds, under cer brospinal fluid simulated conditions (20rpm, 
37ºC, 0.1M PBS, pH7.4) (n=3; SD<0.005 in all cases). 
 
Biphasic release was observed with both nanoparticle formulations, consisting of an initial 
burst release of drug within hours of exposure to PBS, followed a constant release rate of 
AZT over the remaining 30days of nanoparticle analysis (refer to Figure 3.12a). Zn-pectin 
nanoparticles displayed a burst release within 48hours of 7.9% of drug and alginate 
nanoparticles displayed a burst of 14.9% of the entrapped drug after 1 hour post exposure to 
PBS. Burst release was attributed to association of the AZT onto the surface of the polymers 
by weak interactive forces, which was reversed upon exposure to PBS (Li et al., 2008).  
 
Incorporation of alginate nanoparticles, chosen due to its superior DEE, into the polymeric 
scaffold significantly retarded drug release, 2.341% (SD<0.005) obtained with NaCMC-PEO-
ECL scaffolds untreated with HCl and 1.576% (SD<0.005)  obtained with NaCMC-PEO-ECL 
scaffolds treated with HCl, 30days post exposure to PBS, pH 7.4. 
 
Erosion of the scaffold is due to weakening of the crosslinked bonds with exposure to 
phosphate buffered saline (PBS), pH 7.4. ECL degrades by means of hydrolysis of the ester 
bonds, without creating a localised acidic environment upon degradation. When exposed to 
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the CaCl2 salt solution, CaCl2 either forms bonds with the ester groups on the lactone ring or 
the Ca2+ surrounds the ester group and protects it from degradation (Huang et al., 2004; 
Luong-Van et al., 2006; Rezwan et al., 2006). PEO degrades by means of hydrolysis of the 
ester bonds. CMC and PEO imbibes large quantities of water due to its hydrophilic nature, 
resulting in rapid degradation of PEO, subsequently causing break down of the polymer 
scaffold (Rokhade et al., 2006; Zweers et al., 2004). The degree of swelling and subsequent 
drug release is determined by the availability of hydrogen bond in the polymer matrix for 
water molecules to attach to. For scaffolds treated with 1%v/v HCl, the availability of such 
bonds is decreased, thereby resulting in reduced drug release (Rokhade et al., 2006). The 
PBS penetrated the scaffold matrix, which has small uniform pores as well as air pockets, 
causing it to erode, allowing for nanoparticles to diffuse out.  
 
Nanoparticles released drug by a similar method with swelling of the nanoparticles upon 
exposure to PBS playing a major role in drug release. This is consistent with the polymers 
used to prepare the nanoparticles, being alginate and pectin, which are hygroscopic in 
nature and prone to swelling in the presence of water. This swelling behaviour would allow 
for weakening of the crosslinked bonds between the polymers and the CaCl2, and release of 
drug from the nanoparticles. Swelling of the nanoparticles will also facilitate surface erosion 
and subsequent release of drug (Bajpai et al., 2004, Zactiti et al., 2006). 
 
PCL, a hydrophobic polymer, has been extensively investigated for the long term delivery of 
drug molecules (Jeong et al., 2003; Sinha et al., 2004; Tarvainen et al., 2002). Drug 
molecules are integrated into the amorphous regions of PCL (Luong-Van et al., 2006). The 
slow degradation of PCL (Luong-Van et al., 2006; Sinha et al., 2004; Tarvainen et al., 2002), 
which occurs primarily from the amorphous regions of PCL (Rezwan et al, 2006), accounts 
for the drug release of 4.144% obtained 30days post exposure to PBS, pH 7.4 (refer to 
Figure 3.13.2). Copolymerisation of PCL with ECL served to enhance drug release to 
9.001%. This was due to ECL imparting hydrophillicity to the prepared scaffold, thereby 
enhancing water penetration into the polymer matrix, enhancing release of the hydrophilic 
AZT (Thomas and Panchagnula 2003; Prakash et al., 2008). AZT-loaded alginate 
nanoparticles where therefore dispersed within PCL-ECL scaffolds and drug release was 
assessed, which amounted to 2.1% (SD<0.001) 30 days post exposure to PBS, pH 7.4.  
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Figure 3.12.2: Release of AZT from polymer scaffolds prepared using aliphatic polyesters 
with AZT and AZT-loaded nanoparticles dispersed within (n=3; SD<0.001 in all cases). 
 
3.4. Concluding Remarks 
Nanotechnology is a rapidly evolving interdisciplinary field. It is based on the manipulation of 
matter on a submicron scale, with nanomedicine allowing for the development of drug 
delivery devices with superior drug absorption, controlled release of drugs and an enhanced 
side effect profile (du Toit et al., 2007; Park 2006; Park et al., 2007).  
 
From the studies conducted, the controlled gelification of alginate method of producing 
nanoparticles was chosen for further analysis as alginate nanoparticles exhibited a more 
stable formulation, as determined by zeta potential analysis and smaller particles are formed 
using this approach. Drug release obtained with alginate nanoparticles was more suitable 
than that of pectin nanoparticles for dispersion of within a multipolymeric scaffold matrix for 
possible application as an implantable drug delivery device. Alginate nanoparticles prepared 
in the absence of pectin and those crosslinked with BaCl2 was excluded from further studies 
due to the unsatisfactory zeta potential and average particle size distribution results obtained 
with these formulations respectively. 
 
Pectin nanoparticles demonstrated suitable size and drug release properties for application 
as a drug carrier in the absence of a scaffold matrix. However, further investigations are 
required to enhance the stability of the formulation and to decrease agglomeration. 
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Dispersing the polymeric nanoparticles with a multipolymeric scaffold served to noticeably 
decrease drug release. Exposing the multipolymeric scaffolds prepared to 1 %v/v HCl served 
to enhance the swelling behaviour of the scaffolds, thereby enhancing drug release and 
creating a suitable device for the prolonged release of drug over a period of one month. 
 
PCL-ECL multipolymeric scaffolds displayed higher suitability for further analysis. Although 
these scaffolds exhibited a higher drug release than NaCMC-PEO-ECL scaffolds exposed to 
1%v/v HCl, when AZT-loaded alginate nanoparticle were dispersed within the scaffold matrix, 
the lack of swelling detected with these scaffolds renders them more attractive for 
implantation into the brain. 
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CHAPTER 4 
 
Fabrication and Optimization of a Multipolymeric Scaffold 
Incorporating AZT-Loaded Nanoparticles for the Management of 
ADC Applying a Design of Experiments Approach 
 
4.1 Introduction 
Controlled release drug delivery systems have been creating waves in the pharmaceutical 
industry in recent years. Many biodegradable and biocompatible polymers such as 
polycaprolactone (PCL), epsilon caprolactone (ECL), cellulose and polysaccharide 
derivatives have been extensively researched for the design and formulation of controlled 
release drug delivery devices (Jeong et al., 2003).  
 
Due to the selectivity of the blood brain barrier (BBB), delivery of therapeutic agents into the 
central nervous system (CNS) has previously challenged pharmaceutical scientists (Vergoni 
et al., 2009; Kato et al., 2010; Lin et al., 2010; Semreen et al., 2010). Many approaches have 
been investigated to enhance the permeability of the BBB, osmotic pumps, silicone 
reservoirs and prodrugs being just a few (Ciofani et al., 2008; Bennewits et al., 2009) 
Implantation of drug delivery devices into the brain has been utilized in the past. However, 
this procedure requires subsequent removal of the device at a later stage, due to lack of 
biodegradability of the device, and is therefore unacceptable to patients due to its invasive 
nature. Infection, inflammation and device failure add to the unsuitability of such devices 
(Ciofani et al., 2008). Polymeric drug delivery devices (DDDs) are capable of overcoming 
such challenges faced with the use of biodegradable, biocompatible devices capable of 
delivering and sustaining drug concentration over predetermined time periods. This is 
particularly useful for drugs with short half lives (t1/2) as sustained drug delivery negates the 
need for frequent dosage intervals (Ciofani et al., 2008). 
 
Nanotechnology has received significant attention in recent years for the treatment and 
management of CNS conditions (Sahoo et al., 2003; Rao et al., 2008; Yang et al., 2008; Lin 
et al., 2010). This can be attributed to their small size and biocompatibility (Park et al., 2007). 
However restricting nanotechnology to the 100nm and smaller size scale is impractical when 
it comes to drug delivery, as efficiency of a drug delivery device is independent of size (Park, 
2007). 
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Combining polymer technology and nanotechnology is a revolutionary means of overcoming 
many current challenges of drug delivery to the CNS. Polymeric nanomaterials offer superior 
biodistribution and targeted delivery of drug, reducing systemic side effects and drug 
resistance (Park et al., 2007). Targeting drug molecules to the desired site of action is 
imperative for the treatment and management of CNS conditions due to the high 
concentrations of toxic drug required. Exposure of the therapeutic agents to unaffected 
tissue is minimal with site-specific drug targeting, reducing systemic toxicity resulting from 
drug therapy (Kidane et al., 2005; Husseini et al., 2008). Site specific drug delivery is also 
cost effective as lower concentrations of drug are required for therapeutic efficacy (Husseini 
et al., 2008). 
 
The management of AIDS dementia complex (ADC) requires therapeutically effective drug 
concentrations, which is sustained at these concentrations over extended time periods. The 
BBB poses an obstacle for the transport of drugs into the brain.  This impedes effective 
antiretroviral (ARV) therapy and promotes drug resistance as optimum drug concentrations 
are not attained. Clinically useful drug delivery systems which are capable of bypassing the 
BBB and achieving and sustaining therapeutic levels of drug in the brain are therefore 
required (Rao et al., 2008). 
 
Preliminary studies carried out in Chapter 3 yielded sufficient information from which a 
prototype formulation can be established and evaluated. A statistical design of experiments 
(DOE), defined as the strategy used to implement experiments such that information is 
obtained in an efficient and precise manner, was employed to determine critical limits for 
formulation processing of variables (Altekar et al., 2006). DOE have been employed since 
1967 in the optimisation of drug formulations and have found application in numerous 
industries after having first been discussed by Sir Ronald Fisher in „The Design of 
Experiments‟. Since then, this systematic technique is applicable to all conventional dosage 
forms and can be used for the optimisation of all modern drug delivery systems. DOE is 
used to improve the efficiency of experimentation as it allows access to precise and detailed 
information regarding the system under investigation with the minimum number of 
experiments having to be carried out, as the designed experiments are generated based on 
statistical theory (Singh et al., 2005; Altekar et al., 2006).  
 
The Box-Behnken design, developed by George Box and Donald Behnken in 1960, is an 
experimental design used to obtain the responses of the prepared device with regards to 
surface methodology. The design aims to achieve the following goals: 
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 Each independent variable is placed at three equally spaced values, requiring a 
minimum of three levels.  
 The design should fit a quadratic model.  
 The ratio of the number of experimental points to the number of coefficients in the 
quadratic model should be maintained in the range of 1.5 to 2.6.  
 The estimation variance should be based on the distance from the centre, and should 
vary minimally inside the smallest hypercube containing the experimental points.  
 
The 3 factor Box–Behnken design involves the use of three blocks, in which 23 factors are 
varied through the 3 possible high, low and midpoint combinations (Box and Behnken, 1960; 
Annadurai and Sheeja, 1998). 
 
4.2 Materials 
Materials employed were described in Chapter 3. Cellulose acetate phlalate (CAP) 
purchased from Sigma-Aldrich (St. Louise, MO, USA) was included in the preparation of 
multipolymeric scaffold devices. All other reagents were of analytical grade and were used 
as received in accordance with standard operating protocols. 
 
4.3 Methods 
4.3.1 Formulation preparation using the Box-Behnken design 
Various concentrations of polymer and salt solutions were prepared for preparation of 
nanoparticle and multipolymeric scaffold formulations. Temperature, crosslinking time (CT) 
and stirring speed was also assessed to ascertain the impact of these parameters on 
formulation size and potential for nanoparticles and matrix erosion and resilience for 
scaffolds formulations. From these studies, upper and lower parameters were chosen which 
were statistically analysed using a 3 Factor Box-Behnken design template, using 
MINITABS® V15 software (Minitab Inc, Pennsylvania, USA), for the preparation of the 
nanoparticle and scaffold formulations in an attempt to optimize the responses highlighted in 
Table 4.1. The Box-Behnken experimental design was used to optimise the formulations as 
it can efficiently determine quadratic terms in a regression model. The design was used to 
ascertain the effects of the formulation variables on the physicochemical and 
physicomechanical properties of the prepared device.  
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4.3.1.1 Preparation of Nanoparticles 
Nanoparticle formulations were prepared using a controlled gelification of alginate approach 
(Zahoor et al., 2005; Zahoor et al., 2006; Sarmento et al., 2007), whereby sodium alginate 
and zidovudine (AZT) solution was prepared in distilled water. Calcium chloride (CaCl2) was 
added to the solution in a drop wise manner to facilitate crosslinking highlighted in Figure 
4.1.1. A 0.05%w/v pectin solution and a 10%
w/v polyvinyl alcohol (PVA) solution were then 
added to the crosslinked suspension to ensure optimum formulation stability. Upper and 
lower parameters and response factors were determined, as highlighted in Table 4.1, and 
were utilized to to generate a Box-Behnken template. Thirteen formulations were prepared in 
accordance with the 3 Factor Box-Behnken design template, established using Minitab® V15 
software, as outlined in Table 4.2. The nanoparticle solutions were then centrifuged to 
enable precipitation and collection of the nanoparticles, dried at ambient temperature (25°C) 
and lyophilized (Virtis®, Gardiner, NY, USA) for 24 hours to obtain a free flowing powder.  
 
Table 4.1: Upper and lower limits of parameters and response factors used for the 
formulation of nanoparticle and multipolymeric scaffold formulations. 
 
Independent Factors 
Lower 
Levels   
Upper 
Levels 
AZT-loaded Nanoparticles    
Alginate concentration (%
w
/v) 0.06  0.5 
CaCl2 Concentration (%
w
/v) 2  10 
Crosslinking time (min) 15  180 
    
Responses Lower  Upper Objectives 
Average size distribution (d.nm) 33.31 912.5 Minimise 
Zeta potential (mV) -0.659 -14.6 Maximise 
    
Multipolymeric Scaffolds    
CAP concentration (%
w
/v) 5  20 
ECL concentration (%
w
/v) 10  50 
CaCl2 concentration (%
w
/v) 0  15 
    
Responses Lower  Upper  Objectives 
Matrix erosion (%) 7.413 63.269 Minimise 
Matrix resilience (%) 1.113 11.71 Maximise 
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Table 4.2: A 3 Factor Box-Behnken template with randomly generated alginate nanoparticle 
formulations. 
 
Formulations 
[Alginate] 
 (%w/v) 
[CaCl2]  
(%w/v) 
Crosslinking 
time (min) 
1 0.06 10 97.5 
2 0.5 6 180 
3 0.06 6 180 
5 0.28 10 15 
6 0.5 10 97.5 
7 0.06 6 15 
9 0.28 2 15 
10 0.5 2 97.5 
11 0.28 2 180 
12 0.28 6 97.5 
13 0.28 10 180 
14 0.06 2 97.5 
15 0.5 6 15 
       
 
4.3.1.2 Preparation of Polymeric Scaffolds 
Thirteen crosslinked PCL/ECL/CAP scaffold-like devices were prepared in accordance with 
the 3 Factor Box-Behnken design template as illustrated in Table 4.3. The polymers, in 
varying concentrations, were individually dissolved in acetone, after which they were mixed 
together and crosslinked with CaCl2. Nanoparticles were dispersed within the crosslinked 
multipolymeric solution to enable controlled drug delivery over a predetermined time interval. 
The crosslinked polymeric mixture was then poured into glass moulds (6mm in diameter and 
2mm in depth) and  pre-lubricated with liquid paraffin and allowed to dry at ambient 
temperature (refer to Figure 4.1.2). 
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Table 4.3: A 3 Factor Box-Behnken template with randomly generated PCL-ECL-CAP 
scaffold formulations. 
 
Formulations 
[ECL] 
(%w/v) 
[CaCl2] 
(%w/v) 
[CAP] 
(%w/v) 
1 10 15 12.5 
2 50 7.5 20 
3 10 7.5 20 
4 30 7.5 12.5 
5 30 15 5 
6 50 15 12.5 
7 10 7.5 5 
9 30 0 5 
10 50 0 12.5 
11 30 0 20 
13 30 15 20 
14 10 0 12.5 
15 50 7.5 5 
        
 
 
        
  
 
Figure 4.1.1: Schematic representation of nanoparticle preparation employing the controlled 
gelification of alginate approach. 
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Figure 4.1.2: Schematic representation of PCL/ECl/CAP multipolymeric scaffold 
preparation. 
 
4.3.2 Fourier Transform Infrared analysis for the description of the molecular 
transitions of scaffold and nanoparticle formulations 
Fourier Transform Infrared (FTIR) spectroscopy was utilized to assess possible structural 
transitions which had occurred during the preparation process by comparing the functional 
groups of the parent compounds with that of the formulations produced. Polymer, 
nanoparticle and scaffold samples were analysed using a Perkin Elmer FTIR Spectrometer 
(Spectrum 100, Beaconsfield, United Kingdom). 
 
4.3.3 Microscopic analysis of surface morphology  
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) images 
the surface of solid specimens using high-energy beams of electrons. The electrons interact 
with the atoms in the sample producing signals containing information regarding the 
sample's surface topography, chemical composition, crystalline structure, orientation of 
materials making up the sample, as well as electrical conductivity (Suzuki, 2002). Particle 
size can also be obtained from TEM images. 
 
4.3.3.1 Transmission electron microscopy 
Nanoparticle samples were dispersed in methanol and sonicated, after which they were 
placed on carbon grids and analysed using TEM (JEOL 1200 EX, 120keV). 
Photomicrographs were obtained to study the size and morphology of individual particles 
produced. 
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4.3.3.2 Scanning electron microscopy 
SEM, conducted using a thermal emission electron microscope (JEOL JSM, Tokyo, Japan), 
was employed on the multipolymeric scaffolds. Samples were mounted on aluminum stubs, 
coated with carbon and gold-palladium for 10minutes, after which they were visualized at 
acceleration voltages ranging between 5-9keV under different magnifications. 
Photomicrographs were obtained and analysed to study surface morphology. The degree of 
polymer entanglement, network density and porosity of the scaffolds were qualitatively 
determined using the photomicrographs obtained. 
 
4.3.4 Zeta analysis 
Zeta potential and particle size distribution were determined in deionised water using a 
ZetaSizer Nano ZS (Malvern Instruments Ltd, UK). 1mL samples were diluted with deionised 
water, filtered (0.22μm filter Millipore Co., Massachusetts, USA) to maintain the number of 
counts per second in the region of 600 (Layre et al., 2006) and analysed using disposal 
cuvettes, to assess particle size, or capillary cells, to assess zeta potential. The viscosity and 
refractive index of the continuous phase were set to those specific to deionized water 
(Malvern Instruments Ltd, Malvern, Worcestershire, UK). Measurements were taken in 
triplicate, with size intensity and zeta potential distribution profiles used to assess average 
nanoparticle size and stability. 
 
4.3.5 Textural Analysis 
A TA.XT.Plus Texture Analyzer (Stable Micro Systems, Surrey, UK) was used to establish 
various stress-strain parameters of the multipolymeric scaffolds in both the hydrated and 
unhydrated states to determine textural transitions occurring during different degrees of 
matrix hydration. A flat-tipped cylindrical steel probe measuring 50mm in diameter was 
attached to the force transducer and matrix resilience (MR) was obtained using the 
parameter setting listed in Table 3.5 in Chapter 3, Section 3.2.7. Force-time profiles were 
generated by means of Texture Exponent Software (Version 3.2) at a rate of 200 points per 
second and used to calculate matrix resilience.  
 
4.3.6 Matrix Erosion and Swelling Studies 
Pre-weighed samples was immersed in 100mL of PBS (pH 7.4, 37˚C) and placed into an 
orbital shaker incubator set to rotate at 20rpm at 37°C, (LASEC, Model LM-530, South 
Africa). Samples were removed from the PBS solution at specified time intervals, convection 
dried at 25˚C for 48hours and weighed to gravimetrically determine degree of matrix erosion. 
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A second set of samples were tested for change in volume after exposure to buffer at 
predetermined intervals to assess degree of swelling of the multipolymeric scaffolds. 
 
4.3.7 Drug Entrapment Efficiency and Drug Release 
Drug entrapment efficiency (DEE) was calculated as per Equation 3.4, as described in 
Chapter 3, Section 3.2.10 
 
Drug release studies were performed on nanoparticles as well as on multipolymeric scaffolds 
incorporating nanoparticles within the matrix. AZT-loaded samples were immersed into 
100mL of PBS (pH7.4) after which they were placed into an orbital shaker incubator set to 
rotate at 20rpm at 37°C. Samples were taken at predetermined intervals, which were then 
analysed using UV spectroscopy. The time-point approach, a model independent analysis, 
was then used to analyse the dissolution data, whereby the mean dissolution time (MDT) 
was established at 30days for each formulation (Pillay and Fassihi, 1999). MDT, calculated 
using Equation 4, provides a more accurate analysis of drug release as well as a precise 
comparison of numerous data sets. 
 

 M
M
tiMDT t
n
i 1
                                                                                         (Equation 4.1) 
 
Where Mt is the fraction of dose released in time ti = (ti + ti-1)/2 and M∞ corresponds to the 
loading dose (Pillay and Fassihi, 1999). 
  
4.3.9 Optimisation of the nanoparticles and multipolymeric scaffold 
formulations employing a Box-Behnken design of parameters 
Physicochemical and physicomechanical analysis were conducted on both scaffold and 
nanoparticle formulations using a range of polymer and salt concentrations as described in 
Table 4.4, to optimize formulation parameters employing a Box-Behnken statistical design. 
Nanoparticles were prepared incorporating PVA into the formulation to facilitate an 
improvement in the stability of the nanoparticle colloidal system. Of the PVA concentrations 
tested, 10%w/v solutions demonstrated the most favorable surfactant properties as observed 
with the zeta potential and the smaller average nanoparticle size obtained, refer to Table 4.5. 
Larger particles were observed with PVA concentrations above 10%, attributed to the highly 
viscous nature of the polymer solution which facilitated agglomeration of the nanoparticles. 
Nanoparticles prepared with PVA concentrations less than 10% presented with larger 
particles, with instability observed within the colloidal system as demonstrated by the ZP 
 89 
 
obtained as seen in Table 4.5. This can be attributed to insufficient surfactant properties 
instilled to the colloidal systems when prepared with 0.5-2.5%w/v PVA solutions. 
 
Multipolymeric scaffolds were prepared using ethyl cellulose and CAP as plasticiser agents. 
CAP was favored over ethyl cellulose and chosen for further studies, attributed to scaffolds 
prepared with CAP presenting with extended drug release behavior due to slow matrix 
erosion. SEM studies conducted revealed a more porous scaffold prepared with formulations 
containing low PCL concentrations. PCL concentration was fixed at 37.5%w/v as scaffolds 
prepared with higher concentrations of PCL presented with 11.83% to 7.26% drug being 
released over 30 days. The viscous nature of PCL solutions above 37.5%w/v retarded mixing 
of PCL, ECL and CAP solutions and resultantly impeded crosslinking of the multipolymeric 
solution with CaCl2.  
 
A quadratic response was generated using a Box-Behnken design from which a second 
order polynomial model was constructed for the prediction of device behaviour using the 
independent variables previously investigated. This facilitated a mechanistic evaluation of 
correlations between pertinent processing factors such as the polymer type and CaCl2 
concentrations and cross-linking time utilised for the preparation of nanoparticle and scaffold 
formulations. Nanoparticle formulations were characterized according to the average particle 
size, zeta potential and drug release behaviour. Multipolymeric scaffolds were exemplified in 
terms of their matrix erosion, resilience and drug release characteristics. Nanoparticle and 
multipolymeric scaffolds were then optimized in terms of the responses obtained formulated 
for implantation into the rat brain.  
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Table 4.4: Variable levels employed in the optimisation of nanoparticle and multipolymeric 
scaffold formulations. 
 
Input Variables 
Lower 
Levels 
Upper 
Levels 
AZT-loaded Nanoparticles   
Alginate concentration (%
w
/v) 0.06 1 
Pectin concentration (%
w
/v) 0 1 
PVA concentration (%
w
/v) 0 15 
CaCl2 Concentration (%
w
/v) 2 15 
Crosslinking time (min) 5 180 
Stirring speed (where 1 = 100rpm and 
5 = 500rpm) 1 5 
      
Multipolymeric Scaffolds   
CAP concentration (%
w
/v) 5 30 
Ethyl cellulose concentration (%
w
/v) 5 15 
ECL concentration (%
w
/v) 10 70 
PCL concentration (%
w
/v) 10 50 
CaCl2 concentration (%
w
/v) 0 1 
Crosslinking time (mins) 5 60 
Evaporation time (days) 1 14 
      
 
Table 4.5: PVA concentrations employed for the preparations of nanoparticles and 
responses obtained. 
 
PVA concentration 
(%w/v) 
Ave Size distribution 
(nm) 
Zeta potential 
(mV) 
0 752.1 -3.53 
0.5 455.90 -4.13 
1 203.27 -4.99 
2.5 170.65 -6.53 
5 101.95 -6.85 
10 93.21 -8.42 
15 462.8 -8.53 
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4.3.10 Termal analysis of native polymer and prepared nanoparticle and 
scaffold formulations employing advanced Differential Scanning Calorimetry 
(aDSC) 
Thermal analysis is on the oldest analytical methods employed, with the first thermometric 
experiment performed in 1887 by a French sciencetist Henri Louis Le Chatelier (Le 
Chatelier, 1887). 
 
Differential Scanning Calorimetry (DSC) is a thermoanalytical technique used to quantify the 
change in the amount of heat required to increase the temperature of a sample measured as 
a function of temperature, with the behaviour of the sample determined by comparison to an 
inert substance, a reference, with the sample and reference maintained at the similar 
temperatures throughout the experiment. DSC, developed by E.S Watson and M.J O‟Neil in 
1960, is frequently used in the pharmaceutical and polymer industry to study curing 
processes, polymer degradation, melting point (Tm) as well as to evaluate polymer and drug 
purity. Polymer crosslinking can be assessed using thermograms, as crosslinking is an 
exothermic process, with a peak occurring soon after the glass transition temperature (Dean, 
1995; Pungor, 1995; Skoog et al., 1998).  
 
Thermal analysis was undertaken on the AZT-loaded nanoparticles, multipolymeric scaffold 
and the optimised nanoparticle-loaded scaffold formulation to ascertain thermal behaviour 
using DSC (Mettler Toledo DSC1, STARe System, Switzerland). 15-20mg samples were 
accurately weighed using a calibrated scale and were evenly distributed on perforated 40μL 
aluminum pans. The powder was then pressed to the crucible base using a Teflon rod. A 
pin-point hole, measuring 20µm in diameter was punched into the crucible lid, after which 
the crucible was sealed and placed on the heat-flux plate and exposed to temperature 
gradients as per Table 4.6.1 under a constant pressure of N2 atmosphere in order to 
minimise oxidation. The reference crucible was prepared in a similar manner, however, the 
crucible was left empty and two holes were punched into the crucible lid so as to differentiate 
the two crucibles. 
 
Thermal transitions were assessed in terms of the glass transition temperature (Tg), which 
was measured as the reversible heat flow due to variation in the magnitude of the Cp-
complex (Cp), Tm and the temperature of crystallization (Tc). The temperature calibration was 
accomplished with a melting transition of 6.7mg indium. The thermal transitions of the native 
polymers were compared to the prepared nanoparticle and scaffold formulations. 
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Table 4.6.1: Initial and final temperatures employed for DSC analysis 
 
Sample 
Start temperature 
(°C) 
End temperature 
(°C) 
Alginate -15 265 
Pectin -10 230 
PVA -30 218 
AZT -20 172 
PCL -30 85 
ECL -25 280 
CAP -20 250 
Nanoparticles -15 355 
Scaffolds 30 250 
Implants -20 160 
      
 
  
Table 4.6.2: Instrument parameters employed to perform assess thermal transitions. 
 
Sine Segment Loop Segment 
Initial temperature: as per Table 4.6.1 Increments: 0.8°C 
Heating rate: 1°C/min  
Amplitude: 0.8°C End temperature: as per Table 4.6.1 
    
 
4.4. Results and Discussion 
4.4.1 Fourier transform infrared analysis of the native polymer compounds and 
the prepared nanoparticle and multipolymeric scaffold formulations 
Infrared (IR) spectroscopy is the qualitative measurement of spectra in the IR region (0.7-
500 µm) of the electromagnetic spectrum, providing information concerning the chemical 
bonds and structure of molecules based on the manner in which IR radiation is absorbed by 
the chemical bonds in the compound (Mckelvy et al., 1998; Yuen et al., 2008; Roonasi et al., 
2009). Fourier transform infrared (FTIR) spectroscopy is a measurement technique, based 
on the dipole moment of molecules, by which to collect IR spectra (Yuen et al., 2008). 
Vibrational FTIR spectroscopic techniques are non-destructive to the applied sample and 
can potentially provide rapid, convenient solution to analytical problems, providing 
information regarding molecular structures of complex mixtures using a simple sample 
preparation technique (Gillie et al., 2000; Islam et al., 2004). 
 
The nanoparticle formulation, (Figure 4.21e), presented with bands between 3600 and 
3200cm-1 indicating the presence of possible hydroxyl and amino substituents, such as the 
amino group of AZT evidence at 3458cm-1 consistent with the presence of AZT and the 
polysaccharide polymers employed for the formulation of nanoparticles. The band at 
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3332cm-1 is more defined than that of alginate, indicating possible interactions of the 
polymers with the amino moieties present in AZT. Polymer interactions with AZT are further 
supported by the presence of a band at 2110cm-1 which can be attributed to N2 substitution. 
Shifting of the –COO- stretch to 1642cm-1 indicated possible polymer interaction with drug or 
CaCl2. Chemical modifications which occurred during nanoparticle formulation were 
independent of PVA, as seen in Figure 4.2.1. As PVA was incorporated into the formulation 
to merely impart surfactant properties to the nanoparticles, this was expected. 
 
Characteristic peaks between 1050 and 1300cm-1, were observed in the spectra of ECL, 
indicative of the cyclic ester present in the structure of ECL (refer to Figure 4.2.2b) and the 
carbonyl (-C=O) stretching was observed at 1652cm-1 and between 3400 and 3150cm-1. 
Bands between 2800 and 3000cm-1 are due to -C-H stretching. A strong carbonyl band was 
observed with PCL at 1721.02 cm-1, indicating the presence of an aliphatic ester. This band 
was also observed in the multipolymeric scaffold at 1721.40cm-1, consistent with PCL being 
the dominant polymeric entity in the multipolymeric scaffold. Bands at 1163 and 1233cm-1 
are due to -C-O groups and those between 1290-1420cm-1 are attributed to -(CH2)4 groups.  
 
The multipolymeric scaffold presented with a band at 1721.40cm-1, consistent with PCL and 
CAP. The band at 1656cm-1 can be attributed to the presence of a -C=O as observed in the 
spectra of ECL. The band at 3313cm-1 is due to -C=O stretching and those between 3000 
and 2800cm-1 are due to -C-H stretching. This can be observed in the spectra of all 
polymers. Bands between 1500 and 650cm-1 are similar to those observed in the spectra of 
PCL and ECL, with shifting of the bands due to polymer interactions and interaction of the 
polymers with CaCl2. Hydrogen interactions between the hydroxyl groups of CAP and the 
carbonyl groups of PCL also accounts for the band shifting observed (Ruseckaite and 
Jimenez, 2003). 
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Figure 4.2.1: FTIR images of AZT-loaded nanoparticles and their formulatory components 
depicting vibrational transitions occurring during nanoparticle preparation, with some peak 
designations indicated. (a) AZT, (b) alginate, (c) pectin, (d) PVA, (e) nanoparticle 
formulation. 
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Figure 4.2.2: FTIR images depicting multipolymeric scaffolds illustrating interactions and 
alterations in the scaffold as compared to the parent polymer compounds. (a) PCL, (b) ECL, 
(c) CAP, (d) multipolymeric scaffolds. 
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4.4.2 Microscopic evaluation of the prepared formulations 
4.4.2.1 Transmission Electron Microscopic analysis of the nanoparticles 
Spherical particles in the nanometre size range were observed on TEM images obtained as 
observed in Figure 4.3. Nanoparticles prepared with 0.28mg/100mL alginate and crosslinked 
with 10mg/10mL CaCl2 presented with particles ranging between 45-120nm with little 
agglomeration. This was attributed to superior crosslinking of these formulations, yielding 
more stable colloidal systems containing smaller nanoparticles.  
 
Notable agglomeration and larger particles, 300-475nm, were observed with formulations 
containing high alginate and low CaCl2 concentrations. Inadequate crosslinking of Ca
2+ with 
the viscous alginate solution with resultant large particles with a low surface charge 
distribution accounted for this tendency of the nanoparticles to agglomerate. This was 
consistent with zeta analysis findings described in Chapter 3. However, agglomeration was 
less pronounced than that observed with nanoparticles prepared in Chapter 3 due to the 
presence of PVA in the nanoparticle formulations which imparted surfactant properties to the 
prepared colloidal systems (Sanli et al., 2007; Bennewitz and Saltzman, 2009). 
 
Nanotubes were observed with all AZT-loaded nanoparticle formulations. Nanotube 
formation was due to the presence of N2 molecules in the AZT structure which interacts with 
the polymer chains in the nanoparticles.  AZT interaction with alginate and pectin was 
observed in the FTIR spectrum of the nanoparticle formulation, with shifting and alterations 
in the bands observed with the nanoparticle formulation, supporting interaction of the N2 
moieties with the –CH groups in alginate and pectin.  
 
Particles were observed within the nanotubes which is thought to be dispersed and 
entrapped AZT. These entrapped particles are also present in micrographs of spherical 
nanoparticles which were analysed at higher magnifications. AZT-loaded nanoparticles were 
prepared by crosslinking a solution containing both alginate and AZT. It is therefore possible 
for incompletely solubilised AZT to be entrapped within an alginate matrix in the observed 
manner. This would allow for prolonged controlled release of AZT as drug release was 
obtained with swelling and erosion of the alginate core (Bajpai et al., 2004; Moebus et al., 
2009), accounting for the low fractional release obtained with all prepared nanoparticle 
formulations. This observation was not made for AZT-free nanoparticles. 
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Figure 4.3: TEM images of nanoparticle formulations prepared using the Box Benhken 
parameters. (a) F6 presented with a dispersion of large and small spherical particles, 
(1mm=67nm). (b) and (c) F12 presented with evenly distributed spherical particles, ranging 
between 33-60nm, (1mm=33nm and 20nm respectively). (d) Agglomeration was observed 
with F7, indicated by the darker areas on the micrograph, (1mm=33nm). (e) Drug-free F1 
indicating a single nanoparticle imaged at a magnification of 100, measuring 50nm by 80nm 
in diameter, (1mm=10nm). (f) AZT-loaded F1 analysed under high magnifications showing a 
single nanoparticle with entrapped particles, thought to be dispersed AZT (1mm=10nm). (g) 
Nanotube formation, measuring 115nm in diameter, was observed with AZT-loaded 
nanoparticle formulations, (1mm=50nm). (h) and (i) Upon closer magnification, particles 
were seen entrapped within the nanotube structures measuring 55-60nm, proposed to be 
dispersed AZT molecules, (1mm=40nm and 20nm respectively). 
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4.4.2.2 Scanning Electron Microscopic Analysis of the Multipolymeric Scaffolds 
From the photomicrographs in Figure 4.4, it was observed that scaffolds prepared with 
higher polymer concentrations in the absence of a crosslinking agent displayed a more 
densely packed matrix than those containing low polymer concentrations. Small, uniformly 
dispersed pores were present within the polymer matrices, serving as an ideal location for 
the entrapment of nanoparticles (Yuan et al., 2009).  
 
Multipolymeric scaffolds crosslinked with CaCl2 presented with higher porous matrices, with 
a random dispersion of large and small pores observed on the micrographs. Larger pores 
are surrounded by regions of densely packed polymer. This would serve to retard PBS 
penetration into the polymer matrices, allowing for slow degradation of the multipolymeric 
scaffolds. Cracks and fissures observed within the multipolymer matrices can be attributed to 
the brittle nature of the prepared scaffolds. 
 
CAP is used often as a coating agent (Bechard et al., 1995). For the formulation of PCL-
ECL-CAP multipolymeric scaffolds, CAP has applicability with reference to its coating 
properties and as a plasticiser. This accounts for the coating observed around the scaffold in 
Figure 4.4i with a more porous matrix observed below. Larger areas of densely packed 
polymer matrices can be observed with scaffolds prepared with higher CAP concentrations, 
supporting the use of CAP as a plasticiser. CAP has been reported to coalesce upon 
exposure to heat and moisture, with hydrolytic degradation with elevated temperatures (Liu 
et al., 2002). At body temperature, 37°C, coalescence is anticipated to occur allowing for 
slower erosion of the multipolymeric matrix as PBS penetration into the polymer matrices is 
impeded and hence slow release of AZT-loaded nanoparticles from the multipolymeric 
scaffolds results. 
 
Upon erosion of the multipolymeric scaffolds, highly crystalline regions were observed within 
the polymer matrices (refer to Figures 4.4h and i). This is consistent with the high ECL and 
PCL concentrations used to prepare the scaffolds. PCL and ECL are semi-crystalline 
polymers which undergo hydrolytic degradation of the esters bonds primarily within the 
amorphous regions, with the crystalline regions degrading at a much slower rate (Rezwan et 
al., 2006). However matrix porosity was more pronounced with these scaffolds owing to the 
presence of the crosslinking agent due to high PCL and ECL content. Porosity is ideal for the 
dispersion of nanoparticles. Scaffold erosion and subsequent drug release is augmented 
with an increase in matrix porosity. With exposure to PBS, porosity was observed in the 
scaffold matrix due to erosion of the matrix as water penetrated the multipolymeric structure. 
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Figure 4.4: SEM images of the prepared PCL/ECL/CAP scaffolds analysed under various 
magnifications and keV of 5mV. (a) F10, prepared in the absence of CaCl2, presented with a 
tightly packed matrix, (1mm=100µm). (b) 7 days post exposure to PBS, (1mm=33µm) and 
(c) 21 days post exposure to PBS, (1mm=25µm). (d) Formulation 2, crosslinked with a 
7.5%w/v CaCl2 solution presented with similar trends to formulation 10, (e) 7 days post 
exposure to PBS, and (f) 30 days post exposure to PBS (1mm=200µm, 250µm and 250µm 
respectively). (g) Crystallinity was observed with formulation 6, (1mm=333 µm). (h) CAP 
coating can be seen, indicated by the lighter areas, with the inner multipolymeric core 
exposed as the CAP erodes, (1mm=33µm). (i) Larger pores were observed with scaffolds, 
F1, crosslinked with a 15%w/v CaCl2 solution, (1mm=250µm). 
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4.4.3 Size and Zeta Potential Analysis of Nanoparticle Formulation 
Formulations prepared using high alginate and low CaCl2 concentrations presented with a 
large average size distribution, which can be attributed to poor crosslinking occurring, 
especially formulations prepared using a shorter CT (15minutes). Penetration of Ca2+ ions 
into the viscous alginate solution is poor, yielding a loosely crosslinked polymer gel and 
resultant larger particles. These formulations presented with a ZP ranging between -2.41 
and -3.79mV indicating comparatively moderate stability of the colloidal system. As alginate 
is a negatively charged polymer (Bajpai and Sharma, 2004; Zactiti and Kieckbusch, 2006; Li 
et al., 2008), this was expected. However, formulations prepared with high alginate 
concentrations (0.5mg/200mL) and short CT (15minutes), presented with instability, as seen 
with formulation 15, due to the formation of loose aggregates rather than individual insoluble 
nanoparticles. The ZP of -1.87mV observed with formulation 15 can be attributed to poor 
penetration of Ca2+ into the viscous alginate solution due to insufficient agitation of the 
formulation. As with formulation 10, the presence of free Ca2+ ions served to destabilise the 
colloidal system. Charge stabilisation can be achieved by altering the concentration of ions 
in the solution with a resultant decrease in flocculation of the colloidal system leading to the 
formulation of smaller particles (www.malvern.com). This is due to potentially reversible 
adhesion/cohesion occurring between particles. 
 
The DVLO theory, developed by Deraguin, Verwey, Landau and Overbeek in the 1940‟s, 
suggests that the stability of a particle is dependent upon its total potential energy function 
VT, as per the equation below: 
 
SRAT VVVV                                        (Equation 4.2)
               
Where VS is the potential energy due to the solvent, and VA and VR are the van der Waals 
attractive forces and electrical double layer repulsive forces contributing towards formulation 
stability as the particles approach each other (www.malvern.com). 
 
Formulations prepared with lower alginate concentrations presented with average size 
distributions ranging between 102.6 and 38.93nm with PDI‟s above 0.4, indicating an even 
size distribution with the colloidal systems as observed in Figure 4.6.1. The smaller particles 
produced can be attributed to adequate penetration of Ca2+ ions into the less viscous 
alginate solutions, resulting in more effective crosslinking. The peak present in the 
micrometer size range in Figure 4.6.1 can be attributed to agglomeration of nanoparticles 
due to sedimentation upon analysis. Formulations prepared with a longer CT presented with 
smaller particles than those crosslinked for 15 minutes. An average particle size distribution 
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of 88.38nm with a PDI of 0.836 was observed with formulation 1, resulting from the high 
CaCl2 concentration and long CT used in the preparation of this formulation. 
 
 
 
Figure 4.6.1: Formulation 9 presents with a Z-average of 102.6nm and a PDI of 0.692. The 
single sharp peak indicates uniformity of the nanoparticles, supported by the PDI of 0.692 
obtained (n=3, SD<0.005 in all cases).  
 
A positive ZP was observed with formulations 7, 9, and 14. This can be attributed to the low 
alginate concentrations used to prepare these formulations. Alginate is a negatively charged 
polymer (Bajpai and Sharma, 2004; Zactiti and Kieckbusch, 2006; Li et al., 2008). Lower 
alginate concentrations would yield a colloidal system containing a lower distribution of 
negatively charged species than formulations prepared with higher alginate concentrations. 
The ZP of 2.52mV observed with formulation 9 can be attributed to the short CT (15minutes) 
used to prepare this formulation, with resultant free Ca2+ ions present in the colloidal system 
due to inadequate crosslinking of Ca2+ ions with alginate.  
 
Formulation 10 was prepared with a high alginate concentration, however the low CaCl2 
concentration employed to crosslink this formulation yielded a ZP of -0.831mV indicating 
formulation instability. This was due to inadequate penetration of Ca2+ ions into the viscous 
alginate solution, with resultant free Ca2+ ions in the colloidal system, counteracting the 
negative charge distribution imparted to the colloidal system by the high alginate 
concentration. 
 
Formulation stability was observed for formulations 12 and 13 due to the higher CaCl2 
concentrations and longer CTs employed for the preparation of these formulations. 
Formulations 12 and 13 also presented with suitable average particle size distributions of 
38.93nm and 46.15nm respectively, indicating adequate Ca2+ crosslinking.  
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Figure 4.6.2: Stability was demonstrated with formulation 13, indicated by the average ZP of 
-20.5mV obtained (n=3, SD<0.0002).  
 
Electron transfer within the formulation was sufficient enough to allow for repulsion between 
the particles. Additional peaks observed closer to 0mV indicates possible agglomeration of 
particles.  
 
Table 4.6: Zeta analysis results obtained from the 15 formulations generated using the Box 
Benhken design.  
 
Formulation 
Alginate 
(mg/mL) 
CaCl2 
(mg/mL) 
CT 
 (min) 
Z-average 
(nm) PDI 
ZP  
(mV) 
1 0.06 10 97.5 88.38 0.836 -2.47 
2 0.5 6 180 637.7 0.559 -3.79 
3 0.06 6 180 239.7 0.628 -2.59 
5 0.28 10 15 230.8 0.646 -1.66 
6 0.5 10 97.5 552.9 0.368 -2.41 
7 0.06 6 15 284.5 0.836 0.164 
9 0.28 2 15 102.6 0.692 2.52 
10 0.5 2 97.5 388.8 0.498 -0.831 
11 0.28 2 180 155.9 0.533 -3.31 
12 0.28 6 97.5 38.93 0.686 -14.5 
13 0.28 10 180 46.15 0.723 -20.5 
14 0.06 2 97.5 41.97 0.436 0.5 
15 0.5 6 15 399.6 0.381 -1.87 
              
 
4.4.4 Analysis of Polymer Matrix Resilience Using Textural Profiling 
An increase in MR was observed with formulations 1, 4, 5 and 7 after 30 days   of exposure 
to PBS (pH 7.4). This was attributed to low ECL (10-30%w/v), and CAP (5-12.5%
w/v) 
concentrations present in these scaffolds. Crosslinking with CaCl2 served to increase the 
porosity of the scaffolds, allowing for increased PBS permeation into the multipolymeric 
scaffolds. This increases solubility of the unionised CAP which occurs at pH‟s above 6 as the 
phthalic acid groups become ionised, allowing for hydrolysis of CAP (Bechard et al., 1995). 
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Formulation 7, prepared using 10%w/v ECL and 5%
w/v CAP displayed the highest MR at 
11.7% (SD<0.007) 30 days post exposure to PBS, pH 7.4.  
 
Little variation MR was observed with scaffolds uncrosslinked with CaCl2 and an initial MR of 
2.8% (SD<0.007) was observed with formulation 10, which increased to 3.1% (SD<0.007) 
after 30 days of exposure to PBS, pH 7.4. These scaffolds contained small evenly distributed 
pores in the absence of craters. ECL and PCL are known for its slow degradation resulting 
from hydrolytic de-esterification (Tarvainen et al., 2002; Sinha et al., 2004; Rezwan et al., 
2006; Abbah et al., 2009). Smaller evenly distributed pores present in the matrix reduced 
water permeation into the polymer matrix with resultant reduced polymer disentanglement 
and thus matrix erosion. 
 
Scaffolds prepared with high polymer concentrations displayed a decrease in matrix 
resilience upon exposure to PBS. This is possibly due to the degradation of the acetyl and 
phthalic acid groups of CAP, yielding the insoluble cellulose acetate (Bechard et al., 1995), 
which would serve to decrease matrix resilience. The crystalline segments of ECL are more 
stable than the amorphous regions thus contributing to reduced matrix resilience due to 
reduced water permeation into the multipolymeric matrix (Rezwan et al., 2006). 
 
4.4.5 Matrix Erosion and Swelling Studies 
An average weight loss between 20-40% (SD<0.001) was observed 30 days post exposure 
to PBS with scaffolds containing greater concentrations of CaCl2 and CAP displaying higher 
weight loss. The acetyl and phthalyl acid groups in CAP are reported to degrade at pH‟s 
greater than 6 (Bechard et al., 1995). Matrix erosion was assessed in PBS (pH 7.4). 
Penetration of PBS into the matrices of crosslinked scaffolds would therefore serve to 
hydrolyse CAP, resulting in erosion of the multipolymeric matrix. However, matrix erosion is 
expected to decline upon prolonged exposure to PBS due to hydrolysis of CAP to form the 
insoluble cellulose acetate (Bechard et al., 1995). 
 
Scaffolds prepared with 20%w/v CAP displayed slower erosion due to the higher 
concentrations of cellulose acetate present in the multipolymeric scaffolds after hydrolysis of 
CAP, consistent with the decrease in matrix resilience observed with these scaffold 
formulations. Scaffolds prepared in the absence of CaCl2, displayed lower erosion of the 
multipolymeric matrices. This can be attributed to a more tightly packed polymeric matrix, 
with decreased water penetration. 
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Formulation 13, prepared using 20%w/v CAP and 15%
w/v CaCl2, displayed unexpected high 
weight loss, at 59.28% after 30 days of exposure to PBS. Disintegration was observed 0.5 
days after exposure to PBS, pH 7.4. This could be due to possible leaching of Ca2+ ions out 
of the polymer matrix, with a resultant increase in water permeation into the scaffold matrix 
and increased erosion of the scaffold matrix. 
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Figure 4.7: Weight loss observed with the multipolymeric scaffolds prepared using the Box-
Benhken design parameters (n=3, SD<0.001). 
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Scaffolds prepared with higher ECL concentrations demonstrated lower weight loss of the 
multipolymeric matrices. ECL is semi-crystalline polyester which degrades by slow 
hydrolysis of the ester bonds, with the crystalline segments in the polymer more stable than 
the amorphous regions (Tarvainen et al., 2002; Sinha et al., 2004; Luong-Van et al., 2006; 
Rezwan et al., 2006). Enhanced crystallinity of the multipolymeric scaffolds is responsible for 
the low weight loss observed. 
 
No swelling was observed with the multipolymeric scaffolds.  
 
4.4.6 Drug entrapment efficiency of the nanoparticles 
An average DEE of 91.1% was calculated for AZT-loaded nanoparticles. The high DEE 
obtained is accredited to the high drug:polymer ratio and the ability of alginate to form a gel 
in the presence of an aqueous medium, with the hydrophilic AZT encapsulated within this gel 
structure (Zahoor et al., 2005; 2006). Alginate gelation occurs under mild conditions in an 
aqueous environment, enabling the entrapment of a variety of drug molecules into this gel 
structure (Bajpai et al., 2004). As AZT is a hydrophilic drug, a high degree of AZT 
entrapment within the Ca2+-alginate gel structure was expected (Thomas and Panchagnula, 
2003; Prakash et al., 2008). 
 
4.4.7.1 Drug release from the nanoparticles and multipolymeric systems 
Drug release from the nanoparticle formulations not confined within the polymeric scaffold 
displayed burst release of AZT within the first 24-48hours. Burst release of AZT is due to 
association of AZT onto the surface of alginate by weak interactive forces, which is reversed 
upon exposure to PBS (Li et al., 2008). Burst release of drug is not uncommon in monolith 
drug delivery systems, which although dangerous due to potential toxicity resulting from 
dose dumping, can be utilised advantageously for conditions requiring an initial high dose of 
therapeutic agents followed by lower sustained maintenance doses of the drug, such as 
inflammatory conditions and conditions of infectious origin. However, this is not required for 
the treatment of ADC. Dispersion of the nanoparticles within the multipolymeric matrix 
served to alleviate this burst release as nanoparticles were released gradually precluding 
dose dumping as the multipolymeric scaffold eroded allowing for controlled release of AZT 
(Ciofani et al., 2008). 
 
Nanoparticle formulations prepared demonstrated average drug release of between 7-18% 
30 days post exposure to PBS with formulation 6 demonstrating the lowest release at 7.75% 
and formulation 11 displaying with the highest release at 17.31%. Formulation 6 was 
crosslinked with a high concentration of CaCl2, (10%
w/v) resulting in a tightly crosslinked 
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polymer matrix with AZT entrapped within. Drug release was therefore retarded. Formulation 
11 was crosslinked with a lower CaCl2 concentration. Swelling of the loosely packed alginate 
matrix promoted AZT release from the nanoparticles.  
 
An overall low release of AZT from all nanoparticle formulations can be attributed efficient 
crosslinking of the alginate with CaCl2, entrapping AZT within the nanoparticles. Alginate and 
pectin are hygroscopic polymers with a propensity to swell and gel when exposed to water 
(Liu et al., 2003; Sriamornsak et al., 2007; Moebus et al., 2009) with resultant controlled 
release of AZT as the nanoparticles imbibe fluid. Swelling increases the diffusion path length 
for AZT to travel in order to be released into the dissolution media, thereby acting to reduce 
the amount of drug released (Sriamornsak et al., 2007). Addition of pectin to the nanoparticle 
formulation served to extend drug release from the nanoparticles over prolonged periods as 
pectin displays an increased propensity to gel when crosslinked with Ca2+ and when blended 
with alginate. This gel layer poses a barrier to the release of hydrophilic AZT as water 
penetration through this layer was hindered (Liu et al., 2003; Sriamornal et al., 2007; Glavas 
et al., 2009). 
 
Loosening of the polymer network occurs as Ca2+ ions diffuse out of the nanoparticles due to 
ion exchange occurring between Na+ ions present in PBS which facilitated release of AZT. 
(Bajpai et al., 2004; Gao et al., 2009; Moebus et al., 2009). A study conducted by Bajpai et 
al., in 2004 suggested that Ca-alginate swelling occurs as a result of PBS due to ion 
exchange with resultant Ca2+ disassociation from the COO- groups present on the 
mannuronic acid residues. Ca2+ forms calcium phosphate with an increase in the turbidity of 
the PBS as observed by Bajpai et al. (2004). Swelling and turbity was absent when a Tris-
HCl buffer, pH 7.4 was used. Electrostatic repulsion of the negatively charged COO- groups 
with resultant polymer chain relaxation and an increase in the water uptake into the polymer 
matrix account for AZT release from the nanoparticles (Bajpai et al., 2004).  
 
Pectinolysis resulting from enzymatic breakdown by enzymes naturally occurring in the body 
also accounts for polymer chain loosening and drug release (Li et al., 2003). Alginate 
degradation is slow, with hydrolysis resulting from water penetration into the crosslinked 
alginate Ca2+ complex accounting for alginate degradaton (Gao et al., 2009). 
    
 
 
 
 106 
 
2D Graph 4
Time (hours)
0 200 400 600 800 1000
F
ra
c
ti
o
n
a
l 
D
ru
g
 R
e
le
a
s
e
 
0.00
0.05
0.10
0.15
0.20
F1
F2
F3
F5
F6
F7
F9
 
2D Graph 5
Time (hours)
0 200 400 600 800 1000
F
ra
c
ti
o
n
a
ls
 D
ru
g
 R
e
le
a
s
e
0.00
0.05
0.10
0.15
0.20
0.25
0.30
F10
F11
F12
F13 
F14
F15
 
Figure 4.8: Drug release profiles of (a) nanoparticle formulations 1-9, (b) nanoparticle 
formulations 10-15 prepared using the Box Benhken design template (n=3, SD<0.0005). 
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4.4.7.2 Mean Dissolution Time  
In vitro dissolution is used to establish bioequivalence by relating pharmacokinetic 
performance of the drug delivery device to drug release (Ginski et al., 1999). In vitro 
dissolution is used to establish quality of the prepared formulation and is particularly 
important when analysing controlled release devices (Costa et al., 2003). MDT, a model 
independent approach, was used to compute drug release, with the individual characteristics 
of each curve translated into a single value (Ginski et al., 1999; Costa et al., 2003). MDT is 
used to ascertain equivalence between different drug release profiles or to statistically 
compare profiles (Podczeck, 1993). 
 
Table 4.7: MDT values of nanoparticle and scaffold formulations, indicating a decline in the 
rate of AZT release with the dispersion of nanoparticles within a multipolymeric scaffolds. 
 
Nanoparticle 
Formulations MDT 
Scaffold 
Formulations MDT 
1 18.315 1 11.231 
2 20.64 2 16.662 
3 24.422 3 10.364 
5 18.855 4 1.714 
6 17.862 5 -8.27 
7 20.844 6 -11.59 
9 29.753 7 -10.212 
10 33.239 9 -9.816 
11 38.375 10 7.127 
12 25.169 11 11.358 
13 26.398 13 11.085 
14 36.484 14 11.073 
15 24.39 15 -13.38 
        
 
 
4.4.8 Analysis of the Box-Benhken design generated for nanoparticles and 
multipolymeric scaffolds 
4.4.8.1 Zeta size and potential study 
From Figure 4.9.1 it can be concluded that low alginate and CaCl2 concentrations produced 
formulations with optimal size distributions, between 40-250nm (SD<0.0002). Stirring time 
had no influence on the average diameter obtained. However, discrepancies were noted, as 
with formulation 13, which comprised of a 0.28mg/100mL alginate solution crosslinked with 
10mg/10mL CaCl2 solution over 180minutes, yielding nanoparticles with an average size 
distribution of 46.15nm (SD<0.0002) and a PDI of 0.489. Smaller quantities of CaCl2 are 
introduced into the pre-gelation stage over extended periods allowing for more efficient 
crosslinking of alginate with resultant smaller particles being produced.  
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Instability was noted at the upper and lower limits of alginate and CaCl2 concentrations as 
well as with CT, as seen in Figure 4.9.1b. Alginate is an anionic polymer which upon 
crosslinking with the cationic CaCl2 produces nanoparticles with negative zeta potential 
values as seen in Table 4.6 (Bajpai and Sharma, 2004; Zactiti and Kieckbusch, 2006; Li et 
al., 2008). When alginate concentrations are low, an inadequate charge distribution results 
due to the presence of the cationic Ca2+. This would yield a colloidal system with reduced 
negativity, as seen with Formulation 7, which has an average zeta potential of 0.164mV 
(SD<0.00025). A more concentrated alginate solution would consequently yield a thick gel 
upon crosslinking. This would resultantly retard Ca2+ crosslinking, with a larger free Ca2+ ion 
concentration being present in the colloidal system, which would once again instil positivity 
to the system, consequently destabilising it.  
 
 
 
 
 
Figure 4.9.1: Surface plots of (a) average size distribution and (b) zeta potential attained for 
nanoparticles prepared as per the parameters obtained from the Box-Benhken design. 
 
4.4.8.2 Textural Analysis of the multipolymeric scaffold device 
The average MR of the prepared formulations was plotted as a function of time, as per 
Figure 4.9.2.1, from which the correlation co-efficient (R2) and gradient of the curve was 
calculated. A positive gradient indicated an increase in the ave resilience of the formulation 
ove time and a negative gradient indicated a decrease in the average MR of the formulation 
over time as observed in Table 4.8. The R2 value represented the variation in MR observed 
with the formulations, with a higher R2 indicating a larger variation in the MR of a formulation. 
 
Figure 4.9.2.2a indicates that the R2 approached 1 for formulations prepared with low ECL 
and CAP concentrations and a high concentration of CaCl2. This is consistent with the higher 
concentration of crosslinking agent increasing the porosity of the prepared scaffolds, 
resulting in greater variability being oberserved with the MR of the formulations. Low polymer 
(a) 
(b) 
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concentrations used for the preparation of the multipolymeric scaffolds would also serve to 
increase the porosity of the scaffold matrices. 
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Figure 4.9.2.1: MR plots used for the calculation of R2 and gradients used for the 
optimisation of the multipolymeric scaffolds, with (a) indicating a formulation with a high R2 
value and a negative gradient and (b) indicating a formulation presenting with a low R2 value 
and a positive gradient. 
 
As per Figure 4.9.2.2b, the gradient was affected most signicantly with the concentration of 
ECL utilised for the preparation of the multipolymeric scaffolds, with a high concentration of 
ECL producing a negative gradient and hence a formulation displaying a decrease in MR 
y = 0.44x + 2.0782 
 
R
2
 = 0.6326 
y = -0.458x + 5.2301 
 
R
2
 = 0.9904 (a) 
(b) 
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over time. As the concentration of ECL affects the overall crystallinity of the formulation, this 
is expected, with an increase in the crystallinity of the formulation decreasing MR a less 
porous scaffold matrix, less susceptible to erosion will result. 
 
Table 4.8: Textural profiling of multipolymeric formulations prepared using the Box-Behnken 
parameters. 
 
Formulations R2 Gradient 
1 0.9904 -0.458 
2 0.042 -0.1845 
3 0.6392 0.517 
4 0.6326 0.44 
5 0.6598 0.6934 
6 0.8352 -0.4043 
7 0.8971 1.238 
9 0.8266 0.1855 
10 0.0004 -0.0022 
11 0.9334 -0.3189 
13 No Results  
14 0.6932 -0.3238 
15 0.9236 -0.2924 
   
 
 
 
 
 
Figure 4.9.2.2: Surface plots generated using the Box-Benhken design of parameters 
indicating (a) the correlation and (b) the gradient obtained with change in the concentrations 
of ECL, CAP and crosslinking agent used for the preparation of multipolymeric scaffolds. 
 
4.4.8.3 Drug Release from the nanoparticles and multipolymeric scaffolds 
The surface plots generated for the nanoparticle formulations illustrated MDT to be optimum 
when CaCl2 concentrations are low, 30%
w/v and below. This was expected as Ca
2+ reacts 
with the guluronic acid residues on alginate to form a crosslinked interpolymeric network 
capable of entrapping drug molecules within (Li et al., 2008, Moebus et al., 2009). At lower 
CaCl2 concentrations, a more loosely associated polymeric network would form, into which 
(a) 
(b) 
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larger quantities of drug would be entrapped and subsequently release with exposure to 
PBS.  
 
MDT was relatively impervious to the effects of alginate concentration and ST, however 
minor increases in MDT were observed at the upper and lower limit of alginate concentration 
and when ST was kept at 100minutes. This could be attributed to possible leaching of the 
hydrophilic AZT upon prolonged exposure to the aqueous crosslinking solution. Lower 
concentrations of drug would therefore be entrapped within the nanoparticles with ensuing 
lower drug release upon prolonged exposure to PBS. Alginate displays an affinity for amino 
groups (Zahoor et al., 2005), which are present on the AZT molecule (Figure 3.6b). 
Association of AZT to the alginate molecules is therefore independent of polymer 
concentration. This also accounts for the sustained release behaviour of AZT as seen in 
Figures 4.8a and b. However, with high alginate concentrations and low CT, as per Figure 
4.9.3a, a higher MDT is expected. This can be attributed to instability of the colloidal system 
observed with these parameters leading to agglomeration of the nanoparticles. Larger 
nanoparticles are capable of imbibing more water due to the hydrophilic nature of alginate, 
with a resultant increase in drug release due to bulk erosion and swelling of the 
nanoparticles. 
 
 
 
 
 
Figure 4.9.3: Surface plots of MDT values obtained with (a) nanoparticle formulations and 
(b) nanoparticles dispersed within multipolymeric scaffolds. 
 
MDT is optimum when CAP concentrations are high. CAP was used as a hydrophobic 
binding agent in the preparation of the multipolymeric scaffolds. The scaffolds are therefore 
less prone to erosion in an aqueous dissolution medium at higher CAP concentrations, 
retarding nanoparticle and therefore AZT release. Marginal increases in MDT were observed 
as visualised on the surface plots in Figure 4.9.3. At higher ECL concentrations, the 
(a) 
(b) 
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multipolyermic scaffold would undergo degradation in the presence of PBS by hydrolysis of 
its ester bonds (Huang et al., 2004; Luong-Van et al., 2006; Rezwan et al., 2006). 
Resultantly, higher concentrations of nanoparticles are released into the dissolution media 
thereby increasing AZT release. Suboptimal crosslinking of the multipolymeric polymer 
solution occurs at low CaCl2 concentrations with increased water permeation, resulting in 
polymer degradation and subsequent nanoparticle release. 
 
4.4.9 Preparation of the optimised drug delivery device using the Box-Benhken 
design 
Optimised nanoparticle and multipolymeric scaffold formulations were computed using the 
Box Behnken design. Nanoparticles and multipolymeric scaffolds were prepared using the 
method stated in Section 4.3.1.1 and 4.3.1.2 respectively using the parameters stated in 
Table 4.9. 
 
Table 4.9: Parameters generated via the Box-Behnken template utilised for the formulation 
of the optimised nanoparticle and scaffold formulations. 
 
  Nanoparticle formulation Scaffold Formulation 
Parameter Alginate CaCl2 CT CAP ECL CaCl2 
Upper 0.5 10 180 50 15 20 
Optimised 0.3294 2 88.1896 12.285 0.2484 20 
Lower 0.06 2 15 10 0 5 
       
 MDT Size ZP MDT Correlation Gradient 
Objective maximise minimise -10 maximise 0.99 -0.3 
Target 30.9968 155.5005 -10.0013 12.3814 0.99 -0.3 
Deviation 
factor 0,83987 0.98778 0.99987 0.82543 1.00 1.00 
           
 
4.4.10 Analysis of Optimised Nanoparticles and Multipolymeric Scaffold 
Formulation 
4.4.10.1 Zeta size and potential analysis of the nanoparticle formulation 
Drug-free nanoparticles presented with an average particle size distribution of 42.54nm 
(SD<0.0002), with a PDI of 0.604, whereas drug-loaded nanoparticles presented with an 
average particle size distribution of 68.04nm (SD<0.0002), with a PDI of 0.584. Single 
narrow peaks were observed for both formulations, indicating uniform dispersion of the 
nanoparticle colloidal systems. ZPs of -13.4 and -10.61mV (SD<0.0005) were obtained for 
drug-loaded and drug-free nanoparticles respectively, indicating stability of the colloidal 
systems. This can be attributed to the presence of PVA which imparted surfactant properties 
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to the colloidal system, serving to reduce agglomeration and enhance formulation stability 
due to steric hindrance (Bennewitz and Saltzman, 2009). The lower alginate concentration 
used to prepare the optimised nanoparticle formulation served to enhance formulation 
stability due to optimum crosslinking with Ca2+. Alginate concentrations of 0.329mg/100mL 
were used to prepare drug-loaded and drug-free optimised nanoparticle formulations, with a 
CT of 88.19 minutes, allowing for adequate penetration of Ca2+ ions into the alginate 
solutions with optimum crosslinking of Ca2+ with the guluronic units in alginate (Douglas et 
al., 2006; Liu et al., 2008; Sriamornsak et al., 2008; Moebus et al., 2009). Minimal free Ca2+ 
ions were therefore present in the colloidal system resulting in a stable system with a 
negative charge distribution, attributed to the anionic polymers used for the preparation of 
the optimised nanoparticle formulation (Bajpai and Sharma, 2004; Zactiti and Kieckbusch, 
2006; Li et al., 2008). Possible AZT interaction with alginate and pectin allowed for more 
efficient transfer of electrons to the colloidal system, stabilising the drug-loaded optimised 
nanoparticle formulation by enhancing the repulsive forces that exists between the particles 
as they approach each other due to Brownian motion (www.malvern.com). 
 
Drug-loaded nanoparticles presented were larger than nanoparticles prepared without AZT 
due to nanotube formation and AZT encapsulation within the nanoparticles as observed in 
TEM images in Chapter 3, Section 3.3.2.1. The controlled gelification of alginate approach 
allows for the preparation of nanoparticles capable of circulating drug within the CNS due to 
the small size (68.04nm) as particles in the size range of 20-50nm have been found to 
bypass the BBB and circulate within the brain. The negative potential (-13.4mV) obtained 
abets sustained drug delivery throughout the CNS as neutral or negatively charges 
molecules presents with a greater volume of distribution within the CNS (Thorne et al., 2006; 
Yang et al., 2008; Benewitz and Saltzman, 2009; Rahman et al., 2009).  
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Figure 4.10: (a) An average size distribution of 68.04nm was obtained for optimised AZT-
loaded nanoparticles. (b) Stability of the formulation as implied by the ZP of -13.4mV 
obtained owing to electrostatic charge stabilisation of the colloidal system. 
 
4.4.10.2 Matrix resilience studies of the multipolymeric scaffolds 
An average MR of 1.862% (SD<0.007) was obtained 1 hour post exposure to PBS, pH 7.4, 
indicating low porosity of the prepared scaffold. MR increased to 4.451% (SD<0.007) 30 
days post exposure to PBS. Porosity increased with increased exposure to PBS consistent 
with erosion of the scaffold matrix due to CAP degradation. Due to slow degradation of 
aliphatic polyesters, ECL and PCL, MR remained low with prolonged exposure to PBS. 
Water permeation into the polymer matrix was resultantly low, with reduced disentanglement 
of the polymer matrix, ideal for the prolonged release of AZT-loaded nanoparticles from the 
polymer scaffold. Entrapped phosphate ions present within the pores of the scaffold matrix, 
attributed to diffusion of PBS into the multipolymeric matrix, could also be responsible for the 
low matrix resilience obtained. The mechanical strength demonstrated by the prepared 
multipolymeric device is reflected by the ability of the device to remain intact during 
dissolution testing, handling and storage (Liu and Williams, 2002). 
 
4.4.10.3 Thermal transitions between prepared formulations and parent compounds 
DSC thermograms were used to illustrate thermal transitions which occurred in terms of Tg, 
and Tm in the formulation of nanoparticle and multipolymeric scaffold formulations.  
 
Analysis of the thermograms revealed endothermic transitions at the temperatures as listed 
in Table 4.10, corresponding to the meting point of the samples. Changes in the 
thermodynamic behaviour of the nanoparticle and scaffold samples were attributed to 
polymer chain rotation occurring during the preparation of nanoparticle and scaffold 
(b) 
(a) 
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formulations. Interaction of PCL with ECL and CAP yielded a decrease in the Tm observed 
with the multipolymeric scaffold formulation, 50°C as compared to that of PCL which was 
observed at 60°C as depicted in Figures 4.11.2b and 4.11.1b respectively. 
 
Table 4.10: Thermal events observed with native polymer and prepared nanoparticle and 
multipolymeric scaffold samples analysed employing DSC. 
 
  
Temperature transition points 
(°C) 
Formulation 
component Tg Tm  
PCL -60 60  
ECL -18 -15  
CAP 175 192  
Alginate 125 280  
Pectin -5 152  
PVA 119 198  
AZT - 40  
AZT-loaded 
nanoparticles 155 240  
Multipolymeric scaffold - 50  
        
Tg of PCL and ECL was obtained from literature (Kweon et al., 2003; Lee and Yang, 2002). 
 
Tg, observed as a discontinuity of the baseline, is a second order transition involving a 
discontinuous change in a second thermodynamic quantity, specifically heat. Tg occurs when 
crystallisation is impossible under the given conditions being assessed, with Tg being a more 
subtle transition than crystallisation, melting, evaporation or chemical reactions as Tg has 
neither enthalpy or entropy, with changes occurring only in heat capacity (Cp). The specific 
heat capacity change (Cp) is the change observed between the onset and end of the 
transition. Tg is generally taken as the intersection of the midpoint of the Cp with a straight 
line joining the onset and the end of the transition (Aulton et al., 1995). Vertically dashed 
lines are representative of the glass transition and horizontally dashed lines represent 
shifting of the baseline resulting from Cp where β represents the heating rate (T/t), at the 
glass transition, as depicted in Figure 4.11.1a.  
 
The optimised nanoparticle formulation demonstrated typical changes in its structure at the 
Tg, transforming from a brittle, glassy state to rubbery state attributed to increased segmental 
mobility of the polymers. Modification in the Tg of the nanoparticle formulation (155°C) as 
compared to 125°C observed for alginate the primary polymer employed for the formulation 
of nanoparticles, resulted from the interaction of alginate with the copolymers, pectin and 
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PVA, as well as inter- and intramolecular crosslinking of alginate with Ca2+. An increase in 
the Tg indicated a decline in the mobility of the polymer chains upon nanoparticle 
formulation, serving to support the slow release of AZT from the nanoparticles as observed 
in Section 4.4.7.1 above (Takka, 2003). Noteworthy is the large variation between the Tm 
obsevered for the optimised nanoparticle formulation of 240°C and that of the primary 
polymer alginate (280°C). The altered thermal behaviour observed influences the 
physicomechanical behaviour of the prepared nanoparticle and mutlipolymeric scaffold 
formulations as previously demonstrated by FTIR analysis and textural profiling conducted in 
Sections 4.4.1 and 4.4.4 respetively. Figure 4.11.2b and 4.11.2c elucidated no changes in 
thermal events occurring during the dispersion of AZT-loaded nanoparticles within the 
mulitpolymeric scaffold. As no energy was expended during the dispersion process, this was 
expected. 
 
PCL, ECL and multipolymeric scaffold formulations were not analysed due to constraints 
posed by the equipment (the minimum temperature obtained by the Mettler Toledo DSC1 is -
30°C).  
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Figure 4.11.1: DSC thermograms obtained for (a) PVA and (b) PCL indicating the Tg and 
Tm obtained. 
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Figure 4.11.2: DSC thermograms of (a) optimised nanoparticle formulations (b) optimised 
multipolymeric scaffolds and (c) nano-enabled drug delivery device. 
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4.4.10.3 Matrix Erosion exhibited by the multipolymeric scaffold formulation 
The optimised polymeric scaffold exhibited an average matrix erosion of 28% (SD<0.001) 30 
days post exposure to PBS pH 7.4. ECL and PCL are semi-crystalline aliphatic polyester, 
containing both crystalline and amorphous regions. ECL and PCL degrades by hydrolytic 
cleavage of the ester bonds (Rezwan et al,. 2006; Chang and Lee, 2009), occurring primarily 
in the amorphous regions on the polymers as the crystalline regions of PCL are more 
chemically stable (Tarvainen et al., 2002; Sinha et al., 2004; Luong-Van et al., 2006; 
Rezwan et al., 2006; Uto et al., 2008; Abbah et al., 2009). CAP displays low solubility in 
water and is insoluble and unionised in acidic environments. CAP contains 35% phthalyl and 
24% acetyl groups, the hydrolysis of which yields the insoluble cellulose ester (Bechard et 
al., 1995). Erosion of the multipolymeric scaffold is slow as a result. 
 
A 12.285%w/v CAP solution was used to prepare the optimised scaffold formulation. As CAP 
was added to the formulation due to its ability to serve as an internal plasticiser to the 
crystalline ECL and PCL, adequate binding of the polymer solutions occurred (Berchard et 
al., 1995). A 2%w/v CaCl2 solution was used to crosslinked the polymers 
(CT=88.1896minutes). A less porous scaffold was thus formed with low erosion due to 
decreased water permeation into the optimised multipolymeric formulation.  
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Figure 4.12: Matrix erosion of the multipolymeric scaffolds in PBS pH 7.4 over 30 days (n=3, 
SD<0.001). 
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4.4.10.4 Drug release of the optimised nanoparticle and scaffold formulations 
The optimised nanoparticle formulation displayed an average drug release of 28.56% 
(SD<0.0005) 30 days post exposure to PBS and an MDT of 46.046 (SD<0.0005). A burst 
release of 18.10% was observed within 24hours due to adsorbed AZT on the surface of the 
particles. Ca2+ interaction with the COO- groups on the guluronic acid residues yielded a 
tightly packed polymer matrix, with low water permeability. An insoluble gel was the result. 
Interaction of Ca2+ ions with the mannuronic acid residue also occurs, however this does not 
yield a stable compound. Nanoparticle swelling therefore occurs primarily as a result of Ca2+ 
leaching out of the mannuronic acid units, with resultant AZT release. As binding of Ca2+ to 
the guluronic acid units yield a stable compound, Ca2+ diffusion occurs only after prolonged 
exposure to PBS, with extensive swelling of the crosslinked matrix and ultimate degradation 
occurring (Bajpai et al., 2004; Moebus et al., 2009). High CaCl2 concentrations were utilised 
for the preparation of the nanoparticles, with a tightly packed stable matrix resulting, as per 
zeta size analysis. Drug release, proposed to occur due to Ca2+ diffusion out of the 
mannuronic acid units, was therefore slow. 
 
Dispersion of AZT-loaded nanoparticles within a multipolymeric scaffold served to reduce 
drug release to 17.35% and the MDT to 12.570, 30days post exposure to PBS. This is 
significantly lower than that of the nanoparticle formulation alone. Nanoparticles are 
entrapped within the pores of the multipolymeric scaffold. Nanoparticles are released with 
scaffold erosion, resulting in the retarded release of AZT when dispersed within the 
multipolymeric scaffold. However drug release was higher than expected. As polymeric 
scaffolds exhibited a low matrix erosion of 28% (SD<0.001) 30days post exposure to PBS 
pH 7.4, release can be attributed to diffusion of the hydrophilic AZT out of the nanoparticles 
still entrapped within the polymer matrix.   
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Figure 4.13: Drug release from the nanoparticle formulation and the nanoenabled 
multipolymeric scaffold illustrating a decrease in AZT release upon dispersion within the 
scaffold (n=3, SD<0.0005). 
 
 
4.5 Concluding Remarks 
The CNS is one of the principle reservoirs for the harbouring and replication of the HI virus. 
The resultant complications which ensue are debilitating and potentially fatal in nature, 
requiring therapeutically significant drug concentrations in the brain to manage the condition 
(Rao et al., 2008). Nanotechnology offers significant promise for the improvement of quality 
of life of ADC sufferers through the development of novel controlled release drug delivery 
systems capable of achieving therapeutic levels of ARVs in the brain over a period of 
months to years (Yang et al., 2008). Nanotherapeutic agents are capable of enhancing drug 
entry into the CNS due to its small size and larger surface area, as well as sustaining the 
retention of these drugs over prolonged periods. This is critical for the control of viral 
replication and to decrease drug resistance. Nanocarriers have therefore received much 
attention in recent years for the management of neurological disorders (Rao et al., 2008) and 
have therefore been employed in the preparation of the multipolymeric implants. 
 
AZT-loaded nanoparticles dispersed within a multipolymeric PCL/ECL/CAP scaffold 
displayed satisfactory drug release behaviour. High drug loading, suitable size and stability 
was observed with the nanoparticles prepared, with a further enhancement in formulation 
stability observed for the optimised formulation. Robust multipolymeric scaffolds were 
prepared which presented with low matrix erosion attributed to the use of semi-crystalline 
720 360 120 240 600 480 0 
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polymers recognized for their slow degradation in vivo, which served to retard AZT release. 
The prepared nano-enabled multipolymeric drug delivery system has demonstrated 
suitability for application as a brain implant in the management of ADC. In vivo studies in an 
animal model follows in Chapter 5 serving to prove safety and compatibility of the NMDDD 
for human application as there is no standard currently available by which to compare the 
product being developed (Ginski et al., 1999; Costa et al., 2003).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 123 
 
CHAPTER 5 
 
In vivo evaluation of an implantable polymeric configuration for 
application in AIDS dementia complex 
 
 
5.1. Introduction 
Since the introduction of highly active antiretroviral therapy (HAART) in 1995, the morbidity 
and mortality associated with Human Immunodeficiency Virus (HIV)/Acquired 
Immunodeficiency Syndrome (AIDS) has been dramatically reduced. However, millions of 
lives are still lost each year (Schneider et al., 2005; Lewis et al., 2007; das Neves et al., 
2009). The blood brain barrier (BBB) is compromised during infection with HIV, providing a 
means by which infected cells can enter into the brain. The brain forms a sanctuary for the 
HIV. An increased influx of viral cell into central nervous system (CNS) acts to form a viral 
reservoir for the replication of the virus, impermeable to antiretroviral therapy (ARV) therapy 
due to the restrictions posed by the BBB and blood-cerebrospinal fluid (CSF)-interface. An 
increase in neuropathologies, including neurocognitive impairment and ADC observed with 
HIV patients therefore results (Antinori et al., 2007; Toborek et al., 2005; Wang et al., 2008; 
Valcour et al., 2010). 
 
The BBB and blood-CSF interface regulates the access of substances into the brain, thereby 
shielding it from harmful substances (Varatharajan and Thomas, 2009; Georgieva et al., 
2010) as illustrated in Figure 5.1. Many more ARV‟s have been found to cross the BBB and 
blood-CSF-interface as described in Table 5.1. However, of these drugs, zidovudine (AZT) 
remains the drug of choice for the treatment and management of neurological conditions 
associated with HIV infection of the CNS.  AZT, a polar molecule, displays the best CNS 
penetration to date in the NRTI class of ARVs (Sawchuk and Yang, 1999; Narishetty and 
Panchagnula, 2004; Agarwal et al., 2010). PI‟s are capable of traversing the BBB, however 
glycoprotein (P-gp), an ATP-dependent efflux pump, limits the accumulation of 
therapeutically significant concentrations of these drugs in the CNS. The CNS adverse 
effects, such as hallucinogenic dreams, associated with the use of efavirenz, an non-
nucleoside reverse transcriptase inhibitor (NNRTI), limits its use due to the high 
concentrations required for the management of AIDS dementian complex (ADC) 
(Varatharajan and Thomas, 2009). 
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Table 5.1: CNS-penetrating effectiveness (CPE) rank of AVR’s as proposed by Letendre et 
al. (2008). This is based on the physicochemical characteristics of the drugs (adapted from 
Varatharajan and Thomas, 2009). 
 
 
High Intermerdiate Low 
Zidovudine Stavudine Tenofovir 
Abacavir Lamivudine Didanosine 
Delavirdine Emtricitabine Zalcitabine 
Nevirapine Efavirenz Nelfinavir 
 Amprenavir Ritonavir 
 Fosamprenavir Saquinavir 
 Atazanavir Enfuvirtide 
 Indinavir  
      
 
Figure 5.1 presents the major pathways of penetration of drugs through the BBB into brain 
tissue. These pathways are frequently manipulated by pharmaceutical scientists for the 
formulation and development of new neurotherapeutic agents.   
 
A number of approaches have been investigated and utilised for the delivery of therapeutic 
agents into the CNS as listed below: 
 Hyperosmolar BBB opening: transient disruption of the BBB by means of intra-
arterial injection of a hyperosmolar solution (nonelectrolyte solutions such as 
glucose, sucrose, aribinose, mannitol and urea is often used), usually into the carotid 
artery. This induces the widening of the tight junctions by the osmotic shrinkage of 
the capillary endothelial cells with resultant increased permeability of the BBB to drug 
molecules. Limitations include oedema, encephalitis and possible toxicity due to lack 
of selectivity of the substances entering the brain. Seizures have been reported in 
approximately 20% of patients receiving this therapy. Partial vascular distribution 
within the brain is achieved and targeting drug delivery remains a challenge (Prokai 
et al., 2000; Kaya et al., 2004; Fiandaca et al., 2008; Bennewitz and Saltzman, 
2009). 
 Ligand-specific transport systems: brain capillaries contain carrier-mediated 
transport systems for the transport of endogenous molecules into the CNS. Ligands, 
including monoclonal antibodies and modified proteins, are therefore incorporated 
into drug delivery systems to mimic these endogenous substances to enhance drug 
uptake into the CNS. Protection against premature drug degradation in biological 
fluids is offered by the ligand-nanoparticulate complex. Limitations include 
competitive inhibition of the drug delivery system with the natural compounds (Misra 
et al., 2003; Reis et al., 2006; Benewitz and Saltzman, 2009). 
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Figure 5.1: Brain capillary endothelial cells and astrocytes present in the BBB regulate the passage of molecules into the brain. There are 
several pathways present which facilitates the entry and accumulation of drug molecules into the brain. Pathway A facilitates the entry of 
hydrophilic agents into the brain via tight junctions present between the endothelial cells, whereas pathway B facilitates the entry of 
hydrophobic molecules which can readily traverse the BBB by penetrating the phospholipid membrane. Transport proteins present on the 
surface of the BBB, pathway C, aids the entry of peptide and nucleoside drug molecules such as AZT, as well as amino acids, 
monosaccharides and organic cations. Receptors present on the surface of the BBB, pathway D, facilitates drug entry via transcytosis and 
pathway E aids the entry of positively charged drug molecules into the brain by means of adsorptive transcytosis (adapted from Bennewitz and 
Saltzman, 2009). 
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 Prodrugs: a transient chemical modification of drug molecules by the attachment of 
the molecules to removable pharmacologically inactive compounds, with properties 
capable of protecting the active drug molecules from systemic degradation. This 
enables targeted delivery active drug molecules to the desired site of action. The 
prodrug is inactive, with the active parent compound liberated in vivo employing a 
single activating step, usually by means of enzymatic cleavage or hydrolysis. 
Additional molecules can be liberated with the drug molecules which can potentially 
increase lipophillicity of the drug molecules, thereby enhancing penetration into the 
CNS. Limitations include poor tissue retention and short biological activity due to 
non-specific tissue uptake and active efflux from the brain resulting from an increase 
in lipophillicity of the prodrug (Prokai et al., 2000; Misra et al., 2003; Benewitz and 
Saltzman, 2009; Brandt et al., 2010; Semreen et al., 2010). 
 Efflux pump inhibitors: transient modification of BBB permeability is offered by the 
efflux pump inhibitors. Multi-drug resistance protein (MRP), Pgp and multi-specific 
organic anion transporter (MOAT), belonging to the ABC cassette family, are active 
efflus pumps present at the BBB which remove drug molecules from the brain, 
preventing distribution within the brain parenchyma. Inhibition of the activity of the 
efflux mechanism by coadministration of competitive or non-competitive inhibitors 
serves to enhance drug uptake into the CNS (Misra et al., 2003; Bennewitz and 
Saltzman, 2009; Varatharajan and Thomas, 2009). 
 Intracerebroventricular/intrathecal administration: direct administration of drug 
into the CSF or the lumbar region by means of outlet catheters connected to 
implantable reservoirs or pumps, with the implantable pumps the more favourable 
approach as it is capable of achieving continuous, elevated drug concentrations in 
the CSF. Systemic drug toxicity, drug opsonisation by serum protein and premature 
metabolism in the serum is diminished with this approach. Increased drug 
concentrations and half life (t1/2) in the CSF is achieved. Limitations to this approach 
include restricted penetration of drug into the brain parenchyma with localisation 
mainly at the ependymal cells lining the ventricles. The small pores size of the 
extracellular space reduces drug movement within the brain. CSF is recycled through 
the ventricular system every 4-5hours, with subsequent bulk flow into the systemic 
circulation. Intracerebroventricular administration is an invasive technique with the 
potential risk of infection and increased intracranial pressure occurring due to the 
injection of fluid into the brain (Wang and Sawchuk, 1995; Misra et al., 2003; 
Bennewitz and Saltzman, 2009). 
 Convection enhanced delivery: utilised to the enhance drug distribution throughout 
the brain parenchyma by means of gradual infusion of a drug solution using a 
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catheter into the interstitial space. Drug entry into the parenchyma occurs with 
diffusion resulting from an externally applied pressures source. Rapid transport of 
drug molecules occurs as compared to simply diffusion, with an extended distribution 
volume within the brain with high drug concentrations resulting at the desired site of 
action. Limitations include inefficient drug delivery occurring with back flow of drug 
solutions occurring due to the high pressures utilised for drug diffusion. Incorrect 
placement of the catheter within the brain can lead to brain tissue injury and the 
introduction of air bubbles into the CNS (Saito et al., 2005; Bennewitz and Saltzman, 
2009; White et al., 2010). 
 Intracerebral administration: involves direct drug delivery into the brain 
parenchyma by implantation or injection of drug. Direct targeting of the drug to the 
desired site of action is achieved with the drug delivery device having bypassed the 
BBB. Systemic toxicity is resultantly reduced. Utilisation of an implantable drug 
delivery device is favourable to injections as implants are capable of sustained drug 
release with longer drug exposure at the desired site of action. Limitations include 
sluggish diffusion and elimination mechanisms with a resultant drop in drug 
concentrations with increasing distance from the delivery site. Nondegradable 
implants require later removal of the device with the possibility of a foreign body 
response occurring due to the presence of a permanent fixture within the brain 
(Benewitz and Saltzman, 2009). 
 
Folkman and Long first invented implantable polymeric drug carriers for controlled release 
with the implantation of digoxin-releasing silicone rubber devices into the myocardium of 
dogs in 1964 (Popovic and Brundin, 2006). Since then, numerous polymeric implantable 
systems have been developed and utilised for drug delivery applications (Popovic and 
Brundin, 2006; Bennewitz and Saltzman, 2009).  
 
The implantation of a sterile biodegradable polymeric device into the brain would serve to 
reduce or eliminate the problems listed above associated with delivery of drug into the brain. 
A once-off implantation of the device is required with polymeric systems as the 
biodegradable nature of the device eliminates further surgical intervention for device 
removal. The use of nanoparticles as drug carriers ensures optimum dispersion of the drug 
throughout the brain as the small size of nanoparticles enables traversing of the extracellular 
spaces within the brain. Controlled drug delivery with subsequent device and nanoparticle 
erosion results, negating concerns associated with insufficient biodistribution of drug 
particles and systemic toxicity.  
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Numerous experiments have been conducted utilising brain implants, many of which used 
rats as the test specimen. Gamma-aminobutyric acid (GABA) was implanted into both 
hemispheres of the brain, near the substantia nigra, using a rat model, to observe epileptic 
activity in response to electric stimulation (Kokai et al., 1994). Phenytoin, an antiepileptic 
drug, was implanted 1-2mm into the cortex of the brain, also using a rat model, after being 
encapsulated with a non-biodegradable controlled release polymer (Tamargo et al., 2002). 
Álvarez and Ruarte (2003) implanted guide cannulae into the basolateral amygdala and the 
ventral hippocampus of adult male rats to assess the interaction of hippocampal glutamic 
acid-neurons with histamine-neurons in the basolateral amygdala to modulate memory and 
learning processes. Polymeric material, similar to that employed in the present study, was 
used in this experiment, with minimum deleterious effects experienced. Lagares et al. (1996) 
fixated β-amyloid and water implants into the hippocampus of Sprague-Dawley rats to 
assess the effects on psychomotor activity, psychomotor coordination and passive 
avoidance behavior, without significant harm being done to the animals. Tate et al. (1992) 
implanted brain grafts of β/A4 amyloid into the suprachiasmatic nuclei of adult rats to 
examine the relationship between the neuropathology of Alzheimer‟s disease and circadian 
rhythm disruption. Little distress was experience by the animals during the conduction of this 
experiment due to the use of anaesthetizing and sedating agents, as well as other drug 
therapy, such as atropine to ensure the rats could breathe properly. Quester, Knifka and 
Schroder (2002) implanted polyester meshes into the fourth ventricle of Wistar rats to study 
host-tissue response to implants. Rats were anesthetized and provided with artificial 
respiration, with cardiovascular function being monitored using ECG and by monitoring of 
the blood pressure in the femoral artery. Rats were monitored daily by two separate 
researchers to assess for the development of possible neurological symptoms. This study 
was conducted to assess rat skull-brain specimens after implantation of the meshes, so as 
to optimize glycol methacrylate embedding into large specimens for reconstructive surgery. 
These are but a few of the experiments conducted on rats to assess the efficacy of implants 
into the CNS. The rat model is therefore a suitable model for which to conduct in vivo studies 
to analyse the safety and efficacy of the intended for the management of ADC. 
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5.2. Materials 
Vials of Retrovir® (Glaxo Smith-Kline®, Gauteng, South Africa), commercially available AZT 
used for IV administration, was purchased from Milpark Pharmacy (Gauteng, South Africa). 
Ketamine/Xylazine (Bayer Veterinary department, Gauteng, South Africa), phenobarbitone 
(Bayer® Veterinary department, Gauteng, South Africa), caprofen (Pfizer® Veterinary 
medicine, Gauteng, South Africa), lignocaine (Bayer Veterinary department, Gauteng, South 
Africa) and Adrenaline-Fresenius (Intramed, South Africa) were obtained from the Central 
Animal Services (University of Witwatersrand, Gauteng, South Africa). Double deionised 
water was used for chromatographic analysis and was obtained from from a Milli-Q system, 
(Milli-Q, Millipore, Johannesburg). Analytical grade acetic acid and ammonium acetate were 
obtained from Sigma Aldrich (St. Louise, MO, USA) and methyl paraben was purchase from 
Merck (Merck (Pty) Ltd., Darmstadt, Germany). All other polymer and chemicals used were 
as per previous chapters. Healthy male Sprague Dawley rats, purchased from the Central 
Animal Services (CAS) (University of Witwatersrands, Johannesburg, South Africa) were 
used in this study. 
 
5.3. Methods 
5.3.1 Animal husbandry 
75 male Sprague Dawley rats weighing 400-600g were used to carry out in vivo studies as 
per Figure 5.2. Rats were caged in groups of 2-3, depending on the size of the animals, 
and maintained on a 12hour light/12hour dark cycle. The rats had free access to food and 
water at all times. They were weighed weekly so as to indicate their general state of health 
and well being and to ascertain whether rats should be removed from the study as 
indicated by excessive weight loss. Furthermore, by following CAS protocol, any animal 
seen to enter into distress was removed from the study and appropriately treated.  
 
All tests were performed with groups of 5 rats per sample set with a total of 50 rats used for 
the implantation procedure and 25 rats used for systemic administration of AZT as per 
Figure 5.2. 
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Figure 5.2: A schematic diagram indicating the distribution of rats for in vivo studies. 
Systemic drug delivery and implantation of drug-free polymeric devices served as a control 
by which to compare the results obtained from the implantation of drug-loaded devices into 
the CNS. These tests therefore conformed to the tests performed with the drug-loaded 
devices.  
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5.3.2 Rationale for use of sentient animals 
In vivo studies allows for a clinical assessment of the drug delivery mechanisms in a realistic 
environment for the implantable device, allowing an in vivo-in vitro correlation (IVIVC) to be 
established, minimising the need for future in vivo studies on this device.  As there is no 
implant currently on the market for the treatment of ADC, there is no standard by which to 
compare the product being developed.  In addition, in vivo studies serves to correlate the 
results obtained from in vitro studies, allowing for a more accurate indication of the 
pharmacokinetic and the pharmacodynamic parameters of the implant.  
 
5.3.3 In vivo administration of AZT and subsequent harvesting and treatment 
of samples 
5.3.3.1 Intravenous administration of AZT 
Intravenous (IV) administration of commercially available AZT (Retrovir®) was carried out on 
a test group of 25 rats. 0.75mg of AZT (1.5 mg/kg body weight) was injected into the tail vein 
of the rats, with samples being obtained at time intervals 3, 6, 12, 24 and 30 hours. IV 
administration of AZT served to assess drug distribution within the blood, CSF and brain 
after conventional systemic administration of AZT, serving as a standard by which the 
efficacy of the implanted device in the CNS over systemic drug delivery can be compared. 
 
Rats were weighed prior to the study being conducted and the dose of Retrovir® 
administered was calculated for each rat. Rats were then placed into restraining boxes, the 
tail vein was wiped with alcohol to expose the vein and Retrovir® was injected into the tail 
vein using a 1mL syringe and a 26G needle. 
 
5.3.3.2 Preparation and sterilisation of the NMDDD prior to implantation into the 
frontal lobe of the rat brain 
The nano-enabled drug delivery device (NMDDD) was prepared using the method described 
in Section 4.4.9. The implant, measuring 0.000354cm3 in volume was cylindrical in nature 
and was made to accommodate the small size of the rat brain, varying between 0.865 ± 
0.026cm3 to 1.165 ± 0.071cm3 depending on the age of the rat. The implant was therefore 
prepared to be less than 20% of the volume of the rat brain.  
 
Implants were sterilized using gamma radiation to eliminate the risk of infection due to 
impurities introduced into the NMDDD during formulation and handling of the NMDDD prior 
to implantation. Radiation of the NMDDD was carried out at Isotron South Africa (Kempton 
Park, Gauteng), radiated using a trial dose of 25kGy.  
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5.3.3.3 Implantation of PCL-ECL-CAP scaffolds into the frontal lobe of the rat brain 
In vivo studies were conducted whereby placebo and drug-loaded devices were implanted 
into the brain parenchyma of male Sprague Dawley rats, to assess device erosion toxicity, 
as well as drug distribution within the blood, CSF and brain. The implant was implanted into 
the right frontal lobe of the brain using a technique analogous to that used for the insertion of 
an intra-cranial pressure monitor in the human subject.  
 
Rats were intramuscularly injected with a ketamine (80mg/kg)/xylazine (40mg/kg) 
anaesthetic agent, after which their heads were shaved and prepared aseptically. A 
lignocaine/adrenaline solution was injected subcutaneously into the head, near the 
implantation site, to minimise post-surgical bleeding, as well as a subcutaneous injection of 
caprofen, an anti-inflammatory agent, into the neck for pain. Rats were then placed on a 
stereotaxic frame and taken into the sterile theatre. A para-midline scalp skin incision was 
made and the periosteum was reflected to expose the frontal lobe. A 3mm in diameter burr 
hole was drilled into the skull over the frontal lobe to expose the dura. The dura was 
perforated and the device inserted. The site of implantation was then sealed with sterile 
beeswax and the wound was sutured (Storm et al., 2002), as observed in Figure 5.3.2 
below). 
 
Ringer‟s Lactate was administered to hydrate the rats post surgery. The rats were then 
administered an anaesthetic reversal agent and the wound was cleaned with antiseptic 
agent provided by CAS. Rats were housed individually for 24hours thereafter and monitored 
regularly to assess for abnormalities associated with motor activity and response.  
 
   
 
Figure 5.3.1: IV administration of Retrovir into the tail vein of Sprague Dawley rats. 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (c) (b) (a) (b) (c) 
 133 
 
    
 
    
 
    
 
    
 
Figure 5.3.2: Implantation of multipolymeric devices into the frontal lobe of the rat brain. 
 
5.3.3.4 Harvesting of blood, CSF and brain post implantation 
CSF, blood plasma, and brain tissue were removed and analyzed to determine drug 
concentrations in these regions 3, 7, 14, 21, and 30 days post-implantation. Rats were 
anaesthetised with a ketamine/xylazine injection, a cardiac puncture was performed to 
harvest blood (5mL), placed into heparinised test tubes. Intracardial administration of 
phenobarbitone (200mg/kg) to euthanise the rats then followed. Rats were dissected at the 
neck to expose the cisterna magna from which CSF (approximately 100µL) was removed 
using polyethylene tubing, transferred into 2mL ependorfs and placed on ice. Polyethylene 
tubing was prepared 3 days prior to CSF harvesting, with a 25G needle inserted into one 
end of the tube and a 1mL syringe inserted into the other end. The tubing was then flushed 
with an alcohol/H2O solution and then with double deionised water. Excess liquid was 
flushed out of the tube which was then placed into a formalin sterilisation drum for 3 days to 
ensure optimum sterility of the tubing. 
(a) 
(c) (b) (a) 
(k) (j) 
(e) (f) 
(l) 
(g) (h) 
(d) 
(p) (o) (n) (m) 
(i) 
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Brain samples were obtained by dissection of the skull to reveal the brain which was 
removed and placed in a 10%v/v formalin solution for later analysis as observed in Figure 
5.4. 
 
    
 
    
 
Figure 5.4: Harvesting of blood, CSF and brain. 
 
5.3.3.5 Treatment of tissue samples post harvesting 
Blood samples were centrifuged at 10 000rpm for 20minutes (Optima® LE-80K, Beckman, 
USA), to separate the plasma, which was removed and placed in polytops. Plasma samples 
were then refrigerated at -70°C for later analysis. 
 
CSF samples were centrifuged at 10 000rpm for 10mins (Optima® LE-80K, Beckman, USA). 
The supernatant was removed and stores at -70°C for later analysis. 
 
Brain samples were stored at room temperature in a 10%v/v formalin solution. 
 
5.3.4 Bioerosion of the multipolymeric device post implantation 
Bioerosion was assessed at time intervals coinciding with the harvesting of brain tissue in 
rats. Multipolymeric implants were weighed prior to implantation and again post removal 
from the brain, with weight loss calculated as per Equation 3.2 in Chapter 3, Section 3.2.8. 
Microscopy of the implants employing a Olympus® Stereo Microscope (Model SZX-D2-200) 
fitted with an Olympus® SZX-TR30 camera (Tokyo, Japan) prior to implantation and post 
removal of the device was also conducted to ascertain swelling or deswelling behaviour of 
the device. 
 
(b) (a) 
(f) (e) (g) 
(d) (c) 
(h) 
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5.3.5 Ultraperformance Liquid Chromatographic (UPLC) Analysis of Biological 
Samples 
5.3.5.1 Priming of instruments prior to analysis 
All solutions and mobile phases were prepared in double deionised water with a restivity of 
18.2MΩcm-1, and filtered using a 0.22µm Cameo acetate membrane filter (Millipore Co., 
Bedford, Massachusetts), under a constant vacuum pressure.  
 
The UPLC was primed using 50:50 strong acetonitrile/water wash (90/10v/v) and weak wash 
(10/90v/v) solutions set to prime for 2 cycles for 15minutes per cycle. This was performed to 
ensure removal of impurities from the system. 
 
Mobile phases prepared consisted of 100%v/v acetonitrile and a 0.2%
v/v formic acid solution 
prepared in water and was set to flow after the instrument was primed to equilibrate the 
system prior to analysis.  
 
AZT is a polar acid/base compound with a pKa value of 9.68. Formic acid was employed for 
use in the mobile phase to decrease the pH of the mobile phase. This was done to ensure 
optimum elution of AZT and separation of the drug from the internal standard due to 
ionisation of the drug at pH 4.6 as per the Henderson-Hasselbalch Equation, 5.1. 
 
][
][
log
HA
A
pKapH

                                                    (Equation 5.1) 
 
Where, pKa is the acid dissociation constant, [A-] is the concentration of free acid in solution 
and [HA] is the concentration of conjugated base in solution. 
 
5.3.5.2 Development of a UPLC method for AZT analysis 
UPLC analyses were performed using a Waters® Acquity Ultra Performance LC system 
(Waters®, Milford, MA, USA), coupled with a PDA detector.  
 
The UPLC column was equilibrated with an acetonitrile/formic acid (80/20v/v) mixture at a 
flow rate of 0.4mL/min. A 2.5µL sample was then injected into the column with the eluent 
monitored at a wavelength of 254µnm with a run time of 5.5minutes. An Aquity UPLC® BEH 
ShieldRP18 column (Waters
®, Milford, MA, USA), with a pore size of 1.7µm was utilised for 
AZT analysis. Methyl paraben (0.5mg/mL) was employed as the internal standard, 
(Suwanpidokkul et al., 2004). Methyl paraben is a basic compound with a pKa of 8.47 
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(Brooks and Long, 2008; Foye et al., 2008; Ivanovic et al., 1995) which elutes using an 
acetonitrile/formic acid mobile phase; however methyl paraben retains on the column longer 
than AZT (4.3minutes) and was therefore chosen for use as an internal standard. 
 
A calibration of AZT curve was generated in double deionised water which was used for the 
assessment of the efficiency of solid phase extraction. 
 
5.3.5.3 Preparation of AZT standard solutions 
A stock solution of AZT (15mg/mL) and methyl paraben (0.5mg/mL) were individually 
prepared in double deionised water. Standard solutions were prepared by dilution of the 
stock solutions and were employed for generating a calibration curve of AZT in double 
deionised water and for solid phase extraction. All solutions were filtered using a 0.22µm 
membrane filter and were refridgerated at 5°C. Stock solutions were replaced weekly and 
fresh standard solutions were prepared for each day of analysis. 
 
Drug-free plasma was thawed and prepared by vortex mixing (Vortex-Genie 2, Scientific 
Industries, Inc, NY, USA) 2mL plasma with 2mL aqueous dispersion of AZT to obtain serial 
drug concentrations ranging between 0.0038-125µg/mL which was used to generate a 
calibration curve of AZT. CSF was treated similarly. 
 
5.3.5.4 Solid phase extraction 
Solid phase extraction (SPE) was employed for the separation of AZT from the constituent 
impurities present in plasma and CSF samples, with an increase in the purity obtained of the 
analyte (AZT). Interference of the constituent with the analyte decreases the accuracy of 
drug release obtained, necessitating removal. A standard Oasis® HLB SPE technique was 
employed for the extraction of AZT, where serial dilutions of methanol/water (MeOH/H2O) 
solutions (5%-100%) were injected into Oasis® HLB cartridges attached to a Standard Lid 
(Waters®, Milford, MA, USA) and a Visiprep Vacuum Manifold (Waters®, Milford, MA, USA). 
The cartridge was conditioned with 1mL methanol and 1mL deionised water. A 1mL sample 
was then loaded onto the cardridge followed by elution of the analyte with serial dilutions 
(5%-100%) of 1mL MeOH/H2O with the impurities retained on the cartridge (refer to Figure 
5.5). The elute was individually collected in test tubes, spiked with the methyl paraben 
internal standard, loaded into 2mL vials (Waters® LCMS certified clear, pre-slit PTFE/silicone 
Septa screw top vials, Waters®, Milford, MA, USA) and were analysed using UPLC. 
 
SPE was also performed employing the standard Oasis® HLB acid/base SPE technique to 
assess optimum isolation of AZT. The method employed was similar to that explained 
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above, with an additional wash step added as described in Figure 5.5. MeOH/H2O solutions 
were individually spiked with 2% acetic acid and 2% ammonium hydroxide, which were used 
to elute AZT. 
 
5.3.6 Histomorphological characterisation of brain samples 
The advantages of using synthetic polymers such as PCL and ECL for in vivo drug delivery 
include: 
1. Predictable and reproducible mechanical and physical properties. 
2. Control of the form and amount of impurities present in the materials. 
3. Simple structures of the monomeric constituents and therefore lower risk of toxicity, 
immunogenicity and foreign body response (Rezwan et al., 2006). 
  
Rat brain samples were sent to Pretoria (IDEXX laboratories (Pty) Ltd.) for 
histomorphological analysis. Brain specimens were cross-sectioned at the anterior third of 
the brain, being the site of surgical implantation, and at the mid-brain and third section of the 
cerebellum. This was conducted to assess polymer tissue distribution within the brain and 
possible toxicity resulting at sites other than the frontal lobe. Tissue blocks were then 
prepared overnight in an automated histological tissue processor according to standard 
operating procedure (PTA-HISTO-SOP-27). This was followed by the preparation of wax 
blocks and histological sections cut at 6-7µm on a microtome. Slides were then prepared 
and stained with Haematoxylin and Eosin (H/E) stains in accordance with standard operating 
procedure (PTA-HISTO-SOP-49). Selected slides were stained with Luxol-fast-blue-Holmes 
(LFB-H) stains to evaluate myelin and neural tissue reaction. 
 
Slides were then analysed under various magnifications using an Olympus® Stereo 
Microscope (Model SZX-D2-200) fitted with an Olympus® SZX-TR30 camera (Tokyo, Japan). 
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Figure 5.5:   Schematic representation of the generic SPE technique employed to increase purity of the analyte.   
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5.4. Results and Discussion 
5.4.1 Implantation of multipolymeric nanoenabled scaffolds 
Following initial implantation self-limiting nose bleeds were observed. After investigation into 
this, it was found that nose bleeds was as a result of burr holes being drilled close to the 
sinuses in the head of the rats. As the nose bleeds did not persist and rats did not present 
with signs of distress post surgery, these rats were not removed from the study. Re-
evaluation of the surgical procedure followed with intensive studies of the anatomy of the rat 
skull and sinus cavities ensued to ensure optimal implantation of subsequent devices. 
 
Further implantation procedures were successfully undertaken. A stereotaxic frame (refer to 
Figure 32 (c) and (d)) was employed to ensure the head was positioned to curtail movement 
during drilling, ensuring minimal post-surgical bleeding. The use of an electric drill 
guaranteed a clean incision was made into the skull with minimal trauma to the brain.  
 
Larger rats (400-600g) were employed in this study as implantation conducted previously 
with smaller rats presented with adverse effects resulting from surgery. Larger rats 
presented with larger brain volumes with ease of implantation transpiring.  
 
Rats were observed for motor abnormalities and were stimulated as per CAS protocol to 
assess responsiveness. Animals were weighed daily to ensure excessive weight loss did not 
occur post-surgery. An insignificant decline in weight was observed post-surgery which was 
expected. Weight gain and normal activity was observed approximately 5-7days post-
surgery indicating optimal healing occurring. Infection and severe bleeding at the wound site 
was absent serving to reinforce this. 
 
Of the 75 rats used in this study, 1 rat died from pulmonary complications resulting from the 
use of anaesthetic. Post-mortem reports (Appendix C) revealed death occurred due to 
pulmonary distress resulting from the use of anaesthic drugs. 
 
5.4.2 Bioerosion of the multipolymeric device post implantation 
Bioerosion was calculated at 14.14% 30days post implantation. PCL is renowned for its slow 
in vivo degradation post implantation (Sinha et al, 2004; Luong-Van et al, 2006; Rezwan et 
al., 2006), implants were therefore expected to exhibit slow erosion, with high molecular 
weight PCL reported to take 3years for complete removal from the body (Rezwan et al, 
2006). Radiation of the multipolymeric scaffold prior to implantation served to further retard 
bioerosion of the device asUV and gamma radiation is frequently used to crosslink PCL and 
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ECL. Radiation therefore serves to reinforce the density of crosslinked NMDDD and hence 
retards bioerosion of the implant (Lee and Yang, 2002; Kweon et al., 2003; Abdel-Rehim et 
al., 2004) 
 
CSF is reported to be produced at a rate of 25mL/hour with a turnover time of 3.7 times a 
days; erosion of the multipolymeric device within the brain is therefore lower than observed 
with in vitro studies (Citrin et al., 1987; Saunders et al., 2002). However, because of 
fragmentation of the implants during insertion and removal of the multipolymeric device into 
and out of the brains due to the size of the device, 20-15mm in length and 11-8mm in 
diameter, erosion of the device was higher than expected (refer to Figure 5.6).  
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Figure 5.6.1: Bioerosion profile of the multipolymeric scaffold post implantation into the rat 
brain (n=3, SD<0.002). 
 
SEM of the multipolymeric devices prior to implantation revealed a densely packed 
polymeric matrix with uniformly sized pores dispersed within. Nanoparticles can be observed 
dispersed within these pores as viewed in Figure 5.6.2b, ideal for sustained delivery of AZT 
as drug release will occur with matrix erosion and subsequent nanoparticle release from the 
scaffold matrix.  
 
720 360 120 240 600 48  0 
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Figure 5.6.2: SEM images of multipolymeric devices prior to implantation within the rat 
brain. (a) Pores were observed on the surface of the scaffolds, ideal for nanoparticle and 
subsequent AZT release following implantation into the brain. (b) Observation of scaffolds 
under higher magnification revealed a porous interior, with dispersed nanoparticles as seen 
in (c). Plasticity of the prepared device was maintained, revealed by the smooth inner and 
outer surfaces of the scaffold. 
 
As observed in Figure 5.6.3, the multipolymeric device maintains its shape 30days post 
implantation, with erosion of the device occurring over extended periods, indicating that the 
device will remain intact over the required period of treatment.  
 
 
Figure 5.6.3: Light microscopy of multipolymeric scaffolds (a) prior to implantation, (b) 14 
days post implantation and (c) 30 days post implantation within the rat brain. 
 
5.4.3.1 UPLC method validation 
Precision and accuracy of the method employed for AZT analysis was assessed by means 
of intra- and interday validation using 5 quality control samples of AZT in plasma in 
concentrations of 15ng/mL, 150ng/mL, 1.5µg/mL, 15µg/mL and 150µg/mL. Intraday 
validation consisted of multiple injections of samples over five consecutive days (n=5) and 
interday validation was determined by means of multiple sample injections over a 24 hour 
period (n=5). These samples were eluted using SPE and were injected into the UPLC to 
determine percentage extraction yield for the samples which was calculated by comparing 
the peak areas of analytes obtained from standard solutions at the same theoretical 
concentration. Precision and accuracy was expressed as the percentage coefficient of 
variance (CV) and percentage deviation of the mean concentration respectively (Lewis et al., 
2006; Dubey et al., 2009).   
(a) (b) (c) 
12mm 
13mm 
10mm 
10mm 
11mm 
16mm 
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5.4.3.2 AZT Calibration curve generated in water 
Figure 5.7 presents with a calibration curve for AZT obtained at a wavelength of 254nm 
employing UPLC (Waters, Milford, MA, USA).  
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Figure 5.7: AZT calibration curve at λ254nm in double distilled water (n=3, SD<0.0005 in all 
cases). 
 
5.4.3.3 Solid phase extraction of AZT  
SPE was performed using serial dilutions of MeOH/H2O as well as with MeOH/H2O spiked 
with 2% acetic acid (CH3COOH) and 2% ammonium hydroxide (NH4OH). This procedure 
was employed to obtain maximum isolation of AZT indicated by the peak height and 
extraction yield as observed in Table 5.2. 
 
Extraction of AZT was optimum in MeOH/H2O solutions, with the highest extraction yield 
(93.48%) obtained in 5% MeOH/H2O. AZT is a hydrophilic compound (Thomas and 
Panchagnula 2003; Prakash et al, 2008). Extraction of the drug will therefore be more 
efficient in an aqueous solution. Extraction of AZT in plasma was found to be more efficient 
in 2.5% MeOH/H2O solutions (92.13%), with 5% solutions demonstrating minimal isolation of 
the drug (3.40%). 
 
 
 
 
 
 
 
Y = 125691x 
R
2
 = 0.9796 
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Table 5.2: SPE of AZT in double deionised water and plasma.  
 
SPE UPLC AUC Extraction yield (%) 
Extraction in double deionised water 
5 2937333 93.48 
10 2407674 76.62 
15 207469 6.60 
Acid 980823 31.21 
Base 1148911 36.56 
5% acid 53829 1.71 
5% base 18213 0.58 
10% acid 9283 0.30 
10% base 10015 0.32 
15% acid 19862 0.63 
15% base 8446 0.27 
Extraction in plasma  
2.5% 1736915 92.13 
5% 64139 3.40 
7.5% 7781 0.41 
   
 
5.4.3.3 AZT calibration curves generated in plasma and CSF 
Calibration curves of AZT in plasma and CSF, as illustrated in Figures 5.8a and b 
respectively, obtained at a wavelength of 254nm employing SPE methodology. Extraction of 
AZT was performed in a 2.5% methanol/water solution and analysed using UPLC. 
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Figure 5.8: AZT calibration curve at λ254nm in (a) plasma and (b) cerebrospinal fluid (n=3, 
SD<0.0005 in all cases). 
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5.4.3.4 Drug concentrations present in blood and CSF samples 
A release of 11.601ng/mL and 9.180ng/mL (S.D<0.002) was obtained in plasma and CSF 
respectively 30hours post IV administration of Retrovir®. Drug concentrations within plasma 
were high due to systemic administration of drug, with peak plasma concentrations 
(31.923ng/mL) achieved within 3hours post administration. As AZT has been reported to 
reach peak plasma concentrations within 0.4-2hours post oral administration, this was 
expected (GlaxoSmithKline, Combivir package insert 2006; Quevedo and Brinon, 2009).  
AZT is significantly metabolised following systemic administration with only 60-70% of drug 
available in the plasma, attributed to hepatic first pass metabolism of the drug (McDermott et 
al., 1992; Allan Macnab et al., 1996; Carvalho et al., 2010). This, added to the plasma half 
life of 1-1.5hour observed with AZT (Lotter et al., 1991; McDermott et al., 1992; 
GlaxoSmithKline, Combivir package insert 2006; Quevedo and Brinon, 2009), accounts for 
the decline in plasma drug concentrations with time (refer to Figure 5.9a). The low CSF 
concentrations attained can be attributed to metabolism of drug prior to reaching the brain as 
well as the limitations posed by the BBB to the entry of AZT into the brain (Giammano et al., 
1999; Pardridge, 2005; Modi et al, 2009). Efflux of AZT out of the brain is also accountable 
for low CNS concentration of AZT achieved (Dykstra et al., 1993; Brewster et al., 1995; 
Varatharajan and Thomas, 2009; Bennewitz and Saltzmann, 2009). 
 
Optimised scaffolds exhibited a release of 12.793ng/mL and 35.225ng/mL (S.D<0.002) in 
plasma and CSF respectively 30 days post implantation of the nanoenabled multipolymeric 
device. Plasma drug concentrations can be attributed to AZT elimination from the CNS and 
is therefore significantly lower than that of the CSF AZT concentrations. Drug concentrations 
within the plasma and CSF increased with time (refer to Figure 5.9b) consistent with device 
erosion and subsequent release of AZT from the nanoparticles, supporting sustained AZT 
release from the multipolymeric device. As nanoparticles are capable of sustained release of 
the entrapped AZT molecules, they are therefore capable of maintaining therapeutic levels of 
the drug within the brain, thus decreasing viral load (Rao et al, 2008). 
 
Drug concentrations within the CNS obtained from the nanoenabled multipolymeric device 
was superior to that of the commercially available Retrovir® and will therefore offer superior 
management of ADC to Retrovir®. The use of nanoparticles to encapsulate AZT as well 
direct administration of AZT into the CNS is responsible for this. Nanoparticles were 
formulated with PVA which results in steric hindrance of the nanoparticle, serving to reduce 
nanoparticle adhesion to macrophage cells. As macrophage cells are responsible for foreign 
body removal from the brain, the targeting of AZT-loaded nanoparticles to target non-
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macrophage brain cells results in prolonged drug release within the brain (Bennewitz and 
Saltzman, 2009), with a decreased occurenced of systemic toxicity experienced by patient 
as AZT concentrations within the systemic circulation is significantly reduced. 
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Figure 5.9: In vivo AZT release in plasma and CSF following (a) IV administration of 
Retrovir® and (b) implantation of the optimised nanoenabled multipolymeric device (n=3, 
SD<0.002 in all cases). 
 
 
 
 
(a) 
(b) 
720 360 120 240 600 480 0 
72  360 120 240 600 48   
 146 
 
5.4.4 Histomorphological analysis 
5.4.4.1 Brain specimens obtained from intravenous administration of Retrovir® 
Histological evaluation revealed no neuropathology in brain specimens obtained from the IV 
administration of AZT (refer to Figure 5.10.1). LFB-H staining exposed no defects in the 
white and grey matter of the brain. As AZT is routinely used for the management of HIV in 
the brain, this was expected (Dykstra et al., 1993; Brewster et al., 1995; Giammano et al., 
1999; Enting et al., 2000; Mishra et al., 2006). 
 
  
Figure 5.10.1: Histomorphology of normal brain tissue as revealed on the histographs of 
rats injected with Retrovir® (a) using the  H&E staining technique and (b) using the LFB –H 
stain. 
 
5.4.4.2 Brain specimens obtained from the implantation of placebo and AZT-loaded 
devices 
Histomorphological assessment of placebo and AZT-loaded devices revealed no 
discrepancies occurring due to the presence of the drug as findings from both sets of 
histology slides were similar. The presence of inflammatory cells and cells involved in the 
immune cascade can be observed due to the procedure. However, an absence of any 
ischemic events, infection of the implantation site and hyperaemia resulted from device 
implantation as observed in Figure 5.10.2. 
 
(a) (b) 
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Figure 5.10.2: Histographs of cerebral tissue following H&E staining (a) 3 days post 
implantation of the placebo device and (b) 21 days post implantation of the placebo device.  
 
Day 3: the anterior region of the cerebrum (site of implantation) was sectioned to assess 
neuroparenchyma responsive to the presence of the multipolymeric implant. Focal areas of 
encephalomalacia were identified with acute cerebral malacia and neutrophil infiltrates 
visible as seen in Figure 5.10.3b. The leptomeninges (consisting of the arachnoid mater and 
pia mater) adjacent to the area of malacia presented with moderate leptomeningitis with 
lymphocytic round cells predominating, in accordance with the presence of a foreign body in 
the brain. Minor destruction of the cortical grey matter was observed, with acute 
inflammation and necrotic material present. Mild dystrophic calcification and status 
spongiosis was found in the necrotic regions of the parenchyma. Haemorrhage and 
haemosiderin pigmentation was detected indicating post-surgical bleeding, as noted in 
Figure 5.10.3a. LFB-H stains revealed an absence of demylination in the neuroparenchyma.  
 
Sections obtained away from the implantation site presented with normal morphology of the 
neuroparenchyma. Areas adjacent to the site of implantation presented with minimal 
macrophages and lymphocytic cells.  
 
 
 
 
Macrophage cell nuclei due 
to the presence of foreign 
body entry into the brain, and 
activation of the immune 
response. 
 
(a) (b) 
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Figure 5.10.3: Acute hyperaemia was observed on histographs (a) and (b), indicative of post 
surgical bleeding. (c) Neutrophil and macrophage infiltration was present, indicative of 
foreign body entry. 
 
Day 7: focal encephalomalacia with liquefactive necrosis was observed in the anterior 
cerebrum. Heterophils and macrophages originating from microglia cells with phagocytic 
material in the cytoplasm were prominent, as seen in Figure 5.10.3c. Foci of dystrophic 
calcification and minimal inflammation were found in the parenchyma and leptomeninges 
surrounding the site of implantation. Haemorrhage, haemosiderin pigments and fibrin was 
also present at the site of implantation. 
 
LFB-H staining revealed focal areas of subacute encephalomalacia resulting from the 
implant, however demylination and axonal death was absent. 
 
  
Figure 5.10.4: (a) The multipolymeric implant was clearly observed on the histograph with 
macrophage and microglia cell infiltration at the site of implantation. (b) Glitter cell infiltration 
was also observed at the implantation site. 
 
Day 14: focal areas of liquefactive necrosis with moderate microglial phagocytic cells were 
present in the parenchyma. Multiple dystrophic calcified foci were found with necrotic tissue 
containing small fragments of the multipolymeric implant as seen in Figure 5.10.4a. Debris is 
Fragment of the 
NMDDD 
(a) (b) (c) 
(a) (b) 
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therefore still visible in the encephalomalacia. Minimal inflammation was detected in the 
neuroparenchyma and leptomeninges. 
 
Findings from the LFB-H stain were as observed on day 7 above. 
 
Day 21: a focal region of malacia with numerous microglial macrophages containing a 
granular cytoplasm due to phagocytosis of necrotic brain material was seen in the cerebral 
cortex. Few multinucleated cells with minimal inflammatory infiltrates were observed in the 
leptomeninges. Some microglial macrophages and necrotic proteinaceous eosinophilic 
material was visible at sites near the implant, attributed to fragments of the multipolymeric 
device present in the cerebrum, refer to Figure 5.10.5b. 
 
Findings from the LFB-H stain were as observed on day 7 above. 
 
  
Figure 5.10.5: LFH-B stains revealed (a) giltter cell infiltration attributed to the presence of 
necrotic tissue resulting from the erosion of the device. (b) Debri and subsequent 
phagocytosis due to device erosion was revealed with LFH-B staining. 
 
Day 30: sectioning of the anterior cerebrum revealed a focal area consistent with polymer 
tissue destruction indicating erosion of the device as observed in Figure 5.10.6. 
Macrophages, multinucleated cells and proteinaceous material were identified in this region. 
Microglial macrophages with some haemosiderin pigments within were observed in the 
cerebrum close to the site of implantation in the absence of inflammation. Leptomeninges 
appeared normal.  
 
Findings from the LFB-H stain were as observed on day 7 above. 
 
Histomorphological analysis supported biocompatibility of the multipolymeric device, 
negating later removal of the device post implantation. 
(a) (b) 
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Figure 5.10.6: Device erosion and subsequent phagocytosis of the foreign material was 
observed on micrographs (a) and (b). (c) Subsequent nerve tissue damage was noted.  
 
5.5 Concluding Remarks 
In vivo studies were employed to correlate results obtained from performed in vitro studies, 
serving to ascertain device erosion and subsequent drug release within the brain. In vivo 
analysis also served to assess device safety and toxicity within the brain. 
 
The surgical procedure employed for device implantation was successfully implemented, 
ascertained by the lack of morbidity exhibited by the animals post surgery. Recovery was 
quick and efficient with an absence of infection and motor adverse effects observed. 
 
Bioerosion of the multipolymeric device was calculated to be 14.14% 30days post 
implantation. Slow erosion of the device with subsequent slow release of nanoparticles 
accounted for drug release from the nanoenabled multipolymeric device being superior to 
that of the commercially available Retrovir®, 35.225ng/mL (30days post implantation) as 
compared to 9.1796ng/mL (30hours post IV administration) as observed in CSF. This 
indicated suitability of the device for the management of ADC. Plasma drug concentrations 
obtained with the implantable device (12.793ng/mL 30days post implantation) were less than 
that obtained with the IV formulation (31.923ng/mL 3hours post IV administration), 
supporting distribution of AZT within the CNS, with drug concentrations in the plasma post 
implantation thought to be due to AZT elimination from the CNS. 
 
Tissue distribution of AZT within brain tissue is minimal following systemic administration 
(Dystra et al., 1993; Brewster et al., 1995; Mandal and Tenjarla, 1996), incorporation of AZT 
within nanoparticles will allow for an increase in the distribution of the drug within the CNS 
due to the small size range of the nanoparticles prepared (68.04d.nm) and the negative 
potential of -10.61mV attained, allowing ease of entry into the brain tissue and interstitial 
fluid. 
(a) (b) (c) 
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Histomorphological analysis revealed minimal inflammation at the site of implantation which 
decreased with time. Neural apoptosis was not present post surgery, revealed by LFB-H 
staining of brain tissue, supporting biocompatibility of the multipolymeric device. 
Leptomeningitis was seen at the site of implantation and the immune response was elicited, 
observed by the infiltration of machrophages and lymphocytes, due to the introduction of a 
foreign body within the CNS (Rocha and Tanchot, 2004). However, this too was observed to 
decrease with time. Histomorphology of brain samples obtained following IV administration 
of AZT presented with normal brain tissue with no inflammation or neural damage observed, 
supporting the safety of AZT for the treatment of HIV-1 infection of the CNS. 
 
Active influx transporters are found on lymphocytes and CD4+ T-cells and are thought to aid 
the entry of antiretrovirals, including AZT into the brain and into HIV-1 infected cells within 
the CNS (Varatharajan and Thomas, 2009). The use of nanoparticles to transport AZT into 
the CNS, with subsequent drug release as the nanoparticles erode, would serve to protect 
AZT from efflux out of the CNS by means of active efflux transporters. The implantation of a 
nanoenabled multipolymeric scaffold into the brain would serve as a drug reservoir within the 
CNS with the management of ADC significantly enhanced due to site-specific delivery 
therapeutically effective concentrations of AZT. Sustained drug release of AZT results with 
the use of biodegradable polymers exhibiting slow in vivo degradation (Popovic and Brundin, 
2006). 
 
Implantation of a nanoenabled multipolymeric PCL-ECL-CAP device within the CNS has 
proved to be successful within satisfactory distribution of AZT within CSF being obtained. In 
vivo studies in larger animal models, an example being monkeys, will provide greater insight 
into tissue distribution of AZT within the brain and will therefore be considered for later 
studies. 
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CHAPTER 6 
 
Concluding Remarks 
 
 
6.1 Challenges  
Challenges faced during the study focused mainly on the preparation of the polymer 
scaffold. Carboxymethyl cellulose (NaCMC)-epsilon caprolactone (ECL)-poly ethylene oxide 
(PEO) scaffolds were first prepared by means of crosslinking the polymer solution with a 
calcium chloride-sodium thiosulphate-zinc chloride (CaCl2-Na2S2O4-ZnCl) salt solution. 
These scaffolds demonstrated a high degree of swelling, causing the polymer matrix to 
erode at a more rapid rate than polycaprolactone (PCL)-epsilon caprolactone (ECL)-
cellulose acetate phlatate (CAP) scaffolds after exposure to PBS due to excess water intake. 
Further efforts are required to optimise crosslinking of these polymer solutions to ensure 
formulation of a device capable of drug release over extended periods. 
 
A stable nanoparticle suspension was prepared however, further effort is required to 
enhance the stability (expressed as the zeta potential) of the colloidal system. As the 
nanoparticles are dispersed within a multipolymeric device which prevents agglomeration, 
zeta potential is of little importance. Optimisation of the formulation stability will enable 
administration of drug-loaded nanoparticle in the absence of a polymeric scaffold, further 
reducing the costs.  
 
6.2 Recommendations  
Future work will focus on applying the zidovudine (AZT)-loaded nano-enabled polymeric 
device to a human model. Further research is required to optimise the device for human 
application, ensuring the in vitro and in vivo results obtained during the study can be 
correlated to the human model. 
 
In vivo studies using a rat model demonstrated safety and biocompatibility of the nano-
enabled polymer device, as well as a successful implantation procedure. However, due to 
the size of the rat brain (approximately 0.865cm2), adequate distribution of nanoparticle and 
AZT throughout the brain was difficult to establish. Adequate drug loading within a device, 
0.000354cm3 in volume, was challenging.  A larger animal model, an example of which is a 
primate model, will provide more accurate data regarding drug release from the polymer 
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device and distribution of nanoparticles and AZT in the brain. This can then be more 
accurately correlated to the human model.  
 
Distribution of AZT within the brain has not been explored in this study. This should be 
considered in future studies with AZT diffusion within the central nervous system (CNS) 
being the focus. Addition of biomarkers to the nanoparticle formulation, explored previously 
for stem cell and cancer research, will allow tracking of the nanoparticles throughout the 
brain by means of immunofluorescence (Suh et al., 2009). It can then be determined 
whether nanoparticle distribution is localised to the brain or if it distributed systemically 
following implantation into the brain. Nanotechnology has the potential to trace and detect 
brain pathology, with enhanced specificity obtained by the ability of nanostructures to cross 
the BBB and to distribute within the brain tissue. This can be achieved by the coupling of the 
device with quantum dots, enabling imaging of the AIDS dementia complex (ADC) affected 
brain tissue and the progress made resulting from AZT therapy, as quantum dots exhibit a 
low photodegradation rate, enabling imaging over extended periods (Bailey et al., 2004; 
Gommersall et al., 2007). 
 
ADC related cerebral injury is worsened by aging, increasing cognitive impairment 
experienced by patients, as both conditions reduce similar metabolites in the brain, the N-
acetyl methyl group (NA), being of most significance (Chang et al., 2004).  Formulation of a 
combined AZT- anti-dementia drug implant can therefore be explored as it will prove 
beneficial in the treatment of ADC in geriatric patients. As ADC does not exist in isolation, a 
combination of other drugs applicable to HIV related CNS conditions, such as antibiotic, 
steroid and antifungal agents, can be coupled with AZT for the management of ADC as well 
as other HIV related neurological conditions. A combination of fast release and slow release 
nanoparticles can be considered for this. 
 
As the device is intended for application in a multitude of neurodegenerative disorders, drug 
loading of various neurotherapeutics within the device will enable more efficient 
management of CNS conditions. As the development and implementation of new 
neurotherapeutics is limited by drug penetration into the CNS due to size and 
pharmacokinetic parameters, the use of nanoparticles bypasses this obstacle with potentially 
gorund breaking discoveries occurring by tailoring the size of therapeutic agents to the 
nanosize range (Gommersall et al., 2007; das Neves et al., 2009; Suh et al., 2009). 
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6.3 Conclusions  
The past year has heralded a significant increase in the research and development of novel 
drug delivery devices capable of controlled and sustained delivery of drug site specifically. 
However, poor pharmacokinetic parameters, drug solubility and the limitations posed by this, 
in vivo stability and toxicity have limited the advances made by drug formulation scientists. 
The era of nanotechnology promises to change this with the design and development of 
nanoenabled devices capable of overcoming the concerns and challenges previously 
encountered by scientists (Ravichandran, 2004).  To date numerous advances have been 
made in the field of nanomedicine, with the potential to transform the practice of medicine. 
Drug delivery and diagnostics by means of in vivo imaging have been the current market 
leaders, focused mainly in the area of cancer therapy, with it being estimated that in the next 
five years, the market for nanoenabled drug delivery devices will reach $200 billion US 
dollars. The novelty offered by nanotechnology to existing products when formulated using 
nanosystems, coupled to patent extensions and higher profit margins obtained, this target 
will effortlessly be visualized (Ravichandran, 2004; Majuru and Oyewumi, 2009).  
 
Research shows that one in 10 drugs currently on the market and 95% of potentially 
marketable therapeutic agents exhibits pharmacokinetic and biopharmaceutical issues due 
to poor solubility, with drug accessibility into the CNS limiting the development of 
neuropharmaceutical products (Koo et al., 2005; Lemaire and Desrayaud, 2005; Majuru and 
Oyewumi, 2009). The BBB hinders the efficacy of the majority of pharmaceutical products 
developed and marketed for neurological disorders (Bodor and Buchwald 1999; Lemaire and 
Desrayaud 2005; das Neves et al., 2009). A drug delivery device with predictable and stable 
pharmacokinetic and pharmacodynamic parameters therefore has potential for several 
applications, as was prepared in this study. The use of nanotechnology allows for the 
delivery of lipophilic drug molecules due to altered pharmacochemical parameters occurring 
with the preparation of the drug in the nano-size scale (das Neves et al., 2009; Suh et al., 
2009). The device can be used to treat chronic diseases, such as Alzheimer‟s disease and 
other neurodegenerative conditions, as well as systemic HIV infection by means of 
implantation of the device at varying sites in the body.  
 
Despite the invasive nature of the procedure involved in the administration of the 
nanoenabled multipolymeric implants into the brain, the device still has potential to transform 
the management of ADC due to the controlled and sustained delivery of AZT over months to 
a year. This will enable the administration of lower drug concentrations, less frequent dosing 
intervals and will minimise the incidence of adverse effects experienced, all serving to 
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enhance drug therapy (Prokai et al., 2000). Once off implantation of the device in the 
absence of later removal makes the nanoenabled multipolymeric device preferable to non-
biodegradable implants previously developed for the brain delivery of drug molecules 
(Pardridge 1995). Nanoparticles will also enable superior drug distribution within the CNS 
due to the small size of the particles, and therefore will facilitate efficient suppression of viral 
loads within the brain (Modi et al., 2009; Muthu et al., 2009; Suh et al., 2009). 
 
It has been reported that approximately 90% of HIV infected individuals will eventually 
develop CNS manifestation of the virus (Sakaie and Gonzalez, 1999). Dementia affects 
approximately 24 million people worldwide (Modi et al., 2009). Adequate drug concentrations 
within the CNS are necessary to combat this. Drug delivery into the CNS as well as the 
development of new therapeutic agents capable of managing neurodegenerative conditions 
is currently impede by the limited penetration of drug into the brain (Lemaire and Desrayaud 
2005). Nanotechnology, a rapidly expanding technology, can potentially surmount these 
barrier to CNS drug delivery, with the implementation of a multidisciplinary approach, 
consisting of pharmaceutical scientists, doctors and neuroscientists, required for advances in 
the field of nanoenabled CNS drug delivery to be achieved (Koo et al., 2005; Modi et al., 
2009). 
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